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Abstract 
A series of 7 studies was performed on patients with chronic heart 
failure to determine more fully the mechanisms of decreased 
responsiveness to diuretics typically found in this condition. 
Furosemide, a diuretic agent acting on the thick ascending limb of 
the loop of Henle, was chosen for all the studies which follow. A 
steady diuresis was achieved by repeated bolus injections of 
furosemide. 
In the first study described in Chapter 3, the effect of dietary salt 
restriction on diuretic responsiveness was assessed. It was found 
that sodium restriction impaired the diuretic and natriuretic 
response to intravenous furosemide. 
The effect of a single acute-on-chronic oral dose of captopril, an 
angiotensin converting enzyme inhibitor, was compared with 
placebo, see Chapter 4. Captopril enhanced the natriuresis and 
diuresis produced by furosemide, despite causing a fall in blood 
pressure and glomerular filtration rate. 
Dobutamine and sodium nitroprusside, agents which may improve 
cardiac output in heart failure, but by different mechanisms, were 
compared in the next study described in Chapter 5. Dobutamine 
potentiated furosemide induced natriuresis but had no effect on 
diuresis. Sodium nitroprusside diminished the diuretic response to 
furosemide, when compared with dobutamine, but did not 
significantly affect sodium excretion. 
Digoxin was administered intravenously and increased natriuresis 
but not diuresis compared to placebo, see Chapter 6. 
Atrial natriuretic peptide was infused at low, then high doses. 
Chapter 7 describes how this produced no significant effect on 
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furosemide induced diuresis and natriuresis, although a prolonged 
hypotensive response was observed. 
The effect of indirect sympathetic nervous system activation by 
tyramine and alpha-adrenergic inhibition by phentolamine were 
compared. As Chapter 8 shows, neither agent produced any effect 
on diuresis or natriuresis. 
In the last study, the relative diuretic and natriuretic effects of 
dopamine and dobutamine were compared, see Chapter 9. High 
dose dobutamine and dopamine enhanced furosemide induced 
natriuresis but did not significantly affect urine volume. 
It is argued that agents which produce hypotension tend to acutely 
impair diuresis and natriuresis in response to intravenous 
furosemide in patients with heart failure, despite improvement in 
renal plasma flow and cardiac output or apparently beneficial 
alterations in plasma hormone concentrations. The only exception 
found was the response to captopril. Thus chronic supression of 
angiotensin converting enzyme modifies the usual renal response 
to a fall in arterial pressure and glomerular filtration rate associated 
with acute, intense suppression of angiotensin II. 
The work presented in this thesis has formed a detailed, but by no 
means comprehensive examination of mechanisms of reduced 
renal responsiveness to furosemide in patients with heart failure. 
The interrelationship between the sympathetic nervous system, 
the renin-angiotensin-aldosterone system, the atrial natriuretic 
peptides and the systemic and renal haemodynamic status as they 
relate to diuretic responsiveness in patients with chronic heart 
failure have also been explored. 
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Chapter 1 Introduction, historical review and aims 
1 . 1 General introduction 
Heart failure is a clinical syndrome recognised by a constellation of 
symptoms and signs, resulting from deranged cardiac function. Impaired 
pump function leads to activation of the sympathetic nervous system, the 
renin-angiotensin-aldosterone system, natriuretic peptides, endothelin-1, 
arginine vasopressin, kinins and renal prostaglandins (Dusting, Moncada, 
Vane 1979; Dzau, Packer, Lilly, et al1984b; Lilly, Dzau, Williams, et al1984; 
Francis 1985a, Creager, Faxton, Cutler, et al 1986; Laragh 1986; Rieger, 
Kromer, Kochsiek 1986a; Mancia 1990; Hi roe, Hirata, Fujita, et al 1991; 
Remes, Tikkanen, Fyhrquist, et al 1991 ). 
The fall in cardiac output and decreased renal perfusion provide a powerful 
stimulus to activation of salt-retaining neuroendocrine systems (DiBona 
1977; Cannon 1977; Cody 1989; Eiskjaer, Bagger, Danielsen, et al 1991). 
Compensatory retention of salt and water initially restores cardiac output 
and renal perfusion, at the expense of further load on the already weakened 
heart muscle. Declining cardiac function and activation of neuroendocrine 
systems leads to a vicious cycle of fluid retention and worsening heart 
failure. The loss of compensatory vasodilator influences, both in the blood 
vessels and in the kidneys, aggravates peripheral vasoconstriction and 
sodium retention and adds to the haemodynamic burden of the failing heart 
(Packer 1992). 
In the present chapter conventional treatments for heart failure will be 
reviewed with special attention to their effects on salt and water retention. 
The role of activation of various neuroendocrine systems in the pathological 
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sodium and water retention of heart failure will be explored. 
1 . 1 . 1 The kidney 
The primary role of the kidney is to maintain the composition of the 
extracellular fluid within very narrow margins. This is achieved by regulation 
of both the volume and the composition of the fluid excreted as urine. 
Vascular supply of the kidney 
In man, each kidney weighs approximately 300g and contains some 1000-
000 nephrons. Together they receive one fifth of the resting cardiac output, 
nearly 90% of which supplies the renal cortex. The main renal artery divides 
into anterior and posterior branches within the renal hilum just before 
entering the parenchyma. The anterior branch divides into 4 segmental 
arteries which together supply two thirds of the kidney. Segmental divisions 
of the posterior branch supply the posterior surface of the kidney. 
The segmental arteries divide into interlobar arteries within the medulla. 
They ascend towards the renal cortex. At the cortico-medullary junction they 
give off arcuate arteries which run parallel to the surface of the kidney. The 
arcuate arteries then divide and ascend as cortical radial arteries towards 
and perpendicular to the renal capsule. Afferent arterioles branch directly 
from these vessels, carrying blood to glomerular capillaries which are 
distributed throughout the cortex. Cells and plasma exit the glomerular 
circulation not in venules but in efferent arterioles. Efferent arterioles from 
more superficial glomeruli give rise to the post glomerular, cortical 
peritubular microcirculation. Efferent arterioles from deeper glomeruli 
descend into the medulla. There they form the outer medullary peritubular 
capillary microcirculation and the vasa recta. The vasa recta accompany the 
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thin limbs of Henle's loops into the inner medulla. 
The true venous circulation of the kidney begins as blood leaves the 
capillaries of the peritubular networks and the vasa recta. Venules from all 
cortical regions join to form cortical radial veins and these descend towards 
the cortico-medullary junction. Here they are joined by veins draining the 
medullary microcirculations. There are multiple anastomoses between 
veins at all levels of the venous circulation. 
Autoregulation of renal vascular tone 
Renal vascular tone is dynamic and can respond rapidly to a fall in renal 
perfusion with vasodilatation. This effect is most evident at renal perfusion 
pressures of 50-60mmHg. Below this range, renal blood flow diminishes in 
proportion to the fall in perfusion pressure. The myogenic reflex, a property 
of the renal arterioles to respond to a change in wall tension by dilating (in 
response to a fall in tone) or constricting (in response to a rise in tone) is 
rapid and appears to be an intrinsic property of the vessel wall. When mean 
systemic arterial pressure falls below 60mmHg, adequate renal perfusion 
can no longer be maintained and urine formation declines then ceases 
(Guyton 1991 ). 
Hormonal and neural control of renal vascular tone 
The renin-angiotensin-aldosterone system 
The predominant sites of action of vasoactive compounds and the 
sympathetic nervous system are the afferent and efferent arterioles. The 
renin-angiotensin-aldosterone system plays a major role in both renal 
haemodynamics and regulation of salt and water balance. Angiotensin II is 
formed by a series of steps initiated by renin released from the kidney. 
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Renin acts upon angiotensinogen (synthesised in the liver) to form 
angiotensin I, which is subsequently converted to angiotensin II by the action 
of angiotensin converting enzyme, primarily within the pulmonary circulation. 
Angiotensin II is one of the most potent vasoconstrictor substances known 
and is also a specific stimulator of the release of aldosterone, a sodium-
retaining hormone. In addition to the systemic pressor effects of angiotensin 
II, the local renal actions promote glomerular filtration. This is because 
angiotensin exerts more pronounced constrictor effects on the efferent than 
the afferent arterioles (Ichikawa, Miele, Brenner 1979), an effect which raises 
the pressure upstream in the glomerular capillary. The net effect of 
angiotensin II formation is to raise blood pressure and expand the 
intravascular volume. Renin is stored within the granules of specialised 
myoepithelial cells called juxtaglomerular cells located in the walls of the 
afferent arterioles. The rate of release is influenced by a fall in renal 
perfusion pressure, sensed by the renal baroreceptors located in the arterial 
wall. The sympathetic nervous system and circulating catecholamines 
influences renin release through beta adrenergic receptors (Davis 1973; 
Davis, Freeman 1976; Thames 1984). The composition of the fluid (pre-
urine) delivered to th  distal renal tubule also influences the rate of renin 
release. In addition there is a negative feedback from the consequences of 
renin release, that is a rise in blood pressure, intravascular volume and 
improved renal perfusion. Angiotensin II itself inhibits renin release 
(Wathen, Kingsbury, Stouder, et al 1965; Bunag, Page, McCubbin, et al 
1967). 
Circulating catecholamines and the renal nerves 
The kidneys are well supplied with nerves from the coeliac plexus which 
innervate major intrarenal arteries, afferent arterioles and to a lesser extent, 
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the efferent arterioles, tubule structures and glomerular mesangium. As 
mentioned above, j3-adrenergic stimulation activates the renin-angiotensin 
system but a 1-adrenergic stimulation (and to a lesser effect, post-synaptic 
a2-adrenergic receptor stimulation) causes marked vasoconstriction of the 
interlobular arteries and the afferent arterioles and· a fall in renal blood flow. 
Stimulation of the vasomotor centre in the medulla, parts of the cerebral 
cortex and parts of the brain stem results in similar vasoconstriction. Under 
resting conditions, renal neural stimulation is low and has little influence on 
renal function. In low output disease states such as heart failure, sodium 
depletion or haemorrhage, significant neurally mediated vasoconstriction 
can result from an increase in sympathetic neural stimulation (Levine, 
Francis, Goldsmith, et al 1982; DiBona, Sawin 1983; DiBona 1994a; 
DiBona, Sawin 1994b). 
Dopamine is an endogenous renal neurotransmitter with specific dopamine 
receptors. It produces vasodilatation and an increase in renal blood flow at 
low doses but at larger doses also stimulates adrenergic receptors, thus 
causing vasoconstriction (Rosenblum, Tai, Lawson 1972; Robie, Goldberg 
1975; Miller 1984). 
Renal prostaglandins 
Membrane-bound phospholipid is metabolised locally to prostaglandins via 
the cyclo-oxygense pathway (Dunn, Hood 1977). The vasodilator 
prostaglandins prostaglandin E2 and prostacyclin are the primary vasoactive 
end products of arachidonic acid metabolism in the kidney, while 
thromboxane, a powerful vasoconstrictor, is produced to a much lesser 
extent. Production of renal prostaglandins is enhanced by renal 
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vasoconstrictors such as angiotensin II (Walker, Whorton, Smigel, et al 
1978), arginine vasopressin (Usberti, Dechaux, Guillot 1980), endothelin 1 
(Leppaluoto, Ruskoaho 1992), and a-adrenergic neural stimulation 
(Fiamenbaum, Kleinman 1977.; Needleman, Wycke, Bronson, et al 1979; 
Stahl, Paravicini, Schollmeyer 1984). Production is inhibited by Gyclo-
oxygenase inhibitors (non-steroidal anti inflammatory drugs and aspirin). 
Like the neural control of renal blood flow, prostaglandins exert little or no 
influence during basal conditions, but play a major part in maintaining renal 
blood flow during low output states (Dunn, Hood 1977; lino, lmai 1978; 
Dusting, Moncada, Vane, 1979; Schor, Ichikawa, Brenner 1980; Chiu, 
Brown, Barnett 1984; Dzau, Packer, Lilly, et al 1984b; Gottlieb, Robinson, 
Krichten, et al 1992a; Motwani, Fenwick, Struthers 1992c). 
A number of other vasodilator substances have been identified, including 
the kinins bradykinin and kallidin (released from inert precursor kininogens 
by the action of the proteolytic enzyme kallikrein), histamine, acetylcholine, 
serotonin and parathyroid hormone but their precise roles, if any, in 
regulation of renal blood flow are unknown (Munzel, Kurz, Holtz, et al 1992). 
The atrial natriuretic peptides are a group of peptides released primarily 
from the atrium and have vasorelaxant effects in addition to their powerful 
diuretic and natriuretic effects. They will be discussed later. 
Structure and function of the nephron 
Nephrons are described as superficial, mid-cortical, or juxtamedullary 
nephrons, depending on their origins from a superficial, midcortical or 
juxtamedullary glomerulus. They are also described as short-looped when 
Henle's loop turns back in the outer medulla (or cortex); cortical nephrons 
when Henle's loop turns back in the cortex and long-looped when Henle's 
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loop turns back in the inner medulla. 
Each nephron consists of the renal corpuscle and the tubular portions of the 
nephron. The renal corpuscle comprises Bowman's capsule, the 
glomerulus (glomerular tuft) and the urinary space (Bowman's space). The 
glomerulus is composed of glomerular lobules. 
The tubular portions of the nephron are divided into the proximal tubule, the 
intermediate tubule and the distal tubule. The tubular portion is separately 
and independently subdivided on microanatomical grounds into the 
proximal convolution, the loop of Henle (long loop, short loop, cortical loop) 
and the distal convolution. Thus the loop of Henle comprises the straight 
part of the proximal tubule, the intermediate tubule and the straight part of 
the distal tubule. 
The renal corpuscle 
The renal corpuscle consists of a tight bundle of capillaries situated in the 
proximal end of the renal tubule, also known as Bowman's capsule. The 
capillary walls are in intimate contact with specialised epithelial cells or 
podocytes, separated only by an acellular basement membrane. The 
endothelial cells of the capillaries are separated from one another by small 
gaps or fenestra and the epithelial cells of the tubule protrude numerous foot 
processes to cover the outer surface of the glomerular capillary loop, 
separated by slit-like diaphragms (Bulger, Dobyan 1982). 
About 180 litres of fluid are filtered by the glomeruli per day but less than 1% 
is excreted as urine (Brenner, Beeuwkes 1978; Ganong 1987). The fluid is 
driven out of the capillaries and into the tubule by hydraulic pressure. The 
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oncotic pressure tends to pull fluid back into the capillary and the balance 
between the two determines the rate of filtration (Brenner, Coe, Rector 
1986). Tubule fluid protein concentration is minimal, thus the oncotic 
pressure within the urinary space is negligible. In certain disease states, 
hyperproteinaemia elevates plasma oncotic pressure and thus reduces 
glomerular filtration. Likewise, urinary outflow obstruction raises the 
hydraulic pressure in the tubule and reduces glomerular filtration. As 
mentioned earlier, filtration can be enhanced in individual renal corpuscles 
by selectively constricting the efferent arteriole and thus raising capillary 
hydraulic pressure (angiotensin II). Contraction of the supporting cells or 
mesangium in the renal corpuscles in response to vasoconstrictor 
substances reduces the surface area available for filtration. 
Tubuloglomerular feedback 
The rate of fluid delivery to the area of the early distal tubule known as the 
juxtaglomerular apparatus also regulates glomerular dynamics. ihe 
juxtaglomerular apparatus consists of granular cells, extraglomerular 
mesangium and the macula densa. The macula densa is anatomically in 
close proximity to the fferent arteriole and the renal corpuscle and releases 
renin in response to reduced perfusion pressure, renal sympathetic nerve 
stimulation or altered delivery of sodium to the juxtaglomerular apparatus 
region of the distal tubule (Davis, Freeman 1976; Keeton TK, Campbell WB 
1980; Kurtz, Bruna, Pratz, et al 1988; Osborn, DiBona, Thames 1991; 
Persson, Gushwa, Blantz 1984). High distal tubule fluid flows and salt 
delivery rates produce a fall in glomerular filtration, largely as a result of 
increases in afferent and efferent arteriolar resistance. The precise 
mechanism is not certain but may be related to angiotensin II induced 
contraction of mesangial cells, thereby reducing the calibre of the arterioles 
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(Ausiello, Kreisberg, Roy, et al 1980; Barnes, Guy, Lifschitz, et al 1981 ). This 
mechanism is very important as fluid transport mechanisms can be 
overwhelmed by excessive distal delivery of fluid and solutes with resultant 
excessive urinary losses. 
The passage of solutes larger than 20 Angstrom molecular radius across the 
glomerular wall is limited (Brenner, Beeuwkes 1978), consistent with the 
presence of "pores" of specific size and configuration within the membrane. 
There is also a charge-selective barrier because of the fixed negative 
charges within the structural proteins of the surface coat of the epithelial foot 
processes and the slit diaphragms lying between the adjacent foot 
processes (Bulger, Dobyan 1982). Negatively charged macromolecules are 
impeded and positively charged ones facilitated in their passage across the 
capillary wall compared with neutral compounds of the same size (Brenner, 
Beeuwkes 1978). 
In humans the maximum urine flow is about 1.5 1/hour (20% of the GFR or 36 
litres per 24 hours). The remaining 144 liters of plasma filtered per day are 
coupled with solute reabsorption. This occurs primarily in the proximal 
tubule and the thin descending limb of the loop of Henle (intermediate 
tubule). The distal tubule and collecting tubule segments are not entire.ly 
impermeable to water thus some water reabsorption also occurs here. 
The lowest osmolality achievable is finite because of obligatory solute 
excretion, because of the failure of the salt reabsorptive processes and 
because of the finite tubule water permeability. Likewise there is an 
obligatory 600m0sm of waste products to excrete per day and because the 
maximum concentrating power of the human kidney is 1300m0sm, the 
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minimum urine output per day is about 500ml. 
The peritubular microcirculation 
Fluid is returned to the circulation in a two-stage process which involves 
translocation of fluid and solute into the renal interstitium with subsequent 
uptake into the peritubular capillary blood. About two thirds of the fluid 
reabsorption takes place in the convoluted and straight portions of the 
proximal tubule, and the cortical peritubular capillary network lies in close 
proximity to these nephron segments. The blood in these capillaries has a 
high oncotic pressure, having already passed through the glomerulus, and a 
low hydraulic pressure because of the tone of the efferent arteriole (Berry, 
Rector 1980). Fluid reabsorption is thus favoured, indeed equilibrium is not 
reached at the distal end of the capillary network (Berry 1983). The precise 
composition of the reabsorbed fluid is determined by the selective transport 
of individual solutes across the renal epithelial cells. The renal corpuscular 
mechanisms which preserve glomerular filtration when renal perfusion is 
impaired also mitigate against excessive urinary loss of essential body fluids 
by augmenting the proportion of filtered water and solutes reabsorbed in the 
proximal nephron. As efferent artery constriction raises filtration pressure, 
more fluid is filtered and the oncotic pressure in the efferent arteriole is 
higher. The flow of blood into the cortical peritubular capillary network is 
reduced and slower flow allows time for complete reabsorption of solute 
{Brenner, Beeuwkes 1978). 
The medullary microcirculation 
The tubules and vascular supply to the medulla are arranged in close 
anatomic proximity and with precise alignment of ascending and 
descending tubules and vessels (Bulger, Dobyan 1982). This arrangement 
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is essential for the renal concentrating mechanism. A gradient of increasing 
interstitial solute concentration exists from the cortico-medullary junction to 
the papillary tip to allow maximum urinary concentration. The concentration 
gradient is maintained by the renal countercurrent exchange system. The 
hairpin shape of the tubule and of the vasa recta allow a gradient to be 
maintained between the cortico-medullary junction and the deeper medulla 
while the permeability properties of different parts of the tubule allow the 
gradient to be generated (Kokko, Rector 1972; Brenner, Beeuwkes 1978; 
Kokko 1979). 
Urine is concentrated by countercurrent multiplication and countercurrent 
exchange, a complex interaction involving the loops of Henle, the medullary 
interstitium, the medullary blood vessels or vasa recta and the collecting 
tubule (Brenner, Beeuwkes 1978; Kokko 1979). Arginine vasopressin, a 
hormone excreted by the anterior pituitary, regulates concentration of urine 
in the medulla by altering the permeability of the distal renal tubules and 
collecting ducts to water (Kachdorian, Wade, DiScala 1975; Dousa, Valtin 
1976; Wade 1985). The release of arginine vasopressin is stimulated by 
very small (1-2%) increases in plasma osmolality as well as by volume 
depletion (Morton, Connell, Hughes, et al 1985). The circulating hormone 
binds to specific receptors in the basal and lateral aspects of the distal 
tubules and collecting ducts and activates adenylate cyclase (Hays 1976; 
Levine, Franki, Einhorn, et al 1976; Wade 1985 ). The formation of cyclic 
AMP leads to phosphorylation of specific membrane proteins and 
rearrangement of the microtubules and microfilaments of the tubular cells to 
form pores (Schwartz, Schaltz, Kinne-Saffran, et al 1974; Kachadorian, 
Wade, DiScala 1975; Taylor, Maffly, Wilson, et al 1975; Wade 1985). The 
tubule becomes freely permeable to water, allowing it to diffuse passively 
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into the hypertonic renal medullary interstitium (Kokko 1979). 
Countercurrent multiplication occurs in the loop of Henle and requires 
specific permeability and transport characteristics of the descending and 
ascending limbs. When the preurine reaches the loop of Henle, two thirds of 
the water and solute has already been reabsorbed. The remaining third 
which is still isosmotic to plasma, passes down the thin descending limb 
deep into the medulla. Being highly water permeable and virtually 
impermeable to salt and urea, passive water equilibration with the 
hypertonic medullary interstitium results in concentration of the pre-urine. 
The hypertonicity of the medullary interstitium is provided in equal parts by 
urea and sodium chloride (Kokko, Rector 1972; Jamison 1976; Kokko 1979; 
Brenner 1986). Thus the fluid entering the thin ascending limb has a higher 
sodium concentration and a lower urea concentration than the surrounding 
interstitium. The thin ascending limb is relatively more permeable to sodium 
chloride than to urea and is impermeable to water, thus sodium moves out of 
the tubule down its concentration gradient with a smaller amount of urea 
moving into the tubular fluid. The net effect is to dilute the tubular fluid and 
concentrate the medullary interstitium. The fluid passes up into the thick 
ascending limb which is also impermeable to water. Active chloride 
transport provides the energy for passive diffusion of sodium out of the thick 
ascending limb along the electrochemical gradient and further dilutes the 
fluid (Kokko 1979). Urea remains in the fluid as the thick ascending limb is 
relatively impermeable to it. Fluid entering the distal convoluted tubule is 
dilute, but relatively rich in urea. The tubule segment is impermeable to both 
water and urea so the fluid passes unaltered into the collecting duct 
(Brenner, Beeuwkes 1978; Kokko 1979) . 
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When concentrations of arginine vasopressin are high, the collecting duct is 
highly permeable to water, which diffuses freely into the hypertonic 
interstitium, resulting in a concentrated urine (Dousa, Valtin 1976; Hays 
1976). When arginine vasopressin concentrations are low, the collecting 
duct is impermeable to water and highly dilute urine can be formed. The 
initial portion of the collecting duct is relatively impermeable to urea, thus 
with water equilibration, pre-urine reaching the terminal segments is rich in 
urea. It dissipates down its concentration gradient into the papillary 
interstitium, maintaining the hypertonicity of the medulla. 
Countercurrent exchange 
The hypertonicity generated in the papillary interstitium would rapidly be 
washed away by the blood flowing through it if it were not for the 
countercurrent exchange system in the vasa recta. Water and solutes are 
freely permeable across the capillaries and rapid equilibration occurs. 
Because the vasa recta follow the same hairpin bend that the loop of Henle 
does, and ascending and descending portions of the vasa recta are in close 
proximity, at any level of the loop, the concentrations in ascending and 
descending limbs are the same. This allows a gradual rise in concentration 
gradient from the top to the bend in the loops and because of their length, for 
substantial concentration gradients to develop between the bottom and top 
of the loops, without solute washout (Kokko 1979; Brenner, Beeukwes 1978; 
Brenner 1986). 
Renal sodium reabsorption 
99.4% of filtered sodium is reabsorbed, and all parts of the tubule and 
collecting duct play a part. In the proximal and distal tubules and in the 
collecting ducts, sodium diffuses passively down its concentration gradient 
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and electrical gradient from the tubular lumen into the tubular epithelial cells. 
Sodium is actively pumped from the epithelial cells into the interstitial space 
in all parts of the tubule except the thin portions of the loop of Henle 
(Herbert, Schafer, Andreoli 1981; Ganong 1987). 
60% of filtered sodium is reabsorbed in the proximal tubule, powered mainly 
by the Na+-K+-ATPase pump system located in the basolateral membrane 
(Kokko 1979; Berry, Rector 1980; Ganong 1987). There are two phases for 
the transport of sodium from the proximal tubule. Initially it combines with 
specific carrier complexes using the energy derived from the electrical 
and/or chemical concentration gradient for sodium across the luminal 
membrane (Aronson 1981 ). This gradient is maintained by the Na+-K+-
ATPase pump system (Berry, Rector 1980). The sodium-coupled 
reabsorption of glucose and amino acids in the early proximal tubule 
generates a lumen-negative potential difference in this part of the tubule 
(Kokko 1973; Barratt, Rector, Kokko, et al 197 4; Fromter, Gessner 197 4; 
Burg, Patlak, Green, et al 1976). In the latter part of the proximal tubule a 
positive potential difference is generated by the high chloride and low 
bicarbonate concentrations relative to the peritubular plasma (Berry, Rector 
1980; Rector 1983). This serves to accelerate sodium movement out of the 
tubule. Movement from the renal interstitium into the peritubular capillaries 
is governed by Starling's forces (Rector 1983). The peritubular oncotic 
pressure is governed by the percentage of renal plasma flow which 
becomes glomerular ultrafiltrate. This usually amounts to 20%, however 
when more is filtered, the peritubular capillary oncotic pressure is increased 
proportionally and subsequently more fluid and solute is reabsorbed from 
the proximal tubule. 
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The distal tubule 
Dilution of the distal tubule fluid occurs irrespective of the state of water 
balance as described earlier (countercurrent multiplication). Sodium 
reabsorption in the thick ascending limb of the loop of Henle is a secondary 
active transport system similar to that in the proximal tubule, but a lumen-
positive potential difference is generated (Ganong 1987). The thick 
ascending limb of Henle's loop contains a cotransport mechanism for K+ 
and Na+ with two Cl ions using energy from the chemical concentration 
gradient for sodium and chloride. The gradient is maintained by the Na+-
K+-ATPase pump. A parallel potassium diffusion channel replaces the 
tubular potassium. This mechanism is highly sensitive to loop diuretics such 
as furosemide, which act only from the lumen. Furosemide acts by 
combining with the symporter in the luminal membrane and preventing its 
translocation into the cell (Greger 1985; Wittner, DiStefano, Schlatter, et al 
1986; Giebisch, Klein-Robbenhaar 1993a; Giebisch, Klein-Robbenhaar, 
Klein-Robbenhaar, et al 1993b). The distal convoluted tubule continues 
active dilution of the tubule fluid using the Na+-K+-ATPase pump. It 
generates a lumen-negative potential difference and has the highest activity 
of Na+-K+-ATPase of any of the nephron segments (Bulger, Dobyan 1982). 
It is highly impermeable to water thus the fluid becomes further diluted. 
Collecting system 
The collecting system comprises the connecting tubule, the cortical 
collecting duct, the outer medullary collecting duct and the inner medullary 
collecting duct. The final regulation of urinary solute and water excretion 
takes place in the collecting system. 
31 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The connecting tubule connects the distal convoluted tubule to the collecting 
duct and is functionally different from both. It shares some characteristics 
with the distal convoluted tubule, being relatively impermeable to water, with 
high Na+-K+-ATPase activity (Ganong 1987). It contains two cell types, the 
connecting tubule cells and the intercalated cells. The collecting duct has 
two cell types, the collecting duct cells or principal cells and the intercalated 
cells (Bulger, Dobyan 1982). The intercalated cells contain numerous large 
mitochondria and organelles while the principal cells have lighter cytoplasm 
and fewer organelles. In addition they possess a single long cilium 
projecting into the lumen from an apical membrane. As the collecting duct 
passes from cortical to medullary to papillary locations in the kidney, the 
number of intercalated cells decrease and the principal cells increase, with a 
dramatic fall in the carbonic anhydrase content of these cells (Bulger, 
Dobyan 1982). Sodium is reabsorbed from the collecting tubule to very low 
levels (1 mEq during periods of salt deprivation) while chloride reabsorption 
is retarded, generating a large lumen-negative electrical potential difference. 
An increase in the filtered load of Na and Cl ions to the loop of Henle 
stimulates NaCI transport, as does vasopressin, cell volume reduction, 
adrenergic agonists, and aldosterone (Ganong 1987). The opposite occurs 
after prostaglandin E2 administration, medullary interstitial hypertonicity and 
in the response to high levels of K+ in the medullary interstitium surrounding 
the thick ascending limb (Giebisch, Klein-Robbenhaar 1993a). 
Absorption of the principal salts in the collecting duct segments is controlled 
by mineralocorticoids such as aldosterone (Ganong 1987). This increases 
K+ and H+ secretion and Na reabsorption. Some of the effect on K+ 
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secretion is immediate while a 60 minute lag is required for H+ and 90 
minutes for Na+ reabsorption. 
Aldosterone acts by forming an active steroid receptor complex within the 
collecting duct cell cytoplasm. Transcription of m and r DNA follows, which 
leads to increased production of aldosterone induced protein. This protein 
directly stimulates active H+ secretion. It also stimulates cell metabolism 
and this increases the Na+ permeability of the luminal cell membrane 
(Brenner 1986). This leads to increased cell Na+ concentration, which 
stimulates Na+-K+-ATPase activity. This stimulates Na+ reabsorption and 
intracellular K+ concentration. Enhanced cell K+ amplifies the immediate, 
steroid-induced increased K+ secretion (by its effect on K+ permeability). 
Stimulation of the renal nerves increases reabsorption of sodium in the 
ducts not only by enhancing renin release but by a mechanism which is 
independent of prostaglandins and the renin-angiotensin system. Neural 
control of sodium reabsorption is mediated by the a 1-adrenoceptor subtype 
(Gottschalk 1979, DiBona 1977; 1978; 1982; DiBona, Sawin 1983), however 
a2-adrenoceptors modulate the antidiuretic action of arginine vasopressin 
and thus indirectly control renal excretory function (Gellai 1990). 
Sympathetic activation of the renal B-adrenergic receptors stimulates the 
renin-angiotensin system while central adrenergic stimulation increases the 
nonosmotic release of arginine vasopressin (Abraham, Schrier 1994). 
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1.1.2 Treating heart failure 
Loop diuretics 
The introduction of powerful diuretic drugs such as furosemide acting on the 
loop of Henle had a dramatic effect on the treatment of heart failure and still 
remain the mainstay of therapy for most patients with chronic heart failure. 
The treatment of patients with decompensated heart failure requires a 
sustained reduction in total body salt and water. This can only be attained in 
severe cases when both salt and water are restricted, to prevent rapid 
reabsorption in the hours following the diuresis and natriuresis. Patients 
with compensated heart failure maintain a steady salt and water balance 
with the aid of a regular daily diuretic and can often maintain this without 
additional salt restriction. The price paid for diuresis and natriuresis is 
activation of neuroendocrine systems (Brown, Davis, Johnston 1966; 
Schaer, Covit, Laragh, et al 1983, Francis, Benedict, Johnstone, et al 1990, 
Anand, Kalra, Harris, et al 1991 ). 
Intravenous furosemide administration leads to an increase in systemic 
arterial pressure, probably due to renin release, and a small decrease in 
cardiac output (Nelson, Ahuja, Silke, et al 1983; Francis, Siegel, Goldsmith, 
et al 1985b; Petersen, DiBona 1994). Renal effects of furosemide include 
vasodilatation and redistribution of blood towards the cortical nephrons, 
actions thought to be important for the drug's diuretic action. Renal 
prostaglandin E2 release is also stimulated by furosemide (Fujimura, 
Ebihara 1988) through stimulation of renal papillary biosynthesis whether or 
not the renin-angiotensin system is activated at the same time (Katayama, 
Attallah, Stahl, et al 1984). Furosemide prevents retrieval of filtered Na+ and 
K+ by inhibition of a cotransport mechanism with two Cl- ions located in the 
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thick ascending limb of Henle's loop (Greger 1985, Brenner 1986; Wittner, 
Di-Stefano, Schlatter, et al 1986; Giebisch, Klein-Robbenhaar, Klein-
Robbenhaar, et al 1993b). It probably also has an additional inhibitory effect 
on fluid reabsorption in the proximal tubules (Knox, Wright, Howards, et al 
1969; Shalmi, Petersen, Christiansen 1989; Petersen, Shalmi, Abildgaard, 
et al 1991 ). In order to inhibit this cotransporter, furosemide must first reach 
the luminal fluid. 
Enhanced rates of sodium absorption follow chronic treatment with loop 
diuretics (Hropot, Fowler, Kalmark, et al 1985; Stanton, Kaissling 1988, 
Ellison, Velazquez, Wright 1989; Reyes, Leary 1993a&b) and are almost 
certainly tightly related to the maintained increase in sodium delivery and 
sodium uptake into the cells of the distal collecting tubule (Barlet-Bas, 
Cheval, Khadouri, et al 1990). The increased rate of sodium reabsorption by 
these distal tubule segments persists beyond the acute diuresis and is 
functionally significant because it reduces the sodium loss and attenuates 
the apparent potency of loop diuretics during their chronic administration 
(Giebisch, Klein-Robbenhaar, Klein-Robbenhaar, et al 1993b; Loon, Wilcox, 
Unwin 1989; Wilcox 1991; Stanton, Kaissling 1988). Not only does avid 
renal sodium retention take place, but an attenuated early diuretic response 
relative to the initial dose response develops with subsequent doses, both in 
normals and heart failure patients (Reyes, Leary 1992). As heart failure 
worsens, increasing doses of diuretics are required to maintain sodium 
balance with concomitant side effects. 
Angiotensin converting enzyme inhibitors 
Over the past decade, the use of angiotensin converting enzyme (ACE) 
inhibitors has become routine therapy for patients with heart failure and 
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have been shown in several large studies both to improve symptoms and 
functional status and to prolong survival in patients with moderate and 
severe heart failure. Unfortunately the use of ACE inhibitors has had little 
impact on the diuretic requirements of most patients, who generally continue 
to require substantial doses of loop diuretic agents to control fluid 
accumulation and symptoms of failure (Odemuyiwa, Gilmartin, Kenny, et al 
1989; Fitzpatrick, Nicholls, lkram, et al 1983; Cowley, Stainer, Wynne, et al 
1986). Thus diuretics remain one of the mainstays of therapy in most 
patients with chronic heart failure, yet the development of reduced diuretic 
responsiveness or even refractory heart failure with long term treatment 
limits their usefulness. As progressively larger doses are required, side 
effects become more frequent. These side effects include hyponatraemia, 
hyperuricaemia, hypokalaemia, hypomagnesaemia, hyperglycaemia and 
cramp. Tachyphylaxis does not develop to these adverse effects. 
Vasodilators 
Vasodilator drugs should, in theory, be beneficial for the treatment of heart 
failure by reversing the intense vasoconstriction which characterises more 
severe disease. This should interrupt the vicious cycle of further damage to 
the cardiac myocytes and additional neuroendocrine activation (Riegger, 
Liebau 1982; Riegger 1985). Patients treated with conventional vasodilators 
such as hydralazine and isosorbide dinitrate have demonstrated beneficial 
short term haemodynamic responses in several clinical studies (Cogan, 
Humphreys, Carlson, et al 1980; Franciosa 1992b; Franciosa, Jordan, Wilen, 
et al 1984) but only the combination of isosorbide dinitrate and hydralazine 
has been shown to improve survival in patients with heart failure, and this 
effect was found to be significantly less than that achieved by ACE inhibitors 
(Cohn, Johnson, Ziesche, et al 1991 ). Tachyphylaxis develops to the effects 
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of either agent administered alone (Packer, Meller, Medina, et al 1982; 
Franciosa, Weber, Levine, et al 1982c; Packer, Lee, Kessler, et al 1987). 
The clinical course of patients treated with the vasodilator minoxidil was 
worse than that of those on placebo, despite sustained improvements in left 
ventricular ejection fraction (Franciosa, Jordan, Wilen, et al 1984). Wilcox, 
Guzman, Mitch, et al (1987) showed that prazosin in conventional doses has 
no effect on the renal response to furosemide in normal man although Lang, 
Choy, Rahman, et al (1993c) demonstrated a natriuretic effect of a low (non-
pressor) dose of prazosin in patients with heart failure undergoing a water-
diuresis and after conventional doses of furosemide had been administered. 
Calcium channel antagonists 
Agents such as nifedipine and diltiazem have potential benefits in the 
treatment of diastolic dysfunction but can precipitate acute deterioration in 
patients with significantly impaired left ventricular function due to negatively 
inotropic properties (Eikayam, Amin, Mehra, et al 1990; Goldstein, Boccuzzi, 
Creuss, et al 1991; Packer 1989) and thus the use of vasodilators is often 
restricted to the acute management of heart failure. 
Dopamine 
Dopamine was first introduced for the treatment of decomp.ensated heart 
failure in the early 1970's. It stimulates renal dopamine-1 receptors, 
dopamine-2 receptors, systemic 131-adrenoceptors and a-adrenoceptors 
and thus has both inotropic and vasodilator properties (Beregovich, Bianchi, 
Rubler, et al 1974; Brown, Lorenz, Erdmann 1985; Brodde 1991). In the 
kidney, dopamine preferentially dilates the renal arterioles at low dose 
(<5pg/kg/min). At higher doses (5-1 Opg/kg/min), its vasoconstrictor effects 
become more pronounced, with constriction of systemic and renal arterioles 
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and increased peripheral vascular resistance developing . 
Dopamine has been shown to restore diuresis in cardiac patients following 
surgery (Hilberman, Maseda, Stinson, et al 1984; Rosenblum, Tai, Lawson 
1972), shock (Loeb, Winslow, Rahimtoola, et al 1971; Talley, Goldberg, 
Johnson, et al 1969) and in patients with renal impairment (Talley, Goldberg, 
Johnson, et al 1969), but reports of diuretic properties with dopamine in 
patients with heart failure are largely anecdotal (Beregovich, Bianchi, 
Rubler, et al1974; Goldberg, McDonald, Zimmerman 1963; Goldberg 1972; 
McDonald, Goldberg, McNay, et al 1964). A recent study of low-dose 
dopamine infusion in elderly patients with congestive heart failure showed 
no diuretic or natriuretic effect (Robinson, Gariballa, Fancourt, et al 1994) 
while the effect in burns patients was inconsistent (Graves, Cioffi, Vaughan, 
et al 1993). Duke, Briedis and Weaver (1994) suggest that low-dose 
dopamine may even be harmful by masking signs of renal ischaemia. The 
oral dopamine analogue ibopamine causes a diuresis but not natriuresis in 
patients with heart failure (Wehling, Zimmermann, Theisen 1990; Kasmer, 
Cutler, Munger, et al 1990; DeiCas, Metra, Visioli 1992) but whether 
tachyphylaxis will develop with chronic use due to down-regulation of the 
dopamine receptors, as occurs with f3-adrenergic receptors, remains to be 
seen. 
Dobutamine 
Dobutamine is a synthetic catecholamine which stimulates a 1, f31 and f32-
adrenoceptors. The a-adrenergic stimulation results in renal artery 
vasoconstriction, while B2-adrenergic stimulation causes renal 
vasodilatation (lnsel, Snavely 1981 ). Overall the effect on renal blood flow is 
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negligable (Robie, Goldberg 1975). Dobutamine also causes peripheral 
vasodilatation and cardiac inotropy. Because of its balanced inotropic and 
vasodilator properties and preservation of myocardial metabolic function, 
dobutamine is widely used as the inotrope of choice in hypotensive patients 
with left ventricular failure. There are some anecdotal reports and 
uncontrolled studies describing diuresis and natriuresis with dobutamine in 
patients with heart failure (Leier, Webel, Bush 1977; Leier, Heban, Huss, et 
al 1978; Hilberman, Maseda, Stinson, et al 1984; Kiyingi, Field, Pawsey, et 
al 1990) but controlled studies comparing the effect of dobutamine and 
furosemide with furosemide on its own have not been reported. Dobutamine 
may have diuretic effects due to improvement in cardiac output but whether 
the putative diuretic effects of dopamine and dobutamine differ in this group 
of patients is not clear. Diuresis may depend on stimulation of the renal 
dopamine receptor, or on restoration of renal perfusion pressure, through an 
inotropic action. Unfortunately, with chronic use, the beneficial 
haemodynamic effects of j3-adrenergic agonists are lost (Unverferth, 
Blanford, Kates, et al 1980; Krell, Kline, Bates, et al 1986) and survival 
studies both with the oral partial agonist xamoterol and using intermittent 
outpatient infusions of dobutamine have demonstrated increased mortality 
with respect to placebo (Dies 1988; The Xamoterol in Severe Heart Failure 
Study Group 1990; Uretsky, Jessup, Konstam, et al 1990; Packer 1990). 
Phosphodiesterase inhibitors 
Phosphodiesterase inhibitors improve cardiac contractility by increasing 
concentrations of cyclic AMP and are used for the acute treatment of severe 
decompensated heart failure not responding to beta adrenoceptor agonists. 
These drugs were hailed as the breakthrough for outpatient management of 
cardiac failure as, unlike dopamine and dobutamine, · they can be 
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administered orally. Unfortunately survival studies have raised concerns 
that long-term therapy with phosphodiesterase inhibitors can enhance the 
frequency and complexity of ventricular arrhythmias, provoke myocardial 
ischaemia and shorten survival (Kinney, Carlin, Ballard, et al 1982; 
DiBianco, Shabetai, Silverman, et al 1984; Packer, Medina, Yushak 1984a; 
Massie, Bourassa, DiBianco, et al 1985; Likoff, Weber, Andrews, et al 1985; 
Jessup, Ulrich, Samaha, et al 1987; Packer, Carver, Rodeheffer, et al 1991) 
thus their use is restricted to short term treatment of decompensated heart 
failure. 
Digoxin 
Digoxin, a cardiac glycoside with inotropic and chronotropic properties, has 
been used in the treatment of heart failure for centuries (Withering 1785; 
Greeff, Schadewaldt 1981 ). Controversy still remains as to its role in the 
treatment of patients with chronic heart failure in sinus rhythm. William 
Withering in his book "An account of the foxglove, and some of its medical 
uses: with practical remarks on dropsy, and other diseases" reported 
increased excretion of urine with digitalis although it is probable that many of 
his patients had untreated atrial fibrillation and that the beneficial effects he 
noted related to slowing of rate and inotropic properties rather than to a 
specific diuretic effect. Gavey and Parkinson (1938) subsequently reported 
the effect of digitalis in patients with heart failure in sinus rhythm and showed 
that some 50% of patients did exhibit a diuresis but that it occurred more 
frequently in patients in atrial fibrillation. Rader, Smith, Berger, et al (1966) 
found no additional diuresis when digoxin was added to optimal diuretic 
therapy but Hull and Mackintosh (1977) showed that some patients required 
an increase in diuretic therapy when digoxin was withdrawn. 
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Digoxin produces its clinical effects by binding to the extracellularly exposed 
recognition site on the sodium pump, sodium-potassium-adenosine 
triphosphatase (Schatzmann 1953). A diuretic and natriuretic action could 
be explained by inhibition of Na+-K+-ATPase in the basolateral membrane 
of renal tubuloepithelial cells with inhibition of sodium reabsorption. The 
degree of inhibition would theoretically relate to the local density of Na+-K+-
ATPase in different parts of the nephron and its affinity for digoxin. Sensitivity 
to the cardiac glycoside ouabain has been reported to differ markedly in 
different portions of the nephron (Doucet, Barlet 1986). A specific digitalis 
binding site of high affinity and selectivity has been conserved on Na+-K+-
ATPase in all animal species in the course of evolution. It has recently been 
discovered that the endogenous regulator of Na+-K+-ATPase in animals, as 
in several plants, is ouabain (Hamlyn, Blaustein, Bova, et al 1991; Lloyd, 
Sandberg, Edwards 1992; Kelly, Smith 1992; Blaustein 1993). 
There has been a resurgence of interest in the use of digoxin for the 
management of patients with heart failure in sinus rhythm, as it was shown 
that most, if not all other available inotropic agents have been associated 
with increased mortality with long term use in heart failure (Xamoterol in 
Severe Heart Failure Study Group 1990; Packer, Carver, Rodeheffer, et al 
1991; Likoff , Weber , Andrews, et al 1985; Massie, Bourassa, DiBianco, et al 
1985). Some of the beneficial long term effects of digoxin may be due to 
inhibition of the sympathetic nervous system (Gheorghiade, Hall, Lakier, et 
al 1989), the renin-angiotensin system (Covit, Schaer, Sealey, et al 1983; 
Ribner, Plucinski, Hsieh, et al 1985) and. modulation of autonomic tone as 
digoxin has been demonstrated to modulate baroreceptor function 
(Ferguson, Berg, Sanders, et al 1989). G uyatt, Sullivan, Fallen, et al ( 1988) 
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showed benefit from digoxin in patients with heart failure in sinus rhythm and 
Packer, Gheorghiade, Young et al (1993) demonstrated that withdrawal of 
digoxin from patients with chronic heart failure treated with ACE inhibitors 
resulted in deterioration and weight gain, suggesting some diuretic effect, 
even in this patient population, although Gheorghiade and Beller found a 
neutral effect (1983). 
Beta-adrenergic antagonists 
f)-adrenergic antagonists have favourable effects on symptoms of patients 
with idiopathic dilated cardiomyopathy and on survival in patients with heart 
failure due to ischaemic heart disease (Swedberg, Hjalmarson, Waagstein, 
et al 1980; Chadda, Goldstein, Byington, et al 1986; Engelmeier, O'Connell, 
Walsh, et al 1985; Sethi, Nair, Arora, et al 1990). However treatment with the 
partial beta agonist xamoterol was associated with increased mortality in the 
"Xamoterol in severe heart failure study group" (1990) and several authors 
have described worsening heart failure developing in patients on being 
prescribed (3-adrenoceptor antagonists (lkram, Fitzpatrick 1981; Binkley, 
Lewe, Lima, et al 1986; Shanes 1987; Waagstein, Caidahl, Wallentin, et al 
1989; R Lang 1990; Packer 1992). 
Arginine vasopressin antagonists 
Elevated arginine vasopressin concentrations have been reported in 
\ 
patients with congestive heart failure (Yamane 1968; Rouleau, Moye, de-
Champlain, et al 1991) and thus extensive work with antagonists is in 
progress. At the time of writing, no suitable antagonist is available for 
clinical use but research projects in patients with heart failure are underway 
(Nicod, Waeber, Bussien, et al 1985; Creager, Faxon, Cutler, et al 1986; 
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Laszlo, Laszlo, De Wied 1991 ). 
1.2 Possible mechanisms for the loss of diuretic 
responsiveness found in heart failure 
1.2.1 Pharmacokinetics of furosemide 
In severe heart failure, furosemide absorption from the gastrointestinal tract 
may be reduced due to mucosal congestion, however studies in patients 
with stable heart failure showed no change in bioavailabilty of furosemide 
after intravenous or oral doses (Van-Meyel, Gerlag, Smits, et al 1992a), thus 
resistance to furosemide in congestive heart failure manifests as a change in 
pharmacodynamics of response, related probably to altered solute 
haemostasis (Brater, Chennavasin, Seiwell 1980; Brater, Seiwell, Anderson, 
et al 1982). Even in patients with reduced gastric absorption, the 
pharmacokinetics of intravenously administered furosemide appear little 
altered. The small reduction in renal clearance of the drug can be 
accounted for by the reduced glomerular filtration rate in patients with heart 
failure. Patients with more severe cardiac failure show lower glomerular 
filtration rate (GFR) and furosemide renal clearance than those with mild 
failure (Nomura, Yasuda, Minami, et al 1981). 
Despite similar furosemide levels in the plasma and the urine, patients with 
heart failure have a reduced renal response to a given urine furosemide 
concentration when compared with controls. Thus in one series, the 
maximum sodium excretion rate was 30% of that in normal subjects and the 
total natriuretic response was reduced to 50% of normal. Excretion of 
furosemide in heart failure is qualitatively the same as in normal subjects but 
the time course is delayed (Andreason, Mikkelsen 1977; Brater, 
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Chennavasin, Seiwell 1980). Nomura, Yasuda, Minami, et al (1981) 
demonstrated a moderate correlation between renal furosemide clearance 
and urinary sodium concentration. They also found that urinary furosemide 
excretion correlated with natriuretic effect in patients with heart failure. 
The mechanisms for the reduced responsiveness to furosemide in heart 
failure are complex, but include activation of the sympathetic and renin-
angiotensin systems and thus opposing sodium retaining forces. In addition, 
chronic furosemide therapy leads to local renal adaptation, in health or 
disease. Tubular segments distal to the site of furosemide's action in the 
thick ascending limb of Henle's loop respond to the increased load of fluid 
and electrolytes with enhanced reabsorption of sodium and sharply 
augmented secretion of potassium (Stanton, Kaissling 1988; Stanton, 
Giebisch 1992; Giebisch, Klein-Robbenhaar, Klein-Robbenhaar, et al 
1993b). Even in the absence of volume contraction, reabsorption of sodium 
by downstream nephron segments is enhanced (Stanton, Kaissling 1988). 
This transport stimulation is associated with a striking amplification of the 
basolateral membrane area of distal convoluted cells, connecting tubule 
cells and principal cells (Kaissling, Stanton 1988). There is also a striking 
increase in the ATPase content of these tubule segments (Garg, Kapturczak 
1987; Scherzer, Wald, Popovtzer 1987). 
1.2.2 Sodium homeostasis in health and in heart failure 
Normal volunteers initially respond to salt loading with weight gain (Rovner, 
Conn, Knopf, et al 1965; Solomon, Atherton, Bobinski, et al 1987) and a rise 
in blood pressure (Guyton 1980; Guyton 1991; Blaustein, Hamlyn 1991). 
Despite continued dietary sodium loading, weight and blood pressure 
stabilise at a new level. When sodium loading is withdrawn, blood pressure 
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and body mass rapidly return to baseline levels. In the same fashion, an 
intravenous sodium load is quickly excreted by the kidneys in health 
(Blaustein, Hamlyn 1991 ). Administration of mineralocorticoids (DOCA) to 
animals and normal volunteers causes initial fluid and salt retention, usually 
without oedema formation followed by an "escape" from the sodium-
retaining effects after approximately 5 days (August, Nelson, Thorn 1958; 
Rovner, Conn, Knopf, et al 1965; Davis, Urquhart, Higgins, et al 1966). 
Patients with heart failure do not "escape" from the sodium retaining effects 
of mineralocorticoid steroids and continue to retain sodium and water 
despite total body sodium excess (Warren, Stead 1944; Chonko, Bay, Stein, 
et al 1977). Spironolactone, a competitive inhibitor of aldosterone, causes 
little or no increase in sodium excretion in patients with cardiac failure 
(Sanders, Melby 1964 ), and avid sodium can persist in patients in whom a 
high sodium intake suppresses aldosterone concentrations (Chonko, Bay, 
Stein, et al 1977). Aldosterone is thus not the only factor responsible for 
sodium retention in heart failure but it plays a permissive role. Davis, 
Holman and Hyatt (1955) and Davis, Howell and Southworth (1958) showed 
that adrenalectomised dogs were able to retain salt and develop oedema in 
two separate models of heart failure provided a small, fixed dose of 
mineralocorticoid replacement was given. 
1.2.3 Response to diuretics in heart failure and health. 
Healthy volunteers, in normal sodium balance, develop a brisk natriuresis 
and diuresis after a single dose of diuretic. This is rapidly followed by avid 
sodium retention until neutral sodium balance has been regained. The 
natriuretic response to a diuretic depends on the level of external sodium 
balance at which it is assessed (Reyes 1991; Reyes, Leary 1992; Reyes, 
Leary 1993a) and is greater during states of salt excess. During regular 
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once-daily administration, the early-after-dosing diuretic effect persists but 
becomes attenuated with respect to the diuresis following the initial dose 
(Loon, Wilcox, Unwin 1989). The increased rate of sodium reabsorption by 
the distal tubule segments is functionally significant because it reduces the 
sodium loss and attenuates the apparent potency of loop diuretics during 
their chronic administration (Stanton, Kaissling 1988; Loon, Wilcox, Unwin 
1989; Wilcox 1991 ; Giebisch, Klein-Robbenhaar 1993a). The compensatory 
sodium reabsorption occurs distal to the site of action of furosemide in the 
loop of Henle where sodium is being lost (Reyes, Leary 1993b). 
Enhanced rates of potassium secretion also follow chronic treatment with 
loop diuretics such as furosemide (Hropot, Fowler, Karlmark, et al 1985; 
Stanton, Kaissling 1988; Ellison, Velazquez, Wright 1989). This transport 
stimulation in the thick ascending limb of the loop of Henle is associated with 
a striking increase in the basolateral membrane area of distal convoluted 
cells, connecting tubule cells and principal cells (Kaissling, Stanton 1988). 
They are also accompanied by a sharp increase in ATPase content of these 
tubule segments (Garg, Kapturczak 1987; Scherzer, Wald, Popovtzer 1987). 
These morphological and functional changes persist and are independent of 
aldosterone and AVP level alterations (Stanton, Kaissling 1988; Kaissling, 
Stanton 1988). Transport stimulation is almost certainly tightly related to the 
maintained increase in sodium delivery and sodium uptake into cells of the 
distal convoluted tubule (Barlet-Bas, Khadouri , Marsy, et al 1990). 
The. observation that thiazides given in conjunction with loop diuretics during 
chronic diuretic therapy exert a significantly larger sodium diuresis than in 
untreated controls, suggests that a key site of enhanced Na+ reabsorption 'iS 
the distal convoluted tubule (Loon, Wilcox, Unwin 1989). 
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In heart failure, a similar, though blunted diuretic and natriuretic response 
occurs after diuretic administration, followed by avid sodium retention. Fluid 
losses are rapidly replaced after diuretic dosing, unless salt and water intake 
are restricted. Although patients with heart failure are traditionally managed 
with both diuretics and salt restriction, it is not clear that this policy is more 
advantageous than diuretics alone, in stable patients. 
1.2.4 The renin-aldosterone-angiotensin system in heart failure 
The renin-aldosterone-angiotensin system (RAAS) is activated at an early 
stage in experimental heart failure and after myocardial infarction in man, 
with circulating concentrations of angiotensin II and renin falling as a stable, 
compensated state is achieved by salt and water retention. Studies of 
untreated heart failure patients (Anand, Kalra, Harris, et al 1991; Remes, 
Tikkanen, Fyhrquist, et al 1991) have shown that concentrations of renin and 
angiotensin II are usually within normal limits until progressive fluid retention 
is evident or until diuretics are administered. 
Plasma concentrations of renin may increase in heart failure in response to 
a number of stimuli, including decreased renal tubular sodium load, 
reduction in renal perfusion pressure or an increase in sympathetic activity. 
Angiotensin II causes proximal tubular sodium reabsorption, contraction of 
the glomerular arterioles (predominantly the efferent arterioles), stimulation 
of secretion of the antidiuretic hormone and aldosterone and alteration of the 
distribution of blood flow in the kidney (Cannon 1977; Navar, Carmines, 
Huang, et al 1987; Cleland, Dargie 1987b). Angiotensin II also stimulates 
thirst via a central effect and has indirect action on sodium retention through 
stimulation of noradrenaline release from nerve endings (Antonaccio, 
Kerwin 1981 ). The hormone facilitates sympathetic nervous system 
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ganglionic transmission (Purdy, Weber 1988), may modulate baroreceptors 
and has vascular remodelling properties. These effects generally favour 
sodium and water retention. It was thus anticipated (supported by animal 
experiments) that blocking the effects of the activated RAAS should correct 
the pathological sodium and water retention found in heart failure. 
Earlier attempts to inhibit the renin-angiotensin system with the aldosterone 
antagonist spironolactone proved to be a disappointment as only 40% of the 
patients with heart failure tested developed a diuresis (Sanders, Melby 
1964) and there was little relationship between the measured level of 
aldosterone and subsequent diuresis with spironolactone. The drug did 
cause increased levels of renin and angiotensin II and prevented the 
hypokalaemia usually associated with loop diuretics. These results suggest 
that aldosterone is not an overriding factor in the promotion of sodium 
reabsorption in man. 
In addition to the sodium-retaining actions on the sympathetic nervous 
system and through the formation of aldosterone, angiotensin II has powerful 
direct tubular sodium retaining properties. Angiotensin converting enzyme 
(ACE) inhibitors prevent the formation of angiotensin II. This results in 
profound suppression of circulating angiotensin II, at least initially, with high 
concentrations of active renin and angiotensin-! and low levels of 
aldosterone. The fall in circulating angiotensin II results in a fall in 
glomerular filtration rate (GFR) and a rise in renal plasma flow (ERPF) due to 
loss of efferent arteriolar constriction by angiotensin II. Filtration fraction 
(GFR/ERPF), usually elevated in heart failure as a consequence of 
decreased renal perfusion, falls towards normal levels. Thus, in theory, ACE 
inhibition should have powerful natriuretic and diuretic actions by improving 
renal haemodynamics and by decreasing levels of aldosterone and 
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angiotensin II. In practice, several investigators have demonstrated that 
patients with heart failure are extremely sensitive to the hypotensive effects 
of ACE inhibitors and antidiuresis and antinatriuresis is the usual acute 
response (Fitzpatrick, Nicholls, lkram, et al 1983; Cleland, Dargie, Hodsman, 
et al 1984; Cleland, Dargie, Gillen, et al 1986; Cleland, Dargie, Robertson, et 
al 1987a; Flapan, Davies, Waugh, et al 1991 a&b; Motwani, Fenwick, Morton, 
et al 1992b). 
In experiments with normal subjects where diuresis is induced by 
furosemide after salt restriction or in the salt replete state, after a brisk 
diuresis, the RAAS is activated and avid sodium retention occurs until 
sodium balance is restored (Wilcox, Mitch, Kelly, et al 1983). Administration 
of the ACE inhibitor captopril does not prevent the antinatriuresis, nor does it 
produce a negative sodium balance, despite suppression of the activated 
RAAS (Kelly, Wilcox, Mitch, et al 1983; Wilcox, Guzman, Mitch, et al 1987). 
ACE inhibition has been shown to enhance diuresis in animals (Harris, 
Navar, Plath 1984; Navar, Carmines, Huang, et al 1987) and MacDonald, 
Craig and Watson (1989) demonstrated enhanced natriuresis but not 
diuresis in salt replete normal volunteers when ramipril was added to 
furosemide, without any effect on urinary prostaglandin E2 or 6-keto 
prostaglandin F1a- Flapan, Davies, Waugh, et al (1991a&b) showed that 
captopril lowered diuresis and natriuresis after 40mg of furosemide in 
patients in heart failure. They also investigated the effect of posture on the 
response to ACE inhibitors in patients with heart failure and showed that 
captopril blunted the diuretic response to furosemide in the supine position 
while the diuresis was decreased by the erect position with no further 
decline when captopril was added. Double-blind studies of total body 
sodium in patients with heart failure did not demonstrate any natriuresis over 
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6-8 weeks of treatment with ACE inhibitors (Cleland, Dargie, East, et al 
1985b; Cleland, Dargie, Robertson, et al 1987c), probably the mechanism 
for correction of hyponatraemia which is reported with ACE inhibitors 
(Packer, Medina, Yushak 1984b). Introduction of an ACE inhibitor leads to 
a reduced renal response to furosemide initially, supported by the finding of 
enhanced phosphate reabsorption, suggesting enhanced proximal tubular 
sodium reabsorption (Cleland, Dargie 1987b). However studies which have 
examined the longer term response to ACE inhibitors in patients with heart 
failure have shown that the impaired ability to excrete a salt load can be 
restored (Volpe, Tritto, Deluca, et al 1992) or diuretic requirements 
diminished, suggesting enhancement of natriuresis (Dzau, Hollenberg 
1984a; Kubo, Nishioka, Nishimura, et al 1984; Mujias, Fouad, Textor, et al 
1984). 
Motwani, Fenwick, Morton, et al (1992b) demonstrated that the initial sodium 
retention may be dose-related, with natriuresis being seen for a few hours 
after 1 mg of captopril and sodium retention after 25mg. They were not able 
to correlate the sodium retention with fall in blood pressure, suggesting that 
this was not the primary factor accounting for the difference in natriuretic 
response to furosemide observed with different doses of captopril. He 
postulated that the lower dose of captopril preserved enough circulating 
angiotensin II to oppose the post glomerular vasodilator effect of high dose 
diuretic and thus preserve GFR, while antagonising some of the tubular salt-
retaining actions of angiotensin II. 
Thus, despite theoretical considerations, the renal interaction of furosemide 
and ACE inhibitors does not appear particularly beneficial at first sight. The 
interaction of chronically administered ACE inhibitors and diuretics has yet 
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to be assessed. 
Some authors have suggested that the long term beneficial effects of 
captopril may relate more closely to tissue levels of renin, aldosterone and 
angiotensin II than to circulating levels of these hormones. Work in 
hypertensive patients has shown that the extent of individual response to 
ACE inhibitors usually depends on basal circulating levels of active renin 
(MacGregor, Markandu, Banks, et al 1982) but elderly patients, theoretically 
having low renin levels, may still respond to ACE inhibitors as monotherapy 
(Pannier, Garabedian, Madonna, et al 1991; Cox, Duggan, O'Boyle, et al 
1989). Several studies in patients with heart failure have failed to 
demonstrate a relationship between baseline renin levels and response to 
an ACE inhibitor (Davis, Ribner, Keung, et al 1979; Packer, Medina, Yushak 
1984a; Packer, Medina, Yushak, et al 1985; Mettauer, Rouleau, Bichet, et al 
1986). The discrepancy between haemodynamic effects and circulating 
levels of ACE inhibitors (Sakaguchi, Chai, Jackson, et al 1988; MacFadyen, 
Lees, Reid 1991) raises the possibility that some of the effects of ACE 
inhibitors are due to local inhibition of the renal angiotensin system, 
supported by the finding in animals that renal ACE activity is profoundly 
suppressed by ACE inhibitor therapy (Veltmar, Gohlke, Unger 1991 ). There 
is some evidence to suggest that the circulating renin-angiotensin system is 
activated in response to acute changes in circulating volume, while the local 
renal "tissue" RAAS is responsible for local renal haemodynamic effects and 
perhaps vascular remodelling. In spontaneously hypertensive rats the fall in 
blood pressure with an ACE inhibitor correlates better with the inhibition of 
the tissue than the circulating renin-angiotensin system (Cohen, Kurz 1982; 
Unger, Ganten, Lang, et al 1984; Weishaar, Panek, Major, et al 1991 ). 
Circulating concentrations of angiotensin II, whilst initially profoundly 
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suppressed by ACE inhibitors, may "escape" in the long term, despite 
continuing clinical benefit, suggesting that there is continued suppression of 
angiotensin II locally in the kidney, as has been demonstrated in rats 
(Kohzuki, Johnston, Chai, et al 1991 ). The precise contribution of the tissue 
and circulating RAAS to diuresis and natriuresis is still debated. 
1.2.5 Atrial natriuretic peptide 
The diuretic and . natriuretic properties of extracts of atrial tissue was 
described by De Bold, Borenstein, Veress, et al in 1981 and subsequently 
atrial natriuretic peptide (ANP) was isolated from the atrial . secretory 
granules responsible. Unlike conventional diuretic agents, ANP suppresses 
the formation of aldosterone, renin, catecholamines and arginine 
vasopressin (AVP) in man (Maack, Marion, Camargo, et al 1984; Samson 
1985; Cody, Atlas, Laragh, et al 1986a). 
ANP stimulates production of cyclic GMP by particulate guanylate cyclase. 
Cyclic G MP is the second messenger which mediates the vasodilatation, 
diuresis and natriuresis (Appel, Dunn 1987; Brenner, Ballermann, Gunning, 
et al 1990; Wilkins, Settle, Needleman 1990). ANP produces a diuresis, 
natriuresis, suppression of renin and aldosterone as well as a fall in blood 
pressure in normal volunteers and in hypertensive patients. Secretion of 
ANP is regulated by atrial stretch. Concentrations of ANP are raised in 
patients with heart failure by as much as ten to twenty times, but the renal 
response to endogenous or exogenously administered ANP is blunted 
(Cody, Atlas, Laragh, et al 1986a; Moe, Canepa-Anson, Armstrong 1992). 
This may be due to receptor down-regulation, decreased receptor affinity or 
sensitivity, renal tubular changes or antagonism by other neuroendocrine or 
renal haemodynamic factors. Honrath, Chong, Wilson, et al (1994) showed 
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that the renal response to ANP infusion is greatly influenced by the sodium 
intake, varying from zero to supranormal. The effect of enhancing renal 
cyclic GMP excretion with ANP on diuretic responsiveness has not been 
studied in heart failure. 
Invasive studies in patients with heart failure with elevated right atrial, 
pulmonary and capillary wedge pressures showed that beneficial 
haemodynamic changes were evident during infusion of ANP with falls in 
these pathologically elevated pressures. In addition there was a significant 
fall in blood pressure and increased renal blood flow (Cody, Atlas, Laragh 
1986a; Molina, Fowler, McCrory, et al 1988). There may be differences 
between the renal and haemodynamic responses to ANP in heart failure. 
Binding of ANP by antibodies and thus inactivation of the peptide resulted in 
significant anti-natriuresis and anti-diuresis in in animal models of heart 
failure, raising the possibility that ANP continues to play a beneficial role in 
heart failure (Awazu, lmada, Kon, et al 1989; Shepperson, Barclay, Bennett, 
et al1991). 
Atrial natriuretic peptide is inactivated by neutral endopeptidase which is 
found in large quantities on the brush border of the renal tubule. Recently 
the introduction of pharmacological agents which antagonise the action of 
neutral endopeptidase and thus prevent degradation of ANP has generated 
intense clinical research. One interesting finding has been that animals with 
elevated basal circulating concentrations of ANP respond to administration 
of neutral endopeptidase inhibitor with more profound diuresis and 
natriuresis than those with normal basal concentrations. There is some 
doubt as to whether this is the case in heart failure (MOnzel, Kurz, Holtz, et al 
1992). In addition, significant quantities of ANP appear in the urine after 
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administration of neutral endopeptidase inhibitors which is not the case 
when infusions of ANP are administered (Trippodo, Gabel, Harvey, et al 
1991 ; Richards, Wittert, Espiner, et al 1991; Suzuki, Hirata, Matsuoka, et al 
1992; MOnzel, Kurz, Holtz, et al 1992). This raises the potential of 
pharmacological manipulation of ANP activity for therapeutic benefit. 
1.2.6 The sympathetic nervous system 
The sympathetic nervous system is activated in heart failure and, in man, 
plasma concentrations of noradrenaline correlate with prognosis (Cohn, 
Levine, Olivari, et al 1984; Rector, Olivari, Levine, et al 1987). Increased 
efferent renal sympathetic nerve activity has major effects on several renal 
functions: it stimulates renin release, constricts the glomerular afferent 
arteriole, alters the pattern of intrarenal blood flow, decreases glomerular 
filtration rate and enhances renal tubular sodium and water reabsorption 
(Cody, Covit, Schaer, et al 1986b; Mancia 1990; DiBona, Sawin 1994). 
These effects, by restoring circulating volume, blood pressure and cardiac 
output, may be both life-saving in states of hypovolaemia and of benefit in 
the early stages of heart failure. By increasing the load on the failing heart, 
however, ventricular function may further decline. 
Although experiments in hypertensive men suggest that lowering 
sympathetic activity with ganglion blocking agents such as guanethidine can 
produce a diuresis, and prior renal denervation can prevent the impaired 
renal excretory responses in animal models of heart failure, sympathetic 
ganglion blockade results in sodium retention in patients with heart failure 
(Gaffney, Braunwald 1962; Gill, Mason, Bartter 1965). a 1-antagonists also 
results in sodium retention, which cannot be reversed by ACE inhibitors 
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(Riegger, Haeske, Kraus, et al 1987b). The acute effects of f3-adrenergic 
blockade are usually detrimental in patients with heart failure and may result 
in sodium retention (lkram, Fitzpatrick 1981; Binkley, Lewe, Lima, et al 1986; 
Shanes 1987; Waagstein, Caidahl, Wallentin, et al 1989; Lang (R) 1990; 
Packer 1992). Pharmacological interruption of the sympathetic efferent 
pathways, despite theoretical advantages, generally results in sodium 
retention in heart failure. 
Administration of isoprenaline to normal rats raises fractional sodium 
reabsorption in the duct to the same level as that seen in salt-deplete rats 
(Honrath, Wilson, Sonnenberg 1991 ). In normal subjects, phenylephrine or 
noradrenaline infusions decrease sodium excretion (Lang, Rahman, Balfour, 
et al 1993a&b), presumably by renal arterial constriction. In patients with 
heart failure however, dobutamine, a synthetic catecholamine which 
stimulates f31, f32 and a1-adrenergic receptors, may increase sodium 
excretion (Leier, Webel, Bush 1977; Leier, Heban, Huss, et al 1978). This 
could be due to increasing cardiac output, as in contrast to dopamine, no 
specific dopamine receptor stimulation or renal vasodilatation occurs. The 
enhancement of systemic pressure may override the effects of local renal 
arterial constriction or alternatively, dobutamine may have less renal 
vasoconstrictive effects that noradrenaline at the doses used in clinical 
practice. Tyramine has been shown to increase sodium excretion in normal 
subjects (Lang, Rahman, Balfour, et al 1993b) suggesting that circulating 
noradrenaline and neuronally released noradrenaline may have opposite 
effects on renal sodium handling in man. 
Furosemide increases sympathetic activity (Attman, Aurell, Johnsson 1975) 
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which may be largely due to volume contraction,however a specific effect on 
adrenergic inhibition or stimulation cannot be excluded. 
1.2. 7 Abnormalities in haemodynamic responses 
The renal consequences of heart failure are a fall in renal blood flow (ERPF) 
and glomerular filtration rate (GFR). The fall in ERPF exceeds the fall in GFR, 
as constriction of the efferent renal arteriole distal to the glomerulus by 
angiotensin II preserves GFR. This results in a rise in filtration fraction 
(GFR/ERPF) and an increase in proximal tubular forces favouring sodium 
reabsorption, as follows: 
a) Efferent arteriolar constriction lowers the hydrostatic pressure in the 
peritubular capillaries. 
b) Plasma proteins are filtered less and thus become more 
concentrated in the blood in the peritubular capillaries. 
c) The combination of diminished hydrostatic pressure and increased 
colloid oncotic pressure favour the return of renal interstitial fluid into 
the peritubular capillaries. 
d) Changes in the intrarenal distribution of blood flow, with diversion 
of blood flow from the outer cortex to the juxtamedullary nephrons, 
may also contribute to sodium retention. 
As heart failure becomes more severe, renal blood flow declines further and 
afferent, rather than efferent arteriolar constriction becomes predominant, 
resulting in a steeper decline in G FA and pre-renal uraemia. ACE inhibitors, 
by releasing the efferent arteriole from the effects of angiotensin II, reduces 
renovascular resistance, but usually result in a decline in G FR. 
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Sodium nitroprusside (SNP) is a powerful arterial and venous vasodilator 
which increases cardiac output by decreasing systemic vascular resistance 
(Berkowitz, McKeever, Croke, et al 1977; Cogan, Humphreys, Carlson, et al 
1980; Franciosa, Silverstein 1982a). It causes accumulation of cyclic GMP 
in the renal papillary collecting tubule (Appel, Dunn 1987) but has variable 
effects on diuresis in animals (Hamet, Tremblay, Pang, et al 1984; Chiu, 
Vemulapalli, Sybertz 1991) and man (Cogan, Humphreys, Carlson, et al 
1980), depending on whether heart failure is present and on the extent to 
which blood pressure falls in response to the SNP infusion. In the intact 
dog, SNP was found to decrease total peripheral resistance and mean 
arterial pressure without increasing cardiac output and at the same time 
resulted in a fall in GFR, ERPF and sodium excretion. Patients with heart 
failure tend to respond to SNP infusion by increasing ERPF and decreasing 
filtration fraction (Cogan, Humphreys, Carlson, et al 1980) although changes 
in sodium excretion are variable. Miller, Fennell, Young, et al (1982) 
reported that SNP increases ERPF but does not alter GFR in heart failure. 
Minute urine flow, total cation excretion and filtration fraction increased and 
renal vascular resistance fell. It is likely that filtration pressure disequilibrium 
exists, because increases in ERPF produced by vasodilator agents are not 
accompanied by increases in GFR (Krakoff, De Guia, Vlachakis, et al 1973). 
These results suggest that the net hydrostatic pressure gradient across the 
glomerular capillary membrane is the primary determinant of G FA in both 
normal men and in patients with congestive heart failure (Cogan, 
Humphreys, Carlson, et al 1980). 
Pressure natriuresis 
As has been mentioned earlier, urine output is dependent on systemic 
arterial pressure (Guyton 1991) and although intrarenal mechanisms can 
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compensate for falls in renal perfusion pressure it is well known that anuria 
develops when the mean systolic blood pressure falls much below 
60mmHg. In addition, there is circumstantial evidence, at least in essential 
hypertension, that the development of hypertension is a compensatory 
response to a reduced ability of the kidney to excrete a salt load, and that 
elevation of blood pressure results in enhanced natriuresis (Guyton 1991; 
Blaustein, Hamlyn 1991 ). Many of the agents used to treat heart failure have 
hypotensive actions (nitroprusside, phentolamine, ACE inhibitors, nitrates, 
prazosin). One could predict that a balance must exist between the benefits 
of vasodilatation on cardiac function and the deleterious effects of excessive 
hypotension on renal perfusion. Clinicians use inotropic agents such as 
dobutamine to restore urine output in patients with heart failure and it has 
been the author's experience that restoring an adequate blood pressure by 
this means is usually successful in restoring the urine output, without the 
need for specific renal artery vasodilatation. For this reason tyramine, 
dobutamine and dopamine were chosen as pressor agents to explore the 
role of elevating the blood pressure on diuresis and natriuresis. 
1.3 Possible methods of restoring diuretic responsiveness 
Possible ways of restoring the renal effects of furosemide in patients with 
heart failure are listed below. In practice, most available treatment 
modalities potentially influence more than one neuroendocrine or circulatory 
system. For example digoxin has actions on baroreceptors, the renin-
angiotensin system, inotropism and renal plasma flow. 
1.3.1: Enhancement of natriuretic factors such as ANP and renal 
prostaglandins and thus counteracting the vasoconstrictor and salt retaining 
actions of arginine vasopressin, the renin-angiotensin system and the 
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sympathetic nervous system. 
1.3.2: Suppression of antinatriuretic systems such as the sympathetic 
nervous system, the renin-angiotensin system and arginine vasopressin. 
1.3.3: Optimisation of renal haemodynamics by improving renal perfusion 
pressure, glomerular filtration rate and renal plasma flow or by correcting the 
pathological elevation of filtration fraction (GFR/ERPF) found in heart failure. 
1.3.4: Improving cardiac output either by inotropic support or by 
vasodilatation. 
1.3.5: By direct inhibition of renal tubular sodium reabsorption. 
1.4 Problems with extrapolating the results of experiments in 
animal models of heart failure to patients 
Various animal models of heart failure exist, including rapid ventricular 
pacing to induce left ventricular failure (with the added advantage of being 
completely reversible), clamping the pulmonary artery or aorta, clamping 
the inferior vena cava, occluding the left coronary artery or the creation of an 
arterio-venous fistula. Whilst these models have many similarities with heart 
failure in man and the animals respond in a similar fashion with salt and 
water retention and neuroendocrine activation, elevation of filtration fraction 
may not occur, despite being characteristic of heart failure in man. Another 
major difficulty experienced with these animal models is reproducibility of 
the experimental results in man. (Experiments which have given rather 
different results in animals and man include the effect of guanethidine on 
natriuresis and the effect of ACE inhibitors on left ventricular hypertrophy). 
Because of these factors, precisely controlled and repeatable studies in 
animal models of heart failure are not a substitute for controlled clinical 
studies of patients. Small pilot studies, with all their limitations, continue to 
have relevance in the management of heart failure. 
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1.5 Objectives 
Diuretic resistance is an important clinical problem in patients with heart 
failure. There are a number of possible mechanisms by which response to 
diuretics could be improved. 
1.5.1 Objectives of the individual experiments 
1.5.1.1: To assess the effect of salt restriction on : 
(a) the diuretic and natriuretic response to furosemide, comparing a sodium 
intake of 20mmol/day with 150mmol/day. 
(b) body mass in heart failure. 
(c) further neuroendocrine activation. 
(d) renal perfusion. 
1.5.1.2: to explore the role of ACE inhibition by captopril on: 
(a) arterial pressure 
(b) renal haemodynamics 
(c) diuresis and natriuresis 
(d) neuroendocrine activation. 
1.5.1.3: to examine the role of increasing cardiac output using a vasodilator 
compared to an inotropic agent to assess the relative importance of arterial 
pressure and cardiac output in the diuretic response to furosemide with 
increases in cardiac output. 
1.5.1.4: to assess the role of digoxin: 
(a) to determine whether it has diuretic or natriuretic effects in heart failure 
(b) to assess its effects on neuroendocrine activation 
(c) to assess its effects on renal haemodynamics 
(d) to assess its inotropic effects 
1.5.1.5: to determine the effect of atrial natriuretic peptide on: 
(a) diuresis and natriuresis. 
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(b) whether any effects correlate with changes in urinary cyclic GMP 
excretion. 
1.5.1.6: to examine the effect on diuretic responsiveness of sympathetic 
nervous system activation using tyramine compared to antagonism with 
phentolamine infusion. 
1.5.1. 7: to determine whether dopamine augments a furosemide induced 
diuresis and if so, whether the effect is seen at dopamine concentrations 
compatible with a renal vasodilator effect alone, or only at pressor 
concentrations. 
1.5.2 To determine the most important mechanism responsible 
for alteration in the renal response to furosemide 
While the author recognises the impossibility of isolating individual systems 
in clinical studies such as these, an attempt has been made to achieve the 
objectives by accurate recording of arterial pressure, renal plasma flow, 
urinary furosemide excretion, urinary cyclic GMP excretion, plasma hormone 
concentrations and urinary electrolyte excretion. It should be possible to 
reach a conclusion about the most important or overriding factor responsible 
for diuretic resistance in heart failure, even if the precise contribution of and 
interaction of the other systems remains obscure. 
1.5.3 To propose appropriate treatment strategies. 
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Chapter 2 Methods 
2. 1 Inclusion criteria 
Patients were invited to participate in studies if they were between the age of 
18 and 80 years, of either sex, requiring maintenance diuretic therapy for 
control of symptoms of heart failure. All had objective evidence of left 
ventricular systolic dysfunction as assessed by echocardiography (fractional 
shortening <20%) or radionuclide ventriculography (ejection fraction <40%). 
Patients with obstructive valvular pathology, hypertrophic cardiomyopathy, 
constrictive pericarditis, frequent or unstable angina pectoris or a history of 
significant ventricular arrhythmia were excluded. Included were patients 
with idiopathic dilated cardiomyopathy, left ventricular failure as a 
consequence of ischaemic heart disease or heart failure secondary to 
valvular regurgitation. Patients with significant renal dysfunction (elevation 
of serum creatinine to greater than 200mmol/l), or hepatic dysfunction 
(elevation of aspartate transaminase, alkaline phosphatase or total bilirubin 
by more than twice the upper limit of normal) were excluded. All patients 
provided written informed consent. 
2.2 . Study design (Figure 2. 1) 
Studies were conducted on the day surgery ward at the Hammersmith 
Hospital. All patients acted as their own controls and were studied on a 
minimum of two occassions. All patients were interviewed by the senior 
hospital dietician and were provided with individual diet sheets to follow and 
diaries to complete during the three day period prior to each study. Diet 
sheets were collected during each study day and the details checked with 
the patient by the hospital dietician. The prescribed diet contained 1 OOmmol 
of sodium and 40mmol of potassium per day for the three days prior to each 
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study (with the exception of the study investigating the effect of sodium 
restriction on diuresis, where 3-day diets of 150mmol of sodium or 20 mmol 
of sodium were adhered to in random fashion). Caffeine-containing 
beverages and nicotine were avoided on study days. 
Usual therapy was omitted on study days. Patients partook of a light 
breakfast and fluids (excluding caffeine) at least two hours prior to studies 
and subsequently fasted until completion of the study. They w~re studied 
supine, over four hour periods, and hourly identical intravenous boluses of 
furosemide were administered to maintain a constant, moderate diuresis. 
Each patient received identical doses of furosemide on all study days, but 
individual furosemide requirements varied depending on the patients' usual 
diuretic requirements. 
Plastic cannulae were placed in antecubital veins bilaterally for infusions 
and sampling respectively and initial loading boluses of sodium hippurate 
0.8g (PAH) and furosemide 5mg were given. PAH was subsequently 
infused at 30mg/min for the duration of the study. Steady state was 
assumed to have occurred after 90 minutes of PAH infusion, when the first 
blood samples for plasma PAH were collected. After 30 minutes, patients 
passed urine and the study began. Further furosemide boluses were given 
at hourly intervals (time 0, 1, 2 and 3 hours) after each urine collection. The 
dose was constant for each patient for each study and timepoint, .but varied 
between patients, depending on their usual diuretic requirements. Our aim 
was to achieve a steady diuresis of 100 - 300mllhour and a preliminary 
assessment was made prior to the.studies. Patients were brought to the day 
ward and reclined in the same chairs as were used for the studies 
subsequently. Hourly boluses of furosemide were administered 
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intravenously and urine output measured. Urinary losses were replaced 
orally each hour, with allowance made for insensible losses, to a maximum 
of 200mls per hour. The initial urine sample was measured for the purpose 
of accurate volume replacement but discarded. Hourly urine volume was 
measured using graduated cylinders and recorded. After four urine 
collections had been made, lines were removed, patients were examined 
and discharged. 
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Figure 2.1: Study design 
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2. 3 Measurements 
2.3.1 Hourly urine collections 
Urine was saved for measurements of: 
2.3.2 Blood samples 
cyclicGMP 
electrolytes: sodium 
potassium 
chloride 
urea 
creatinine 
magnesium 
phosphate 
furosemide 
para-aminohippurate (PAH) 
inulin (for captopril study only). 
The following electrolytes were analysed at one, two and three hours after 
dosing: 
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2. 3. 3 Plasma hormones 
Three or more of the following were measured in each study: 
atrial natriuretic peptide (ANP) 
active renin concentration (plasma renin) 
noradrenaline 
adrenaline 
aldosterone 
arginine vasopressin (A VP) 
angiotensin II (A-ll) 
Effective renal plasma flow was calculated from para-aminohippurate (PAH) 
clearance in all studies. After a bolus of 800mg, an infusion of 30mg/min was 
commenced. After 90 minutes, hourly blood and urine samples were 
collected for PAH estimation. 
Glomerular filtration rate was calculated from inulin clearance in the 
captopril study only. After a bolus of SOmg/kg, inulin was infused at 
32.5mg/min. After 90 minutes, hourly urine and blood samples were 
collected for inulin estimation. 
2.3.4 Haemodynamic measurements 
Blood pressure was measured at 30 minute intervals using a mercury 
sphygmomanometer for the salt and captopril studies. 
For the remaining studies blood pressure was measured at 15 minute 
intervals using an automated oscillomanometric device ("Dynamap-
Criticon"). 
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Heart rate was monitored continuously from the electrocardiogram. 
Effective renal plasma flow was estimated from clearance of sodium 
hippurate 
(PAH) using the formula ERPF = urine flow (mls/min) x urinary PAH 
concentration p I a s m a P A H 
concentration 
Although the original equation referred to renal arterial plasma, the 
concentration in systemic venous plasma is used in clinical practise as the 
concentrations are virtually identical. 
Glomerular filtration rate was estimated from clearance of inulin 
(captopril study) or clearance of creatinine using the formula 
inulin clearance = urine flow rate x urinary inulin concentration. 
plasma inulin concentration. 
Changes in ejection fraction and cardiac index were assessed at 15 
minute intervals by thoracic bioimpedence using the "Bomed NICOM3" (an 
automated ZCG-related non-invasive technique for measurement of cardiac 
output by means of electrical impedance). A detailed description of the 
technique follows (2.8.1 ). 
2. 4 Interventions 
All the studies began with a 30 minute run-in period to ensure that patients 
could empty their bladders before the start. During the first hour there were 
no active interventions to allow steady state clearance of PAH and inulin to 
be achieved. Agents with a relatively long half life (captopril and digoxin) 
were administered at the start of the second hour. The remaining infusions 
(nitroprusside, dobutamine, ANP, tyramine, phentolamine and dopamine) 
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took place during the second and third hours only. The exception was the 
salt study, where the intervention consisted of the normal or salt deplete diet 
which had been followed for the preceeding 3 days. Studies were all at 
least 48 hours apart. A steady, moderate diuresis was maintained by hourly 
intravenous furosemide injection. This hourly dose was arrived at after an 
initial assessment on the ward when hourly boluses were administered in 
incremental fashion starting at 3mg if the patient was taking 40mg of 
furosemide per day, 4mg if the daily dose was 80mg and 5mg if the daily 
dose was 120mg or more. The final dose chosen was that which resulted in 
two consecutive hourly urine outputs of between 100 and 300m I. 
Agents were infused at very low dose for one hour, then increased 
incrementally at five minute intervals to a predetermined maximum, that rate 
being continued for the duration of the following hour. This sequence was 
not followed with digoxin, because of its relatively long plasma half life, nor 
with captopril as it was administered orally. Thus digoxin was administered 
intravenously over 30 minutes and captopril was taken orally at the 
beginning of the second hour. 
A variety of agents were compared with respect to the effect they had on a 
furosemide induced diuresis. 
a) Salt restriction versus normal salt intake. 
b) Acute-on-chronic suppression of angiotensin converting enzyme with 
captopril. 
c) Atrial natriuretic peptide infusion. 
d) Stimulation the efferent sympathetic outflow with tyramine or blockade 
with phentolamine. 
e) Increasing cardiac output using an inotropic agent (dobutamine) as 
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compared to a vasodilator (sodium nitroprusside). 
f) Comparing the effect of dobutamine with that of dopamine, which 
stimulates the renal dopamine receptor. 
g) Assessing the effect of digoxin on diuresis and natriuresis. 
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Figure 2.2 Study design (SALT) 
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2.4.1 The effect of dietary sodium restriction on diuretic 
responsiveness to frusemide (Figure 2.2). 
Patients were studied on two occasions, but the two study days were 
preceeded by 3 days of 150mmol of sodium/day (normal sodium intake) or 
three days of 20mmol of sodium/day (low sodium diet) in random fashion. 
The following measurements were made: 
a) Heart rate and blood pressure were measured at half hourly intervals 
b) Urine volume, electrolytes, PAH and cyclic GMP were measured at 
the end of each hour. 
c) Plasma PAH was measured at the end of each hour. 
d) Plasma electrolytes were measured at 0, 2 and 4 hours. 
e) Active renin concentration, argenine vasopressin, noradrenaline, 
adrenaline and atrial natriuretic peptide concentrations were 
measured at 0, 2 and 4 hours. 
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Figure 2.3 Study design (Captopril} 
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2.4.2 The effect of maximal suppression of angiotensin 
converting enzyme on diuretic responsiveness to intravenous 
furosemide (figure 2.3) 
Patients were asked to adhere to a diet containing 1 OOmmol of sodium and 
40mmol of potassium per day for the three days prior to each study. All had 
been prescibed an ACE inhibitor for at least 3 months and. this was 
substituted for captopril 12. 5mg tds for at least 2 weeks prior to the study. 
Patients omitted their usual medication on the morning of each study but in 
addition omitted three doses of captopril prior to each study to allow 
circulating angiotensin II concentrations to return to baseline. In addition to 
infusion of PAH, inulin was administered as a bolus (50mglkg) then infused 
at 32.5mg/min to calculate glomerular filtration rate from inulin clearance. At 
the end of the first hour of the study, captopril 12.5mg or matching placebo 
was given in random fashion. 
The following measurements were made: 
a) heart rate and blood pressure at half hourly intervals. 
b) urine volume, electrolytes, PAH, cGMP and inulin 
c) plasma PAH and inulin 
d) electrolytes and haematocrit at 0, 1, 2, 3 and 4 hours. 
e) plasma hormones at 0, 1, 2, 3 and 4 hours (aldosterone, angiotensin 
II and active renin concentration). 
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Figure 2.4. Study design (Dobutamine, nitroprusside) 
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2.4.3 The effect of agents which improve cardiac performance 
on the diuretic response to furosemide (figure 2.4) 
Patients adhered to the standard diet as set out above. PAH was infused for 
the duration of the study and intravenous furosemide was injected at hourly 
intervals. After the first hour, infusion of sodium nitroprusside, dobutamine or 
normal saline was commenced, in random fashion and continued over the 
following two hours. 
Sodium nitroprusside was infused at 0.2J1glkg/min during the 2nd hour then 
increased incrementally at 5 minute intervals during the 3rd hour to a 
maximum dose of 0.6J1glkg/min. 
Dobutamine was infused at 1J1g/kg/min during the 2nd hour then increased 
incrementally at 5 min intervals during the 3rd hour to a maximum of 
1 OJ1g/kg/min. 
Placebo (normal saline) was infused at 30mllhour during the 2nd hour then 
at 60mllhiur for the 3rd hour. 
The following measurements were made: 
Heart rate and blood pressure 
Cardiac index, jection fraction, stroke volume and thoracic fluid 
index. 
Urine volume, electrolytes, PAH, cGMP and furosemide. 
Plasma PAH 
Plasma electrolytes and hormones (atrial natriuretic peptide, 
noradrenaline, adrenaline and active renin concentration) at 1 , 2 and 
3 hours. 
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Figure 2.5. Study design (Digoxin) 
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2.4.4: The effect of intravenous digoxin infusion on a furosemide 
induced natriuresis and diuresis (figure 2.5) 
Patients adhered to the standard diet and had PAH infused. At the end of 
the first hour, digoxin 500pg was infused over 30 mins. 
The following measurements were made: 
a) heart rate and blood pressure 
b) urine volume, electrolytes, PAH, cGMP and furosemide. 
c) plasma PAH 
d) plasma electrolytes and hormones (atrial natriuretic peptide, active 
renin concentration, noradrenaline and adrenaline) at 1, 2 and 3 
hours. 
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Figure 2.6. 
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2.4.5: The effect of atrial natriuretic peptide (ANP): Figure 2.6. 
Patients adhered to the standard diet and had hippurate infused. At the end 
of the first hour, ANP infused at 0.05 meg/kg/min for an hour and increased 
at 5 minute intervals incrementally to 0.15mcg/kg/min for the third hour was 
compared with placebo (normal saline). 
The following measurements were made: 
a) heart rate and blood pressure 
b) cardiac index, ejection fraction, stroke volume and thoracic fluid 
index. 
c) urine volume, electrolytes, PAH, cGMP and furosemide. 
d) plasma PAH 
e) plasma electrolytes and hormones (atrial natriuretic peptide, active 
renin concentration, noradrenaline and adrenaline) at 1, 2 and 3 
hours. 
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Figure 2. 7. Study design (Tyramine, phentolamine) 
Tyramine, ~_lo_w_-,..--_h_ig_h---1.1 phentolamine infusion 
PAH infusion 
_____________ ___,.,,... 
Furosemide ./ ./ ./ ./ ./ 
I I I I 
-30 0 1 2 3 4 
m hours 
Urine 
collections 
* * * * * 
BP, HR + BP 
1/2 hourly 
Electrolytes 
ANP, renin 
noradrenaline, 
adrenaline 
PAH 
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2.4.6 The effects of sympathetic activation and inhibition on 
diuretic responsiveness (figure 2. 7) 
The study was identical to the preceeding one apart from the interventions: 
Tyramine or phentolamine were infused at 1 meg/kg/min from the begining to 
the end of the 2nd hour, then increased at 5 minute intervals incrementally to 
a maximum of 1 Omcg/kg/min for the 3rd hour, or placebo (normal saline) 
infused at 30ml/hour during the 2nd hour and 60ml/hour during the 3rd 
hour. Treatments were given in random fashion on 3 separate occassions, at 
least 48 hours apart. 
The following measurements were made: 
heart rate and blood pressure 
cardiac index, ejection fraction, stroke volume and thoracic fluid 
index. 
urine volume, electrolytes, PAH, cGMP and furosemide. 
plasma PAH 
plasma electrolytes and hormones (atrial natriuretic peptide, active 
renin concentration, noradrenaline and adrenaline) at 1, 2 and 3 
hours. 
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Figure 2.8. Study design (Dobutamine, ·dopamine) · 
I low high Dopamine, I dobutamine infusion 
PAH infusion 
..... 
Furosemide ./ ;/ ./ ./ ./ 
I I I. I 
-30 0 1 2 3 4 
m hours 
Urine 
collections 
* * * * * 
BP, HR + BP 
1/2 hourly 
I Electrolytes 
ANP, renin 
PAH 
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2.4. 7 The effect of a dopamine receptor agonist on diuretic 
responsiveness (figure 2.8) 
The study followed the same design as the previous two, with interventions 
consisting of dopamine or dobutamine infused at 1JJg/kg/min during the 
second hour and increasing incrementally at 5 min intervals to a maximum 
of 1 OJJg/kg/min during the 3rd hour, or placebo (normal saline) infused at 
30ml/hour for the 2nd hour and at 60ml.lhour for the 3rd hour. 
Measurements were as in the previous studies, excluding measur!3ment of 
catecholamines. 
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2. 5 Analysis of samples 
2.5.1 Electrolyte analysis. The following kit manufacturers, 
methodological codes and analysers were used for plasma sample 
analysis: 
Analyte Kit man. 
Mg Wako 
Cl Chemlab 
P04 Bayerdiag 
Na Bayer diag 
K Bayer diag 
Urea Bayer diag 
Great Bayerdiag 
Urine sample analysis: 
Na Beckman 
K Beckman 
Meth.code 
999-83909 
proprietary 
SG4-0004J81 
SG4-0033J81 
SG4-0034J81 
SG4-0001J81 
SG4-0011 B83 
proprietary 
proprietary 
Analyser 
RA-XT (Technicon) 
CCM 1 chloride meter 
(Chemlab Sci Equipt) 
SMAC-2 T echnicon 
SMAC-2 Technicon 
SMAC-2 T echnicon 
SMAC-2 Technicon 
SMAC-2 T echnicon 
E2A ISE analyser 
(Beckman) 
E2A ISE analyser 
(~eckman) 
Magnesium, chloride, phosphate, urea and creatinine were assayed as 
blood was. 
Assays were kindly performed by Dr Jeremy Beacham, Mr John Meek and 
Mr Andrew Mashford in the chemical pathology laboratory, The Royal 
Postgraduate Medical School, London. 
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2.5.2 Hormonal analysis 
2.5.2.1 ANP 
Plasma atrial natriuretic peptide was measured after pre-extraction from 
plasma by radioimmunoassay (Richards et al; 1987). Blood was collected in 
chill.ed tubes containing EDTA and aprotinin and centrifuged at 3000rpm 
within 10 minutes of collection. Samples were stored at -80 Oc until assay 
by Dr JJ Morton's team at the MAC laboratories in Glasgow. In brief, ANP 
was extracted from 1-4ml of plasma on C18 reverse phase columns ('Sep-
Pak', Waters Associates). Standard solutions were prepared by serial 
dilution of synthetic alpha-ANP in Buffer A from 100 to 0.4pg/tube. 1 OOpl of 
the sample, 1 OOpl of the antibody at a dilution of 1/10 000 and 2pg 1251-
alpha hANPin 50pl of the buffer, were incubated at 40C for 24 hours. All 
assays were set up in duplicate. Non-specific binding of radioligand was 
estimated for standard solutions, plasma and plasma extracts by the addition 
of excess synthetic alpha-hANP (1 Ong) to duplicate samples and also by 
incubation and separation in the absence of antiserum. Non-specific binding 
in both standard solutions and plasma extracts was consistently less than 
4%. Sensitivity of the assay was 2pg/ml of plasma. Intra-assay and inter-
assay variations were 3.6% and 1.4% respectively. 
2.5.2.2 Methodology for aldosterone assay 
Aldosterone was kindly assayed by Dr Jeremy Beacham, Department of 
Chemical Pathology, Royal Postgraduate Medical School. 
Plasma aldosterone was measured using a commercial solid-phase (coated 
tube) radioimmunoassay (Count-A-Coat Aldosterone kit; DPL, (UK) L TO). 
Venous samples were collected in chilled tubes on ice containing lithium 
heparin and spun down in a cooled centrifuge within 10 minutes of 
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collection. Cross-reactivity to other compounds was extremely low, as set out 
in the table below. Compounds listed as 'NO' were below the detection limit 
of the assay, even when assayed at great concentrations. Intra-assay 
variation was less than 8.3%, sensitivity was 15pg/ml and the normal range 
for recumbent subjects on a fixed sodium intake is <25ng/1 OOml of plasma. 
Table 2.1 Cross-reactivity of the aldosterone assay 
Aldosterone 100% Estriol NO 
Androstendione NO Estrone NO 
Androsterone 0.0005% Fludrocortisone NO 
Corticosterone 0.002% Prazosin HCI NO 
18-0H-Corticosterone 0.033% Prednisolone 0.00003 
Cortisol NO Prednisone NO 
Cortisone 0.0003% Pregnenolone NO 
11-Deoxycorticosterone 0.006% Progesterone 0.007% 
11-Deoxycortisol 0.0004% 17a-Hydroxyprogesterone NO 
Dexamethasone 0.00005% Spironolactone 0.06% 
DHEA 0.0005% Testosterone NO 
Estradiol NO 
2.5.2.3 Methodology for plasma renin concentration 
Samples were kindly assayed by Dr JJ (lan) Morton's team at the Medical 
Research Council laboratories in Glasgow. Blood was collected in chilled 
tubes containing disodium EDT A as anticoagulant and separated within 1 0 
minutes. Plasma was stored at -80 degrees until assay. No converting 
enzyme or angiotensinase inhibitors were added. Plasma active renin 
concentration was measured by a modification of an antibody trapping 
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technique in the presence of added excess renin substrate (Miller, 1980). 
Radioimmunoassay of angiotensin-! generated during the incubation of 
plasma and excess ox renin substrate was performed. Results for its assay 
were calibrated with the International Standard Renin. In order to measure 
active renin concentration, ox renin substrate was included in the reaction 
mixture at concentrations sufficient to ensure zero-order reaction kinetics 
with respect to substrate. Reaction velocity was therefore proportional to 
renin concentration. External calibration against the International Standard 
Renin allowed results to be expressed in enzyme concentration units rather 
than velocities. Units are expressed in f.JU renin/ml plasma as derived from 
a calibration graph constructed using pure human renin. The intra-assay 
variation was 3.4% with a sensitivity of 1/)U/ml of plasma. The normal range 
for recumbent subjects on a fixed sodium intake is <40/)U/ml. 
Buffers and reagents: 
a) Incubation buffer: 3 mol/1 Tris/HCI, pH 6.9, containing O.OOSmol/1 
disodium ethylenediamine tetraacetate (EDTA). 
b) Radioimmunoassay buffer: 0.25 mol/1 Tris /HCI, pH 7.4, containing 
0.01% human s rum albumin (HSA). 
c) lieS-angiotensin I (National Institute for Biological Standards and 
Control, London House) was used as an antigen for antibody · 
production, as a routine radioimmunoassay standard, and in the 
calibration of reaction velocity with the International Standard Renin. 
d) International Reference Standard Renin was obtained from the 
National Institute for Biological Standards and Control, London. 
House standard human kidney renin was prepared from kidneys 
obtained post mortem. 
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20J1I of plasma was incubated at 370 C for 30 minutes with 20J1l of a 
premixed solution consisting of ox or sheep renin substrate, incubation 
buffer and antibody at appropriate trapping concentration. This 
concentration is unique to each antibody and was determined by formal 
titration as described. Abnormally high or low renin samples were assayed 
by longer incubations or in dilution, respectively. The enzyme reaction was 
terminated by dilution and cooling, obtained by addition of SOOJ.II of ice-cold 
buffer followed at once by trace 125 !-angiotensin I (Spg, 5000-1 OOOOcpm). 
The radioimmunoassay for angiotensin I was completed by further 
incubation at 40 C for 18 hours. Separation of free and bound ligand was 
achieved by addition of Dextran-coated charcoal. Standard curves for 
angiotensin I were prepared by serial dilution of lieS -angiotensin I in 20J1I 
buffer from 200-3.1 pg per tube in duplicate. Pooled human plasma was 
used as assay quality control. Control high and low renin samples were run 
with each assay. 
2.5.2.4 Methodology for angiotensin II estimation (A-ll) 
Samples were kindly assayed by Dr JJ Morton's team at the MRC 
laboratories in Glasgow. Plasma angiotensin II was measured by 
radioimmunoassay using pre-extraction of angiotensin II from plasma prior 
to assay (Morton & Webb1985). The normal range for recumbent subjects on 
a fixed sodium intake was 2-12pg/ml plasma. Venous blood samples were 
taken into chilled tubes containing EDTA I o-phenanthroline to inhibit 
converting enzyme and angiotensinase enzymes. The samples were 
extracted by passage through Sep-pak C18 cartridges (Waters Associates, 
MA, USA). The cartridges were pretreated with methanol (Sml) and then 
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water (5ml). Plasma (5ml) was then passed through the cartridge under 
gentle vacuum. After washing with water (5ml), angiotensin II was eluted 
from the column with 20% aqueous methanol (2ml). The extracts were dried 
and redissolved in Tris buffer (50mmol/l; pH 7.5) for assay. Sensitivity of the 
assay was 2pg/ml of plasma with an intra-assay variation of 10%. 
2.5.2.5 Methodology for PAH estimation 
Samples were kindly assayed by Dr JJ Morton's team at the MAC 
laboratories in Glasgow. Plasma and urinary PAH were measured using the 
colourometric method of Waugh and Beall (1974), incorporating a buffered 
protein-precipitating reagent of optimal and controlled pH for the formation of 
coloured product. The buffered protein precipitant of pH 1.4 was prepared by 
dissolving in distilled water 129.0g of 1.0M dichloroacetic acid, 57.0g of p-
toluenesulfonic acid and 34.0g of NaOH ellets to a 1 ml volume. One 
percent p-dimethylaminobenzaldehyde-57% ethanolic solution was 
prepared by dissolving 5g of highly purified p-dimethylaminobenzaldehyde 
in 300ml of 95% ethanol and distilled water was added to yield a final 
volume of 500ml. The standard solution was prepared by dissolving free p-
aminohippuric acid in distilled water at a concentration of 1 OOmg/1 OOml. 
A preliminary dilution was performed where neccessary to attain a 
urine/plasma ratio near 1.0 and an estimated plasma concentration below 
6mg/1 OOml. One volume of plasma or urine was mixed with 10 volumes of 
the buffered 1.0M DCA-0.3M TSA reagent. After standing for a few minutes, 
the protein-containing samples were centrifuged. Aliquots of the 1:11 
supernatants or samples were then mixed with an equal volume of 1 %p-
dimethylaminobenzaldehyde-57% ethanolic reagent. After 5 or more 
minutes standing, absorbances are measured in a photometer at 450nm, 
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using the reagent blank to set the photometer at zero absorbance. 
Concentrations of PAH were calculated from the measured absorbances, 
with reference to a standard working curve. Sensitivity of the assay was 
1 mg/1 OOml of plasma and 50mg/1 OOml of urine with an intra-assay variation 
of 6.2%. 
Effective renal plasma flow was calculated from the formula UPAHV 
APAH- VPAH 
where UPAH =the urine PAH concentration and V =urine flow rate and 
APAH- VPAH =the arterio-venous PAH concentration difference. 
About 90% of PAH is extracted in a single pass across the renal vasculature 
in normal humans when plasma PAH is allowed to range from 1-6mg/dl. 
Under these circumstances the renal venous PAH concentration is low, and 
neglecting this term introduces an error of only about 10% in the calculation 
of renal plasma flow. Although serial samples were not tested, 90 mins were 
allowed for equilibration of the PAH at which point steady state was 
anticipated. 
2.5.2.6 Methodology for inulin estimation 
The assays were kindly performed by Dr JJ Morton and his laboratory staff. 
Plasma and urinary inulin were measured using a slight modification of the 
method of Higashi and Peters (1950). In brief, 2.5 ml of water was mixed 
with 0.5 ml of plasma or urine. 1.3 ml CdS04 solution (prepared by 
dissolving 17.34g CdS04,8H20 in 84.6ml of 0.5mmolll sulphuric acid and 
diluting to 500ml with water) and 0.5ml of NaOH solution (1.1 mmol/1) were 
added sequentially and mixed. After standing for 5 minutes the sample was 
centrifuged and 1 ml of the supernatant or standard solution was transferred 
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to a test tube with a ground glass joint, to which 1.5 ml of resorcinol was 
added and mixed. Ferric chloride 1.5 ml was then added and mixed. 
Samples were held in a water bath for 40 minutes at 80oC then cooled and 
read against the reagent blank within 20 minutes. Sensitivity of the assay 
was 20mg/l of plasma and 200mg/l of urine with the intra-assay variation 
3%. 
2.5.2.7 Plasma vasopressin 
Plasma vasopressin was measured by radioimmunoassay of pre-extracted 
plasma. The assays were kindly performed by Dr JJ Morton and his 
laboratory staff. 
Blood samples for AVP measurement were collected in chilled tubes 
containing heparin and aprotinin and separated within 1 0 minutes. Plasma 
samples were stored at -aoOc until assay. AVP was extracted from the 
plasma using prepacked C1a reverse-phase cartridges (Sep-pak, Waters 
Associates, Milford, Mass., USA). Cartridges were initially washed with 
methanol (5ml) followed by distilled water (5ml). Plasma (3-5ml) was applied 
to the cartridge under gentle vacuum followed by washing with 1% acetic 
acid (5ml). AVP was eluted from the column by washing with methanol 
(2ml). The methanol extracts were dried under a stream of air and the dried 
extracts dissolved in 50mmolll Tris pH7.4 for assay. A specific AVP 
antiserum was raised in New Zealand white rabbits by immunization with 
AVP conjugated to bovine thyroglobulin. Standard AVP (International 
Institute for Biological Standards and Control) or unknown was incubated 
with AVP antiserum at a final dilution of 1 :75 000 and 1251-AVP (0.5pg, New 
England Nuclear, Dreich, West Germany) for 48 hours at soc. Bound from 
free A VP was separated using dextran-coated charcoal. The inta-assay 
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variation was 6.1% and values for normal recumbent subjects after overnight 
fluid restriction are 0.2-1.0pg/ml plasma. (Morton, Connell, Hughes, et al 
1985b). Sensitivity of the assay was 0.1 pg/ml of plasma. 
2.5,2.8 Plasma noradrenaline and adrenaline 
Plasma noradrenaline and adrenaline were extracted from plasma and 
assayed by high performance liquid chromatography and electrochemical 
detection after the method of Goldstein, Feuerstein, lzzo, et al (1981 ). The 
assays were kindly performed by Dr JJ Morton and his laboratory staff. 
Venous samples were collected in chilled glass tubes with heparin and 
separated within 1 0 minutes. Plasma samples were stored at -8oOc until 
assay. The reagents and apparatus for liquid chromatography with 
electrochemical detection (LCED) were all commercially available. 
For assay of plasma catecholamines, 1-1.5ml of freshly thawed plasma was 
added to 25mg acid-washed alumina and SOJJI of of SmM sodium 
metabisulphite in a 4ml plastic tube. To this was added SOJJI of 1 Ong/ml 
DBHA, the internal standard, and 400 JJI of 1M Tris-2gm% EDT A which had 
been adjusted with HCI to a pH of 8.6. The sample was shaken for 10 
minutes, centrifuged, and the supernatant discarded. The alumina was 
washed twice with 1.5ml of 0.2%tris/EDTA, pH 8.1 and the catecholamines 
then desorbed with 1 OOJJI of 0.1% acetic acid containing 0.1 mM sodium 
metabisulphite. The tube was shaken on a vortex mixer for 10 seconds and 
in order not to inject particles of alumina, was spun in a microcentrifuge and 
the supernatant transferred to an empty plastic tube. 40JJI of the supernatant 
was analysed using a Waters automated HPLC system for catecholamine 
analysis with electrochemical detection. 
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Recovery was calculated from the ratio of DHBA peak heights in the two 
injections, since 500pg of DHBA had been added to the plasma sample, and 
50 of the 1 OOpl of solution used to elute the catecholamines had been 
injected. The concentrations of noradrenaline and adrenaline were then 
calculated by dividing the peak adrenaline or noradrenaline height by the 
recovery, multiplying by 500 and dividing by the peak height for the 
corresponding 250pg standard, with the results expressed in pg/ml. 
Recoveries from the alumina extraction averaged about 65%. 
The assays were kindly performed by Dr JJ Morton and his laboratory staff. 
Sensitivity of the assay was 0.1 nmols/1 of plasma for both adrenaline and 
noradrenaline with an intra-assay variation of 5.3% and 5. 7% respectively. 
2.5.2.9 Urinary Cyclic GMP 
Guanosine cyclic monophosphate (cGMP) was assayed by 
radioimmunoassay, kindly performed by Dr Jane Kirk and her laboratory 
assistants in Dr Martin Wilkins's laboratory at the Royal Postgraduate 
Medical School. A commercial antibody to rabbit cGMP from Sigma 
Chemical Co was used as the radioligand. 5pl of urine (or appropriate 
dilution; 1 :1, 1 :1 0 or 1 :50) was incubated overnight in 300pl sodium acetate 
buffer (pH 5.9) with primary antibody (final titer 1 :75 000), goat antirabbit 
antibody (final titer 1 :12 500) and radioligand ( 1 0 OOOcpm). The following 
day, each tube received 2ml of distilled water (40C) and was centrifuged at 
3000 rpm for 30 minutes. The supernatant was discarded and the pellet 
counted by automatic gamma counter. The limit of detection of the assay 
was 0.25 pmol/tube with intra-and interassay variability of 6% and 14% 
respectively. There was no crossreactivity with cyclic AMP (Wilkins, Settle, 
Needleman 1990). 
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2.5.3 Urinary concentrations of furosemide 
Furosemide concentrations were determined using a spectro-fluorimetric 
HPLC method. These assays were kindly performed by Mr Faruq 
Noormohamed in Prof Landt's .laboratory at the Westminster Hospital. 
Internal standard (bumetanide, 250ng) was added to 0.25ml urine sample 
which was subsequently made up to 1 ml with distilled water. The samples 
were mixed and centrifuged at 6000 rpm to remove any particulate matter. 
The supernatent was injected (30tJI) via an autosampler (WISP 71 OB, 
Waters Millipore, Milford, Mass.) on to a 25 em mixed alkyl-cyano bonded 
reverse phase column (Sherisorb 5J.1 ODS/CN;PhaseSep, Deeside, UK). 
The peaks were eluted with an isocratic buffer (0.1 M H3 P04: Acetonotrile; 
60:40, pH 3.5 with NaOH) pumped at 1 ml/min. Furosemide (5.5 min) and 
bumetanide (8.5 min) peaks were detected with a Kratos FS970 fluorimeter 
(Applied Biosystems, Manchester UK; excitation wavelength 220nm, 
emission cut-off at 379nm) and quantified with an integrator (model SP4270, 
Spectra Physics, San Jose, California.) using peak height ratios. The urinary 
furosemide curve was linear from 150 ng/ml to 5000 ng/ml with an intra-
assay and inter-assay coefficient of variation of 1 and 7% respectively. The 
minimum detection limit of the assay was 40ng and the minimum 
quantifiable limit was 1 OOng. With the exception of patients on nifedipine, 
whose urine samples exhibited multiple peaks, none of the other drugs 
administered concomitantly interfered with determination of furosemide. 
2. 6 Statistical analysis of data 
A visual impression of the data was displayed graphically using means with 
error bars representing ±1 standard error of the mean (S. E. mean). 
The data was tested for normal distribution using the Kolmogorov-Smirnov 
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test for goodness of fit (Conover 1971 ). Without exception the data was not 
normally distributed, thus non-parametric tests were used. The Friedman 
test for analysis of variance was used to test significance of any differences 
between groups at different time points where time points and factor levels 
(active and placebo) were regarded as within-subject factors. Differences 
between time points were analysed using Wilcoxon matched pairs signed 
ranks tests. All probabilities were two-tailed. One-tailed t-tests were 
avoided as there was a greater likelihood of introducing a Type 1 error. 
Values of p<0.05 were considered significant. Data was imput to a computer 
database and analysed using Statview SE software and Apple Macintosh. 
Mrs Julie Jeacock's help with revision of the statistics is gratefully 
acknowledged (Senior Statistician, Trafford NHS Trust). 
2. 7 Ethical and safety considerations 
All studies were approved by the research and ethics commitee of the 
Hammersmith Hospital. Informed written consent was obtained from all 
patients. 
It was clearly stated that the studies were unlikely to be of direct benefit to 
the patients. In addition it was made clear that the studies would be 
terminated at any stage, at the patient's request, in the event of discomfort, 
chest pain, breathlessness, dizziness, or indeed any other symptom. No 
patient requested that a study be stopped, but the infusion rate was 
decreased in several patients, in accordance with the protocol, when heart 
rate or arterial pressure rose or fell above or below the predetermined limits 
set for each patient. 
The main potential dangers involved in these studies are secondary to the 
inotropic and chronotropic effects of adrenergic agonists, with the risk of 
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provoking angina pectoris, breathlessness or arrhythmias in patients with 
heart failure, some with underlying ischaemic heart disease, and that of 
precipitating hypotension or even syncope by administration of the powerful 
vasodilators sodium nitroprusside and phentolamine in patients with 
reduced circulating volume. These risks were minimised by excluding 
patients with a history of recent angina pectoris, or of ventricular tachycardia 
within the last two years requiring maintenance therapy. All patients who 
received tyramine infusions had urine collections tested for catecholamine 
breakdown products to exclude phaeochromocytoma. With the exception of 
ANP and tyramine, all these drugs are licensed for therapeutic use in 
patients with heart failure and have well documented actions and side 
effects. 
2.8: Description of the BOMED NCCOM-3 with a detailed 
explanation of the methodology. 
BOMED NCCOM3 (revision 7) Bomed Medical Manufacturing L TO, Irvine, 
California was used to measure thoracic bioimpedance. The NCCOM3 is a 
computer which extrapolates measures of cardiac filling and contractility 
from measurement of transthoracic impedence during cardiac ejection, 
using electrocardiogram electrodes both to sense and to deliver the current. 
A small sinusoidal current is applied to electrodes at the base of the neck 
and inferior aspect of the thorax (see diagram). A set of electrodes 5cm 
inside the stimulating electrodes record the changing impedance over that 
length of thorax. The electrocardiogram is monitored concurrently to time the 
cardiac cycle. The thorax is treated as a conducting cone, with adjustments 
made for height and weight of the individual. The equation of Berstein 
calculates cardiac output from the equation SV=VEPT 
xtLvEx(dZ/dt)max/Zo, where SV =stroke volume; VEPT= volume of 
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electrically participating tissue calculated from height and weight, tLvE= left 
ventricular ejection time (s); (dZ/dt)max= maximum rate of impedance change 
during systolic upstroke; and Zo= baseline thoracic impedance. 
Ag/AgCI (Kimal) monitoring electrodes were positioned carefully according 
to the manufacturer's instructions after prior preparation of the skin with 
abrasion and alcohol. Averaged recordings over 16 cardiac cycles were 
collected at 15 minute intervals. 
2.8. 1 Parameters 
The NCCOM3 displays 12 cardiodynamic parameters: cardiac output or 
index (CO/CI), heart rate (HR), stroke volume or stroke index (SV/SI), peak 
flow or peak index (PF/PFI), ejection fraction (EF), end diastolic volume or 
index (EDV/EDI), index of contractility, thoracic fluid index (conductance), 
acceleration index, ventricular ejection time, ejection ratio (preload index) 
and systolic time ratio. 
Peak flow: this is defined as the highest rate of left ventricular volumetric 
delivery during the ejection phase (ml/sec). The flow reaches its peak value 
in the first half of systole, typically 65msec after opening of the aortic valve. 
PF time remains unchanged with alterations in heart rate. PF is linked 
directly to the ejection phase contractility and thus is dependent on the 
volaemic state and is a good index of ventricular performance. 
Ejection fraction is directly related to measurement of systolic time 
intervals and is a non-linear inverse function of heart rate. Ventricular 
ejection time, however, is related to stroke volume (it takes less time to eject 
a smaller volume). 
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The systolic time ratio: this is the pre-ejection period (PEP) I ventricular 
ejection time (VET). PEP is the duration of isovolumic contraction. 
Ejection fraction is estimated by the following equation based on the 
results of a comparative study with Bomed and Muga EF: EF= 0.84-(0.64 
x (PEP I VET)) 
This assumes that the PEP and /or VET do not change without a change in 
haemodynamics, and this may not be the case in states of adrenaline surges 
such as is found with acute myocardial infarction, which shorten both PEP 
and VET, (underestimates EF) or left bundle branch block (LBBB) which 
artificially prolongs the the PEP (overestimates EF). 
End diastolic volume (EDV) is calculated from SV I EF. EDV is thus an 
estimate from the calculated EF, (however the widely accepted 
measurement of the 'wedge pressure' by occlusion catheter (pressure) is 
used to estimate left ventricular end diastolic volume, ie conversion of 
pressure to volume). 
Index of contractility: Maximum ejection flow (peak flow) or index is fluid-
volume dependent and can be used to determine the patient's volaemic 
status. 
Thoracic fluid index (TFI) is an impedance measurement which varies 
inversely with the conductance of the chest. It is influenced by age, sex and 
posture. Changing from the standing to the supine position leads to a 10% 
increase in TFI due. to decreased venous return, resulting in less fluid in the 
chest and thus less conductance. Pulmonary oedema causes a decrease in 
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TFI (ie increased conductance) but non cardiac pulmonary oedema and 
cardiac pulmonary oedema can be distinguished by the indices of cardiac 
function, that is changes in contractility index (ACI). A decrease in 
contractility index indicates impaired cardiac function. 
Acceleration index is the initial acceleration of blood in the left ventricle, 
which takes place 10-20 msec after the AV valve opens and is much less 
load-dependent than PFI. 
Ventricular ejection time is a direct measurement of mechanical systole 
which is heart rate and pump status dependent. The absolute value of VET 
does not have a specific use as it varies widely with different circumstances. 
Ejection ratio eliminates the effect of heart rate on VET, giving 
ER=VETIHRP. 
(Heart rate period). 
Systolic time ratio is calculated from PEPNET and is a sensitive 
indicator of ventricular performance. 
Summary 
a) Global blood flow related parameters: CO, SV, EDI, PFI, HR 
b) Left ventricular performance: SV, PF, IC, AI, STR 
c) Heart chamber sizes, efficiency: SV, EDV, EF 
d) Volaemia-related parameters: TFI, IC, ER 
2.8.2 Validation of the technique 
a) Validation in normal volunteers. 
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Moore (1992) compared the technique with rebreathing of C02, at rest and 
during bicycle steady state exercise, in normal subjects. He found that 
results were acceptably in agreement at mild or moderate levels of exercise 
but found that there was no acceptable agreement between the techniques 
at rest, or at high workload exercise. He found that impedance 
measurements seemed less reliable at high workloads, while rebreathing of 
C02 appeared less reliable at rest. 
b) 24 hours following myocardial infarction, Northridge (1990) compared 
bioimpedence with thermodilution and Doppler in 25 patients. The meari 
cardiac output by Doppler was 4.03 (range 2.2-6.0), by thermodilution 3.95 
(range 2.1-6.2) and by bioimpedance 3.79 (range 1.1-6.2). In three patients 
the Doppler result differed from thermodilution by more than 11/min and in 3 
patients thermodilution and bioimpedance differed by more than 11/min. The 
95% limits of agreement for bioimpedance and thermodilution were -1.43 to 
+ 1.111/min. The coefficient of variation for the repeated measurements of 
cardiac output using bioimpedance by the same observer was 2. 7%. Thus 
both non-invasive methods were accurate and reproducible in most patients 
with acute myocardial infarction. 
3) Comparison of thoracic bioimpedance with thermodilution in normal 
volunteers and intensive care patients (Jewkes, Sear, Verhoeff, et al 1991 ). 
Variability: there was good correlation for individual subjects at rest with 
repeated measurements on the same day. SV variation on 4 different days 
had coefficient of variation of 10.9%. This was similar to the variation in 
heart rate and blood pressure that was measured at the same time. For the 
patients, there was a correlation coefficient of 0. 72 for cardiac output, 
p<0.001. The mean difference in SV for the 2 methods was -0.861/min. TBI 
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tended to underestimate stroke volume at higher cardiac outputs and 
overestimated stroke volume in the lower cardiac output ranges. It is 
accepted that a 1 0% variability between thermodilution and dye test (which 
itself has a variability of aproximately 8%) measurement of cardiac output 
exists, so the difference between thermodilution and thoracic bioimpedence 
was of the same order of magnitude. Thus TBI was able to follow individual 
patient trends. 
4) De Mey, Matthews, Butzer, et al (1992) examined agreement and 
reproducibility of thoracic bioimpedance versus M-mode echocardiography 
in healthy subjects. They found that the methods were not interchangable as 
coefficients of reproducibility between the two methods were 25% of 
baseline. 
5) Ng, Walley, Tsao, et al (1991) compared Doppler and thoracic 
bioimpedance in healthy volunteers. There was no systematic difference 
between the methods but individual differences were wide. 
2.8.3 The present studies 
Thoracic bioimpedance (TBI) was chosen to assess changes in 
haemodynamic parameters because of its simplicity and the ability to take 
repeated measurements. As an in-house control, changes in SV and EF 
were compared during 20 minutes of incremental dobutamine infusion and 
sodium nitroprusside infusion in 8 patients. After the dobutamine or 
nitroprusside study was completed, patients were transferred to the 
echocardiography laboratory and received an additional infusion, while 
simultaneous TBI and Doppler measurements were made. (It was not 
possible to make measurements in duplicate throughout the individual 
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studies because of the limited availability of Doppler echocardiography and 
the layout of the hospital). 
Although there was some agreement between stroke volumes measured by 
the two techniques during dobutamine infusion (figure 2.2), this was not the 
case during nitroprusside infusion and individual reproducibility of baseline 
data was poor for both methods. One reason for the wide baseline 
variability could have been residual effects from the 2 hour infusion although 
there was a minimum delay of 90 minutes between stopping the high dose 
infusion and starting the next infusion in the echocardiography suite to allow 
washout. When the changes in all TBI parameters during all the definitive 
infusion studies were analysed there were no significant changes in stroke 
index or thoracic fluid index in the group during .either intervention (table 
2.4). Looking at individual patient data, some individuals (the minority) did 
show a clear rise or fall. The mean plasma concentrations of ANP of the 
group were elevated, indicative of elevated left atrial pressure and 
significant falls in blood pressure occurred with nitroprusside infusion, which 
would be anticipated to predict a rise in cardiac output as changes in arterial 
pressure of a similar magnitude in a group of patients with heart failure 
treated with nitroprusside were associated with clear changes in 
haemodynamics measured invasively (Young, Leon, Pratt, et al 1988). 
Subsequent analysis of results for the remainder of the studies showed that 
no parameter changed significantly in any study, despite significant changes 
in arterial pressure and heart rate (Tables 2.4-2.6). In view of these findings, 
the validity of the thoracic bioimpedance technique in these patients is in 
doubt and the results have not been included in subsequent chapters. 
Reasons for the poor reproducability of TBI may include poor or variable 
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timing of the cardiac cycle by the equipment due to the presence of left 
bundle branch block in some patients. The elevated catecholamine levels 
induced by infusions of dopamine, dobutamine and tyramine might in theory 
have interfered with calculation of ejection fraction as the equation used 
assumes that the PEP and /or VET do not change without a change in 
haemodynamics, and this may not be the case in states of adrenaline surges 
such as is found with acute myocardial infarction, which shorten both PEP 
and VET, (underestimates EF) or left bundle branch block (LBBB) which 
artificially prolongs the the PEP (overestimates EF). These theoretical 
considerations can only partly explain the consistent lack of significant 
change in stroke volume, ejection fraction and thoracic fluid index in each 
study performed, thus for whatever reason, the method proved unreliable in 
this patient population. 
Table 2.2 Doppler and thoracic bioimpedance stroke volume 
Table showing changes in stroke volume at baselin (B'LINE), during incremental dobutamine 
infusion and washout (W'OUT) measured by Doppler and by thoracic bioimpedance (TBI). 
DOBUTAMINE 
pg/kg/min 
TBI 
DOPPLER 
B'LINE 
64±7 
63±5 
104 
2.5Jlg 
67±8 
65±5 
67±8 62±7 
69±5 68±4 
W'OUT 
73±9 
75±5 
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Table 2.3 Absolute and % change in stroke volume 
Changes from baseline measured by Doppler and thoracic bioimpedance (TBI) during 
infusion of dobutamine 1 OJlg/kg/min. 
ABSOLUTE CHANGE IN STROKE VOLUME TBI 9.3±3.5mls 
DOPPLER 12.1 ±6.0mls 
% CHANGE IN STROKE VOLUME TBI 14±5% 
DOPPLER 24±1 3% 
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Figure 2.9 Stroke volume measured by Doppler and 
Thoracic Bioimpedance during dobutamine infusion 
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Table 2.4 Thoracic bioimpedance data for placebo, 
dobutamine and nitroprusside in 8 patients with chronic heart 
failure 
Changes in peak flow index (PFI) ejection fraction (EF), end diastolic index (EDI), cardiac index 
(CI), stroke index (SI) and thoracic fluid index (TFI) during infusion of placebo (PLAC), 
dobutamine (DOBUT) and nitroprusside (SNP) 
PFI 
EF 
EDI 
Cl 
Sl 
TFI 
PLACEBO 
DOBUTAMINE 
SNP 
PLACEBO 
DOBUTAMINE 
SNP 
PLACEBO 
DOBUTAMINE 
SNP 
PLACEBO 
DOBUTAMINE 
SNP 
PLACEBO 
DOBUTAMINE 
SNP 
PLACEBO 
DOBUTAMINE 
SNP 
START 
205±16 
281±42 
232±19 
51±4 
51±5 
48±4 
62±11 
75±9 
63±6 
2.2±0.2 
2.8±0.4 
2.2±0.2 
29±3 
37±6 
30±3 
36±3 
29±2 
32±4 
0-1 HRS 
209±17 
282±45 
235±28 
50±5 
49±6 
48±3 
68±11 
84±12 
65±7 
2.2±0.2 
3.0±0.5 
2.3±0.3 
30±3 
38±6 
31±4 
35±3 
28±3 
31±4 
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1-2 HRS 
215±17 
289±53 
223±27 
50±5 
48±5 
46±3 
67±10 
82±12 
64±8 
2.2±0.2 
3.0±0.6 
2.2±0.3 
31±3 
39±8 
29±4 
35±2 
31±3 
34±4 
2-3 HRS 
217±16 
288±44 
230±25 
51±5 
52±4 
44±4 
66±9 
78±12 
68±8 
2.3±0.2 
3.5±0.8 
2.2±0.3 
30±2 
38±7 
29±4 
35±2 
28±2 
30±4 
3-4 HRS 
215±16 
262±34 
228±23 
51±5 
51±3 
50±3 
66±10 
64±8 
64±7 
2.2±0.2 
2.7±0.4 
2.3±0.3 
29±2 
34±5 
31±4 
34±2 
29±2 
32±3 
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Table 2.5 Thoracic bioimpedance data placebo and digoxin 
Changes in peak flow index (PFI) ejection fraction (EF), end diastolic index (EDI), cardiac index 
(CI), stroke index (SI) and thoracic fluid index (TFI) at baseline and during infusion of placebo 
(PLAC) and digoxin (DIG). 
B'LINE Q-1 HRS 1-2 HRS 2-3 HRS 3-4 H RS 
PFI DIGOXIN 225±14 236±20 236±20 245±19 244±18 
PLACEBO 216±18 214±16 224±17 223±15 222±16 
EF DIGOXIN 55±3 55±3 57±3 58±3 58±5 
PLACEBO 55±2 54±2 56±3 56±3 56±2 
EDI DIGOXIN 57±5 61±6 61±5 64±5 65±6 
PLACEBO 55±6 59±5 60±5 59±4 58±5 
Cl DIGOXIN 2.3±0.1 2.4±0.2 2.4±0.2 2.5±0.2 2.5±0.2 
PLACEBO 2.3±0.1 2.2±0.2 2.3±0.2 2.3±0.2 2.3±0.2 
Sl DIGOXIN 31±2 33±3 35±3 37±3 37±4 
PLACEBO 31±3 32±3 33±3 32±2 31±3 
TFI DIGOXIN 32±3 31±3 31±3 32±3 31±3 
PLACEBO 36±3 36±3 36±2 35±2 35±2 
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Table 2.6 Thoracic bioimpedance data: placebo, dopamine and 
dobutamine 
Changes in peak flow index (PFI) ejection fraction (EF), end diastolic index (EDI), cardiac index 
(CI), stroke index (SI) and thoracic fluid index (TFI) at baseline and during infusion of placebo 
(PLAC), dopamine (DOPA) and dobutamine (DOBUT). 
B'LINE Q-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
PFI DOPAMINE 287±49 278±41 288±36 308±41 269±21 
DOBUTAMINE 281±42 282±45 289±53 288±44 263±34 
PLACEBO 290±67 291±65 288±56 283±51 294±58 
EF DOPAMINE 50±2 51±3 52±3 53±3 48±3 
DOBUTAMINE 51±5 49±6 48±5 52±4 51±3 
PLACEBO 52±2 52±2 52±3 53±2 54±2 
EDI DOPAMINE 74±11 75±10 77±8 80±9 74±5 
DOBUTAMINE 75±9 84±12 82±12 78±12 64±8 
PLACEBO 76±19 79±16 74±12 74±12 78±15 
Cl DOPAMINE 2.9±0.4 2.8±0.4 2.9±0.4 3.2±0.5 2.7±0.3 
DOBUTAMINE 2.8±0.4 3±0.5 3±0.6 3.5±0.8 2.7±0.4 
PLACEBO 3.1±0.8 3.0±0.7 3.0±0.6 2.9±0.6 3.0±0.6 
Sl DOPAMINE 38±6 39±6 41±6 42±6 36±3 
DOBUTAMINE 37±4 38±6 39±8 38±7 34±5 
PLACEBO 40±9 41±9 39±7 39±8 42±10 
TFI DOPAMINE 30±2 30±2 29±2 30±2 31±2 
DOBUTAMINE 29±2 28±3 31±3 28±2 29±2 
PLACEBO 33±3 33±3 33±3 32±3 32±3 
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Table 2.7 Thoracic bioimpedance data: placebo, ANP, tyramine 
and phentolamine 
Changes in peak flow index (PFI) ejection fraction (EF), end diastolic index (EDI), cardiac index 
(CI), stroke index (SI) and thoracic fluid index (TFI) at baselin (B'LINE) and during infusion of 
placebo (PLAC), ANP, tyramine (TYR) and phentolamine (PHENT). 
B'LINE 1 HOUR 2 HOURS 3 HOURS 4 HOURS 
Sl PLACEBO 37±3 36±3 38±3 37±3 38±3 
ANP 33±2 34±2 35±3 37±3 37±4 
TYRAMINE 36±3 38±3 39±4 40±3 39±3 
PHENTOLAMINE 36±3 37±2 37±3 36±3 36±3 
Cl PLACEBO 2.6±0.1 2.5±0.2 2.6±0.2 2.5±0.2 2.5±0.2 
ANP 2.3±0.1 2.3±0.1 2.3±0.2 2.4±0.1 2.4±0. 1 
TYRAMINE 2.6±0.2 2.6±0.2 2.7±0.3 2.7±0.2 2.7±0.3 
PHENTOLAMINE 2.5±0. 1 2.5±0. 1 2.7±0.2 2.9±0. 1 2.7±0. 1 
EF PLACEBO 57±2 56±2 58±3 58±3 57±3 
ANP 52±3 54±3 55±3 55±2 55±2 
TYRAMINE 56±2 57±2 58±2 60±3 58±3 
PHENTOLAMINE 52±4 55±5 56±3 56±3 54±4 
PFI PLACEBO 252±11 245±14 252±13 246±14 245±11 
ANP 239±11 232±9 239±13 246±13 256±18 
TYRAMINE 250±15 155±18 255±17 257±16 262±19 
PHENTOLAMINE 252±1 4 245±10 252±17 265±17 260±17 
TFI PLACEBO 38±1 37±1 37±1 37±1 37±1 
ANP 37±2 37±2 37±2 37±2 36±2 
TYRAMINE 34±3 34±3 34±3 34±3 34±3 
PHENTOLAMINE 35±3 35±3 35±3 35±3 35±2 
110 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 The effect of dietary sodium restriction on 
furosemide induced diuresis and natriuresis 
3. 1 Introduction 
Dietary sodium restriction is traditionally advocated in patients with heart 
failure. The renal response to furosemide is known to be impaired in 
patients with heart failure, despite plasma and urinary concentrations of 
furosemide which are similar to those in normal subjects. Patients with heart 
failure controlled with diuretics have an excess of total bodily sodium, but 
still exhibit renal sodium avidity. It is not known whether sodium restriction 
will decrease sodium output in response to furosemide in heart failure or 
whether it will merely reduce weight and blood pressure. In normal subjects, 
sodium depletion with concomitant furosemide administration for three days 
was found to cause a fall in weight of approximately 2 kg and a fall in G FR 
but no change in blood pressure (Memoli, Libetta, Sabbatini, et al 1991 ). 
The present study was conducted to assess the effect of sodium restriction 
on the diuretic and natriuretic response to furosemide in patients with mild to 
moderate chronic heart failure. 
3.2 Subjects and methods 
Nine patients, of whom one was female, aged 57-73 years (mean age 62 
years) with chronic heart failure requiring regular diuretics were studied on 
two occasions, not less than one week apart. Subjects with severe failure 
were excluded because of the risk of precipitating acute cardiac 
decompensation by increasing salt intake. The mean maintenance dose of 
furosemide was 62mg (40-120mg)/day. 7 patients were assigned to NYHA 
class II and 2 patients to NYHA class Ill. 
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Table 3.1 Patient characteristics 
Table showing individual patients' age, sex, New York Heart Association classification 
(NYHA), daily diuretic requirements in milligrammes (furosemide-F), type of ACE-inhibitor 
and daily dosage (captoprii-CAPT) and aetiology of heart failure (ischaemic heart disease-
IHD, dilated cardiomyopathy-DCM). 
PATIENT AGE SEX NYHA DIURETIC ACE-I (mg) AETIOLOGY 
1 64 M liB F40 IHD 
2 68 M IIA F40 IHD 
3 73 M Ill F80 CAPT 37.5 IHD 
4 69 F liB F40 IHD 
5 58 M liB F40 CAPT 37.5 IHD 
6 65 M Ill F 120 IHD 
7 64 M liB F 40 IHD 
8 51 M Ill F 120 CAPT 75 IHD 
9 66 M IIA F 40 DCM 
Patients adhered to a diet containing 20mmol of sodium and 40mmol of 
potassium per day for three days (sodium restriction) or 150 mmol of sodium 
and 40mmol of potassium per day for three days (high salt) in random, 
crossover fashion. Furosemide was infused at a predetermined rate 
throughout the study to maintain a moderate, constant diuresis and urinary 
and insensible losses were replaced orally. PAH was infused for estimation 
of renal blood flow. Blood was drawn at 0, 2 and 4 hours from the start of the 
study for measurement of electrolytes, plasma hormones (AVP, plasma 
renin, ANP, adrenaline and noradrenaline) and PAH. Urine was measured 
and retained for measurement of electrolytes and PAH. Heart rate was 
counted from the apex and arterial pressure was measured with a mercury 
sphygmomanometer (See chapter 2 for further details of methodology). . 
3. 3 Statistics 
The Friedman test for analysis of variance was used to test significance of 
any differences and where indicated, differences were compared using 
appropriate t-tests. Figures denote mean± one standard error of the mean. 
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3.4 Results 
Mean weight was lower on the low salt diets (76. 7 and 77.3kg on low and 
normal salt diets respectively) but the differences did not reach significance. 
One patient on a calorie-restricted diet lost 2kg in the 2 week period 
between studies. When this patient was excluded, mean weight fell by 1 kg 
on sodium restriction. 
Table 3.2: Individual weights on normal and low salt diets 
PATIENTS LOW SALT (Kg) NORMAL SALT (Kg) 
1 64.5 65.5 
2 70.0 70.5 
3 78.5 80.0 
4 63.3 65.2 
5 86.0 86.0 
6 76.6 77.0 
7 66.0 65.5 
8 68.6 70.7 
9 106.0 104.0 
Cumulative urine volume over 4 hours decreased (1175±302ml to 
956±459ml, p<0.05) during salt restriction (Figure 3.1) although differences 
between individual hourly collections did not reach statistical significance. 
Excretion of sodium (p=0.07, Figure 3.2) and chloride (p<0.07, Figure 3.3) 
showed a trend to fall during the first hour of the study with salt restriction. 
Cumulative sodium and chloride excretion over 4 hours did not differ 
significantly on the two study days. Excretion of potassium fell during the 
first hour of the study with salt restriction but cumulative excretion over 4 
hours was similar to that during salt repletion. Fractional excretion of 
electrolytes did not change (Table 3.3) but concentrations of urea and 
creatinine were higher at baseline and at 2 hours during salt restriction. 
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Figure 3.1 Hourly urine volume. 
The differences in hourly volume did not reach statistical significance although 
cumulative urine output over the four hour period fell during salt restriction (p<0.05). 
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Figure 3.2 Hourly sodium excretion after salt restriction 
and normal salt intake. 
Sodium excretion tended to fall during the first two hours of the study but this did not 
reach significance. 
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Figure 3.3 shows changes in hourly chloride excretion after salt restriction 
and normal salt intake. The trend towards a reduction in chloride excretion 
during the first hour of the study did not reach statistical significance. 
Figure 3.3: Hourly chloride excretion 
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Figure 3.4: Potassium excretion 
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TABLE 3.3 Excretion of urea and creatinine and fractional 
excretion of electrolytes 
There was no significant difference between fractional excretion of sodium (Na), potassium (K), urea 
(U), chloride (CI), magnesium (Mg) or phosphate (Ph) to creatinine (Creat, Cr) after high or low salt diets. 
Urea 
mmol/hr 
Creat 
mmol/hr 
Na/Cr 
mM/mM 
K/Cr 
mM/mM 
U/Cr 
mM/mM 
CI/Cr 
mM/mM 
Mg/Cr 
mM/mM 
Ph/Cr 
mM/mM 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
HIGH SALT 
LOW SALT 
0-1 HRS 
23±2 
19±2 
0.52±0.06 
0.44±0.08 
57±12 
45±8 
13±2 
16±4 
42±7 
49±4 
47±9 
55±17 
0.6±0.1 
0.8±0.1 
1.7±0.4 
2.3±0.3 
116 
1-2 HRS 
22±1 
24±2 
0.51 ±0.04 
0.54±0.09 
55±11 
51±14 
16±3 
15±2 
48±4 
47±5 
57±10 
55±17 
0.7±0.1 
1.1 ±0.2 
2.1 ±1.4 
2.3±1.1 
2-3 HRS 
18±2 
21±1 
0.40±0.06 
0.47±0.06 
71±16 
49±13 
16±2 
14±2 
48±5 
49±4 
64±18 
55±18 
0.8±0.1 
0.8±0.1 
2.7±0.5 
2.6±0.3 
3-4 HRS 
17±1 
17±2 
0.38±0.06 
0.34±0.04 
70±16 
75±35 
15±2 
16±3 
49±5 
54±6 
67±21 
69±29 
0.8±0.1 
0.9±0.2 
3.1±0.5 
3.4±0.5 
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Table 3.4 Plasma electrolyte concentrations 
Changes in plasma sodium (Na), potassium (K), urea, creatinine (Great), chloride (CI), 
magnesium (Mg) and phosphate (Phos) concentrations. *denotes p<at least 0.05. 
START 2 HOURS 4 HOURS 
Na HIGH SALT 139±1 138±1 138±1 
mmol LOW SALT 138±1 138±1 137±1 
K HIGH SALT 3.8±0.2 3.7±0.1 3.5±0.1 
mmol LOW SALT 3.6±0.2 3.5±0.1 3.4±0.1 
Urea HIGH SALT 7.9±0.8 7.4±0.7 7.0±0.7 
mmol LOW SALT 8.5±0.8 8.2±0.8* 7.7±0.7 
Creat HIGH SALT 99±7 96±7 95±6 
,umol LOW SALT 1 06±8" 101±8" 100±9 
Cl HIGH SALT 104±1 102±1 101 ±1 
mmol LOW SALT 102±1 102±2 100±2 
Mg HIGH SALT 0.82±0.03 0.83±0.01 0.82±0.02 
mmol LOW SALT 0.84±0.02 0.84±0.02 0.81±0.02 
Phos HIGH SALT 0.85±0.07 0.86±0.06 0.98±0.05 
mmol LOW SALT 0.82±0.08 0.88±0.07 1.00±0.05 
Hormones Plasma ANP levels were lower at the start of the study and at 2 
hours after salt restriction (p<0.03, Figure 3.6), while plasma renin showed a 
trend to rise after salt restriction, reaching statistical significance after 4 
hours (p<O.OS, figure 3.5). Adrenaline (p<O.OS) and noradrenaline (p=0.05) 
rose. AVP levels were not affected (Figures 3. 7 & 3.8). 
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Figure 3.5 Plasma active renin concentration 
Renin concentrations tended to rise after salt restriction, significant only 
at 4 hours (p<O.OS). 
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Figure 3. 7 Plasma adrenaline concentration 
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Figure 3.8 Plasma noradrenaline concentration 
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Haemodynamic variables 
Heart rate did not change between study days. Systolic blood pressure at 
baseline was lower during salt restriction (112 vs 119mmHg, p<0.01: figure 
3.9). 
ERPF was lower for the first 3 hours after salt restriction (p<0.005: figure 
3.1 0, table 3.5). Creatinine clearance was not significantly different on salt 
restriction compared to normal sodium intake (table 3.5). 
Table 3.5 Haemodynamic variables 
Changes in heart rate (HR), systolic and diastolic blood pressure (SBP, DBP), glomerular 
filtration rate (GFR) and effective renal plasma flow (ERPF) following usual salt intake (HIGH) 
and salt restriction (LOW). *denotes significance at at least p<0.05. 
START Q-1 HAS 1-2 HAS 2-3 HAS 3-4 HAS 
HR HIGH 74±4 71±5 69±4 71±4 69±4 
bpm LOW 72±4 70±4 69±4 69±4 70±4 
SBP HIGH 119±7 111 ±7 117±8 116±7 115±7 
mmHg LOW 112±7* 109±7 110±7 115±7 113±7 
DBP HIGH 75±5 72±5 77±5 76±5 74±5 
mmHg LOW 71±6 72±5 73±6 73±5 71±5 
GFR HIGH - 90±13 106±20 72±12 72±11 
mls/min LOW- 70±14 81±10 83±13 54±7 
ERPF HIGH - 267±31 298±31 300±33 308±36 
mls/min LOW - 250±32* 252±32* 244±31* 230±29 
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Figure 3.9 Systolic blood pressure 
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3. 5 Discussion 
In the present study, sodium restriction was associated with further activation 
of the renin-angiotensin system and sympathetic nervous system and a fall 
in ANP. Systolic blood pressure and body weight were lower at baseline 
during salt restriction and prolonged furosemide infusion was associated 
with a fall in ERPF, a decline in the cumulative furosemide induced diuresis 
over 4 hours and a non-significant fall in natriuresis (p=0.07) during the first 
hour of the study. 
The braking phenomenon 
Quite clearly compensatory mechanisms come into play to prevent 
progressive dehydration with regular diuretic therapy. Wilcox, Mitch, Kelly, et 
al (1983) showed that normal subjects develop resistance to the effects of 
furosemide when sodium is restricted, with attendant falls in GFR, but also 
demonstrated that compensatory renal sodium retention could only be 
prevented after furosemide by salt restriction. The overall sodium balance 
thus depends not only on the initial diuresis but the subsequent 
compensatory sodium retention. It is likely that many of the mechanisms 
involved in the braking phenomenon are the same as those resulting in 
furosemide resistance in heart failure, although in heart failure the 
mechanisms co-exist with total bodily sodium excess. 
The mechanisms for the decreased furosemide induced natriuresis are 
various. There is evidence that diminished delivery of sodium to the loop of 
Henle as a consequence of alteration in glomerular filtration rate impairs the · 
action of furosemide. Honrath, Chong, Wilson, et al (1994) found that 
chronic salt deprivation effectively prevented the diuretic and natriuretic 
actions of ANP in rats. Salt deprivation caused a fall in GFR and marked 
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elevation in tubular reabsorption of delivered loads of fluid and electrolytes 
in the medullary collecting duct. This blunting could be rapidly reversed by 
intravenous infusion of isotonic sodium chloride, although interestingly, the 
effect was more complete in the collecting duct and only partially corrected 
in the more proximal nephron segments. The authors speculate that at least 
two salt-conserving mechanisms exist, one quickly reversible, operating 
upstream as well as in the duct and a second, which is not acutely 
reversible, operating upstream only. 
Sodium intake may modulate the responsiveness of the tubular epithelium 
to furosemide. Reduced amounts of sodium in the ascending loop of Henle 
may adversely affect the renal action of furosemide (Nomura, Yasuda, 
Minami, et al 1981 ). (The furosemide assay only became available after this 
study was completed, hence furosemide excretion was only measured in 
subsequent Chapters). Micropuncture studies in rats suggest that salt intake 
modulates the responsiveness of tubular epithelium to furosemide (Gutshe, 
Muller-Suur, Hegel, et al 1980) but the role this plays in patients with heart 
failure is not known. 
Falls in blood pressure modulate renal sodium handling (Schrier, De 
Wardener 1971) and falls in arterial pressure can blunt the natriuretic and 
diuretic effects of furosemide in animals (Haeusler, Gerold 1979). A 
statistically significant fall in systolic blood pressure was observed in the 
present study during salt restriction, thus this mechanism may also have 
contributed to the blunted natriuresis and diuresis observed. Although GFR 
did .not change significantly in the present study, a fall cannot be excluded 
because of the wide scatter. Reduced renal plasma flow has been shown to 
increase reabsorption of sodium at the proximal tubule in patients with 
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advanced heart failure. 
Activation of the RAAS by salt restriction was previously thought to be 
responsible for the reduced responsiveness to furosemide, but elegant 
studies by Wilcox, Guzman, Mitch, et al (1987) and Kelly, Wilcox, Mitch, et al 
(1983) showed that elevated concentrations of A-ll were not a prerequisite 
for furosemide resistance. In addition Wilcox, Guzman, Mitch, et al (1987) 
showed that resistance to the renal effects of furosemide persisted when 
both the a1-adrenoceptor and formation of A-ll were blocked by prazosin 
and captopril respectively. Whether elevation of catecholamines by salt 
restriction (as was the case in the present study) further reduces renal 
responsiveness to furosemide remains speculative. Cody, Covit, Schaer, et 
al (1986b) described similar neuroendocrine activation and impaired 
natriuresis with salt depletion in patients with heart failure but did not 
measure plasma ANP concentrations. 
Urine creatinine excretion did not change significantly after salt restriction in 
the present study, although creatinine clearance is a less reliable estimate of 
GFR than inulin clearance (it tends to overestimate GFR because of tubular 
secretion of creatinine in addition to filtration). Further error could be 
introduced by administration of furosemide, although the doses were 
identical for individual patients, who acted as their own controls. 
There were 3 patients taking ACE-inhibitors which could have influenced the 
results of the study. All were converted to captopril two weeks prior to study 
and 3 doses omitted to allow washout, and patients acted as their own 
controls. These measures would minimise the error introduced. 
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Limitations of the study 
It is always difficult to be sure that apparently statistically significant results 
are valid or that the non-significant results are truly negative in small clinical 
studies (for example the GFR measurements). Wide variations in individual 
response occur and the possibility that some findings were merely the result 
of chance cannot be excluded. Using two-tailed t-tests reduced the bias but 
decreased the sensitivity of the tests to show significance. 
24 hour sodium excretion was not measured in all patients to confirm that 
the diet had been strictly adhered to, although changes in weight and 
neuroendocrine activation supported adherence to the appropriate salt 
intake. Although differences in sodium excretion did not reach significance, 
the mean hourly sodium excretion after three days of salt restriction was 
20mMol and after normal sodium intake, 25mMol. If these results were 
extrapolated to 24 hours, the difference (120mMol) was very similar to the 
difference in daily sodium intake (150mMol vs 20mMol). Patients were not 
catheterised to ensure complete bladder emptying but any patients with a 
history suggestive of outflow obstruction were excluded from the study and it 
was not felt to be ethical to catheterise the patients repeatedly. This may 
have introduced error in urine collections but the patients acted as their own 
controls, stood to micturate and furosemide infusion was maintained to 
ensure a constant but modest diuresis in order to minimise the error. 
The plasma hormone samples were saved and assayed as a batch. 
Individual patient samples for both days were assayed in the same assays to 
reduce interassay variability inaccuracies. This may have resulted in loss of 
some ANP activity (Nelesen, Dimsdale, Ziegler 1992) although a recent in-
house study of variability of ANP concentrations in samples sent from 
126 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
patients under different storage conditions and stored for different periods of 
time prior to assay showed good agreement between results of samples 
assayed within 3 days of sampling and those saved for 6 weeks. Individual 
patients had samples collected within 14 days of one another so any loss of 
hormone activity was likely to have affected both sets of samples, thus 
minimising error. There was little baseline variability in plasma hormone 
concentrations in the patients although inter-patient variability was wide. 
Conclusion 
Appropriate renal sodium retaining mechanisms come into play when 
dietary sodium is severely restricted or urinary sodium loss is greatly 
enhanced by diuretic therapy in normal subjects. In patients with heart 
failure, similar compensatory responses may reduce diuretic efficacy despite 
total body sodium excess. Sodium restriction is also associated with 
activation of sympathetic nervous system and renin-angiotensin system and 
decreased circulating concentrations of ANP. Effective renal plasma flow 
also falls. These neuroendocrine and haemodynamic effects are not 
dissimilar to those achieved by a further increase in the dose of loop 
diuretics. Although only furosemide was used in the present study, and the 
neuroendocrine response to incremental dosing was not tested, other 
authors (Nicholls, Espiner, Hughes, et al 1976; Turini, Brunner, Ferguson, et 
al 1978; Levine, Francis, Goldsmith, et al 1982; Schaer, Covit, Laragh, et al 
1983) have demonstrated neuroendocrine activation with increasing doses 
of all diuretic agents, the least marked with thiazide diuretics. While sodium 
restriction is essential to achieve diuresis in patients with refractory 
congestive heart failure, its role in controlled heart failure appears to be no 
more physiological or beneficial than the loop diuretic agents. It is difficult to 
motivate patients to restrict dietary sodium to less than 40mMol per day. 
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When symptoms and signs of heart failure are controlled on a loop diuretic 
such as furosemide, routine dietary sodium restriction appears to be of 
limited additional value and adds to the misery of patients. 
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Chapter 4 The effect of suppression of angiotensin II on a 
furosemide induced diuresis and natriuresis in patients on 
chronic angiotensin converting enzyme inhibitor therapy 
4. 1 Introduction 
Suppression of A-ll in the circulation and in renal tissues should increase 
sodium loss, either by withdrawing a direct sodium retaining effect of A-ll on 
the renal tubule or by reducing plasma concentrations of aldosterone 
(Cleland, Dargie 1987b; Cleland 1991). In practice, most patients with heart 
failure not only fail to reduce their diuretic requirement but tend to retain fluid 
and sodium in the days following initiation of an ACE inhibitor (Fitzpatrick, 
Nicholls, lkram 1983; Cleland, Dargie, Ball, et al 1985a; Cleland, Dargie, 
East, et al 1995b; Cleland, Gillen, Dargie 1988; Flapan, Davies, Waugh 
1991 b; Motwani, Fenwick, Morton, et al 1992b). Although the direct renal 
effects of suppression of A-ll and aldosterone predict that a natriuresis 
should occur, ACE inhibitors also reduce arterial pressure, plasma 
natriuretic peptides and G FR. All these effects favour salt and water 
retention (Cleland 1990b). 
The measurement of weight and total body sodium suggest that ACE 
inhibitors have a neutral effect on water and sodium balance over 6-8 weeks 
(Cleland, Dargie, East, et al 1985b; Cleland, Dargie, Gillen, et al 1986), 
indicating reversal of the initial trend with chronic use. The interaction of 
diuretic agents and ACE inhibitors during long-term combined therapy has 
not been addressed. Intense ACE inhibition may be associated with more 
pronounced effects on arterial pressure and GFR than with partial ACE 
inhibition which would tend to attenuate the diuretic effects of furosemide. 
However intense inhibition would lead to greater reductions in aldosterone 
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and A-ll which would favour a greater diuresis than with partial suppression 
with lower doses of captopril. 
The aim of the present study was to compare the effects of furosemide 
during periods of intense A-ll suppression with a period when circulating A-ll 
was not suppressed. Monitoring and collections of blood and urine were 
continued as plasma A-ll concentrations began to rise again towards the 
end of the study period. 
4.2 Subjects 
Eight patients with chronic heart failure due to left ventricular dysfunction 
were studied. All had a left ventricular ejection fraction of less than 30% on 
radionuclide ventriculography or a fractional shortening of less than 20% 
and impaired left ventricular systolic function on echocardiography. All had 
been taking ACE inhibitors for at least 3 months and had changed to 
captopril 12.5mg tid two weeks prior to being included in the study. 
Table 4.1 Patient characteristics 
Table showing individual patients' age, sex, New York Heart Association classification (NYHA), daily 
diuretic requirements in milligrams (furosemide-F. metolazone-MET), type and daily dosage of ACE-
inhibitor (captoprii-CAP) and aetiology of heart failure (ischaemic heart disease-IHD). 
PATIENT AGE SEX NYHA DIURETIC ACE-I (mg) AETIOLOGY 
1 60 M liB F80 CAPT 37.5 IHD 
2 74 M Ill F80 CAPT 37.5 IHD 
3 66 M liB F 120 CAPT 37.5 IHD 
4 64 M Ill F40, MET5 CAPT 37.5 IHD 
5 48 M liB F 120 CAPT 37.5 IHD 
6 63 F Ill F80 CAPT 37.5 IHD 
7 58 M liB F80 CAPT 37.5 IHD 
8 73 M Ill F80 CAPT 37.5 IHD 
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4. 3 Study design 
Patients adhered to a diet containing 40mM of potassium and 100mM of 
sodium/day for 3 days prior to each study. Each patient was studied twice, 
not less than 48 hours apart, in random fashion. Usual medications and 
caffeine-containing beverages were omitted on the study days. On arrival, 
cannulae were inserted into antecubital veins bilaterally and boluses of 
inulin 50mg/kg and PAH 800mg were administered. Infusions were 
continued for the duration of the study at rates of 32.5mg/min and 30mg/min 
respectively. Heart rate and arterial pressure were measured at half hourly 
intervals. 
A bolus of furosemide 5mg was given and patients rested supine for 30 
minutes before passing urine. Subsequent hourly boluses of furosemide 
were given in identical ·fashion to maintain a steady, moderate diuresis (3-
5mg/hour, depending on usual daily dose of furosemide). Urinary and 
insensible losses were replaced hourly with water. Blood was drawn hourly 
for estimation of plasma hormones, electrolytes, PAH and inulin. Urine was 
collected hourly for estimation of electrolytes, PAH, inulin and cGMP. At the 
end of the first hour, blood and urine samples were collected then 12.5mg of 
captopril or matching placebo was given in random single-blind fashion. 
Heart rate and arterial pressure were measured at half hourly intervals. 
Blood samples were collected at 1 , 2, 3 and 4 hours from the start of the 
studies and saved for analysis of plasma hormones (ANP, active renin 
concentration and aldosterone), electrolytes, PAH and inulin. Urine was 
collected hourly (at 1 ,2,3 and 4 hours) and saved for measurement of 
electrolytes, PAH, inulin, cGMP and furosemide (see Chapter 2). 
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4. 4 Results 
Urine volume increased during the first and second hours after captopril 
compared to placebo. Both sodium and chloride excretion increased during 
the first and second hours after captopril compared with placebo (figure 4.2 
& 4.3). Urinary concentrations of cGMP and furosemide were found not to 
differ significantly after captopril or placebo. 
Table 4.2 Changes in urine volume and excretion of electrolytes, 
furosemide and cGMP 
Changes in hourly excretion of urine, sodium (Na), potassium (K), urea, creatinine (Great), chloride (CI), 
magnesium (Mg), phosphate (Phos), furosemide (F'MIDE) and cGMP. * denotes p< at least 0.05. 
Results are expressed as mean ± one standard error of the mean 
uv 
mlslhr 
Na 
mmol/hr 
K 
mmollhr 
Urea 
Mmollhr 
Creat 
Mmollhr 
Cl 
Mmollhr 
Mg 
Mmollhr 
Phos 
Mmollhr 
F'MIDE 
mglhour 
C GMP 
ng/min 
0-1 HRS 
PLACEBO 245±39 
CAPTOPRIL 273±38 
PLACEBO 25±4 
CAPTOPRIL 28±5 
PLACEBO 6.6±1.2 
CAPTOPRIL 7.1±1.3 
PLACEBO 19±2 
CAPTOPRIL 21 ±5 
PLACEBO 0.44±0.06 
CAPTOPRIL 0.48±0.1 0 
PLACEBO 23±4 
CAPTOPRIL 27±5 
PLACEBO 0.37±0.06 
CAPTOPRIL 0.38±0.05 
PLACEBO 0. 97 ±0. 19 
CAPTOPR IL 0. 93±0. 16 
PLACEBO 1.7±0.4 
CAPTOPRIL 1.8±0.4 
PLACEBO 1.7±0.4 
CAPTOPRIL 2.6±0.6 
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1-2 HRS 
238±32 
303±35* 
22±3 
26±4* 
5.5±1.0 
5.9±1.1 
17±2 
16±2 
0.36±0.04 
0.33±0.03 
20±3 
24±4* 
0.33±0.05 
0.33±0.06 
0.92±0.1 
0.82±0.12 
1.5±0.2 
1.9±0.3 
2.4±0.7 
2.8±0.9 
2-3 HRS 
245±27 
312±33* 
22±3 
28±4* 
5.8±0.8 
6.4±0.6 
17±2 
18±2 
0.37±0.04 
0.40±0.04 
20±2 
25±4* 
0.32±0.03 
0.34±0.04 
1.1±0.1 
1.08±0.13 
1.7±0.3 
1.9±0.3 
1.9±0.4 
2.7±0.8 
3-4 HRS 
262±30 
256±23 
23±3 
22±3 
5.2±0.7 
5.2±1.1 
17±3 
15±2 
0.38±0.05 
0.33±0.04 
20±3 
19±3 
0.30±0.04 
0.27±0.05 
1.2±0.12 
0.88±0.08 
1.8±0.3 
1.7±0.3 
1.5±0.4 
1.4±0.4 
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Figure 4. 1 Changes in hourly urine volume after 
placebo and captopril. Bars denote one standard error 
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Figure 4.2 Changes in hourly sodium excretion after 
placebo and captipril. Bars denote one standard error 
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Figure 4.3 Changes in hourly chloride excretion after 
placebo and captopril. Bars denote one standard error 
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Fractional excretion of sodium (sodium/creatinine) increased (figure 4.4), as 
did excretion of sodium/phosphate (20±3 to 27±4, p<O.OS at 2 hours post 
dosing) and excretion of sodium/potassium (figure 4.5). 
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Figure 4.4 Changes in hourly fractional excretion of 
sodium after placebo and captopril 
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Figure 4.5 Changes in hourly excretion of sodium 
/potassium after placebo and captopril 
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Fractional excretion of furosemide and cGMP was not significantly different 
after captopril and placebo (table 4.3). 
Table 4.3 Fractional excretion of furosemide (F'MIDE) and cGMP 
0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
F'MIDE/Cr PLACEBO 3.6±0.4 3.8±0.3 4.4±0.4 4.4±0.5 
mg/pmol CAPTOPRIL 4.2±0.4 4.7±0.7 4.6±0.6 4.3±0.6 
cGMP/Cr PLACEBO 4.5±1.1 6.8±1.9 5.3±1.2 4.5±1.4 
ng/pmol CAPTOPRIL 6.3±1.3 7.6±2.3 7.7±2.5 5.0±2.5 
Plasma electrolyte concentrations and haematocrit did not differ significantly 
after captopril and placebo (table 4.4). 
Table 4.4 Plasma electrolyte concentrations and haematocrit 
Changes in hourly haematocrit (HCT), plasma sodium (Na), potassium (K), urea, creatinine (Cr), chloride 
(CI), magnesium (Mg) and phosphate after captopril (CAPT) and placebo (PLAC). 
START 
HCT PLAC 41±1 
% CAPT 40±2 
Na PLAC 139±1 
mmol CAPT 140±1 
K PLAC 3.8±0.2 
mmol CAPT 4.1 ±0.1 
Urea PLAC 10.7±1.4 
mmol CAPT 9.9±1.7 
C r PLAC 127±4 
pmol CAPT 119±12 
Cl PLAC 104±1 
mmol CAPT 1 03±3 
M g PLAC 0.85±0.02 
mmol CAPT 0.86±0.02 
Phos PLAC 0.96±0.05 
mmol CAPT 1.05±0.08 
1 HOUR 
42±3 
40±1 
139±1 
139±1 
3.8±0.2 
4.1 ±0.2 
1 0.5±1.4 
9.5±1.7 
123±5 
114±1 0 
105±2 
104±3 
0.85±0.01 
0.87±0.02 
0.96±0.07 
1.00±0.09 
136 
2 HOURS 
41±3 
39±2 
138±1 
138±1 
3.8±0.3 
4.0±0.2 
10.2±1.3 
9.2±1.7 
120±4 
117±10 
102±3 
104±3 
0.86±0.03 
0.87±0.03 
0.98±0.07 
1.07±0.09 
3 HOURS 
40±1 
40±2 
138±1 
139±1 
3.7±0.3 
3.8±0.1 
1 0.1±1.3 
9.0±1.7 
119±4 
11 3± 11 
102±3 
103±2 
0.84±0.03 
0.84±0.03 
1.09±0.07 
1.16±0.1 0 
4 HOURS 
40±1 
39±2 
138±1 
138±2 
3.6±0.2 
3.5±0.1 
1 0.0±1.3 
8.8±1.7 
120±5 
112±1 0 
103±2 
103±3 
0.83±0.03 
0.76±0.03 
1.16±0.07 
1.20±0.11 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Plasma hormones 
Plasma concentrations of A-ll were maximally supressed one hour after 
captopril had been administered (22 to <5, p<0.02) and gradually increased 
thereafter, although baseline values were not achieved during the time 
course of the study (figure 4.6). Plasma concentrations of aldosterone fell 
throughout the study in both groups but were consistently lower in the 
captopril treated group, reaching significance one hour after dosing (82 
to52ng/100ml, p<0.03: figure 4.7). plasma renin rose one hour after 
captopril and remained elevated throughout the study (figure 4.8). 
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Figure 4.6 Plasma concentrations of angiotensin II 
after placebo and captopril 
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Figure 4.8 Plasma active renin concentration after 
placebo and captopril 
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Haemodynamic variables 
There was no change in heart rate after captopril, but both systolic and 
diastolic blood pressure fell one and two hours after captopril (table 4.5). 
There was a fall in GFR 1 and 2 hours after captopril while ERPF rose after 
captopril, achieving significance two hours after dosing. There was a sharp 
fall in filtration fraction for the entire three hour period following captopril with 
the most marked change two hours after dosing (p<0.003). 
Table 4.5 Haemodynamic variables 
Changes in heart rate (HR), systolic and diastolic blood pressure (SBP, DBP), GFR and ERPF. p< 0.02 
for systolic blood pressure at 1-2 and 2-3 hours from the start. p<O.OS for diastolic blood pressure at 1-2 
and 2-3 hours from the start. 
START 0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
HR PLAC 69±5 68±3 67±4 66±3 69±3 
bpm CAPT 69±4 67±3 66±3 67±2 66±3 
SBP PLAC 127±11 130±10 128±11 129±10 130±9 
mmHg CAPT 127±10 129±9 120±10* 121±10* 127±9 
DBP PLAC 69±5 71±4 73±5 73±4 73±5 
mmHg CAPT 72±4 72±4 67±4* 68±3* 73±4 
GFR PLAC - 55±8 57±7 60±9 58±8 
ml/min CAPT - 55±8 50±7* 55±8* 53±5 
ERPF PLAC - 180±21 201±24 214±25 210±21 
ml/min CAPT - 180±17 223±13 259±24* 223±15 
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Figure 4.9 Changes in GFR, ERPF and filtration fraction 
after placebo and captopril 
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4. 5 Discussion 
The present study demonstrated that, in patients with heart failure treated 
chronically with ACE-inhibitors, salt and water excretion in response to 
furosemide was enhanced by supression of A-11. This contrasted with the 
findings during initiation of ACE inhibitor therapy in patients with heart 
failure, where the diuretic effect of furosemide was usually reduced by ACE 
inhibition (Fitzpatrick, Nicholls, lkram, et al 1983; Cleland, Dargie, Hodsman, 
et al 1984; Di Nicolantonio, Morgan 1987; Flapan, Davies, Waugh, et al 
1991; Motwani, Fenwick, Morton, et al 1992b). It is possible that angiotensin 
II receptors could have been up-regulated during chronic ACE-inhibition and 
hence have been more responsive to acute changes in angiotensin II during 
the studies. 
The present study gives some insight into the site of the renal effects of 
captopril on sodium handling. The increased natriuresis induced by 
captopril in the present study was due to reduced tubular reabsorption of 
sodium, since GFR fell and the ratio of sodium to creatinine increased. Most 
phosphate reabsorption occurs in the proximal tubule. Excretion of sodium 
relative to phosphate did not change after captopril, suggesting that a fall in 
sodium reabsorption at this site contributed to the natriuresis (Bijovet, 
Morgan, Fourman 1969), however uncoupling of proximal tubular handling 
of sodium and phosphate after a loop diuretic has been described 
(Noormohamed, Lant 1991 ). The ratio of sodium to potassium excretion 
increased, suggesting that distal sodium reabsorption decreased, 
associated with the fall in plasma concentrations of aldosterone, contributing 
to the natriuresis. 
Increased delivery of furosemide to its receptor site in the ascending limb of 
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the Loop of Henle following renal vasodilatation might account for the 
potentiation of the diuresis by captopril. Furthermore, captopril has been 
reported to impair the renal tubular secretion of furosemide (Toussaint, 
Masselink, Gentges, et al 1989). However, we observed no increase in the 
urinary excretion of furosemide after administering captopril. 
ACE inhibitors have effects on both parasympathetic and sympathetic tone 
and alter baro-receptor function (Poleur, Rosseau, Oakley, et al 1991 ). 
Arterial pressure is a powerful determinant of renal salt and water handling 
and each individual appears to operate around a "set point" relating these 
variables. It is possible that chronic but not acute ACE inhibition alters the 
relationship between pressure and natriuresis accounting for the reversal of 
the initial tendency for fluid retention. 
Angiotensin II exerts powerful vasoconstrictor effects on the renal 
vasculature; the efferent arteriole is particularly sensitive to its effects. 
Reduction of blood flow by angiotensin II in the vasa recta that descend into 
the renal medulla may increase salt and water reabsorption and captopril 
could reverse this (Cl land, Dargie 1987b; Cleland 1991), diverting global 
flow to the more superficial cortical nephrons. 
Captopril enhances intra-renal production of prostaglandins, either directly 
or mediated through increases in bradykinin (Usberti, Minno, Ungaro, et al 
1986), that may be important in preventing more profound falls in glomerular 
filtration than those actually observed after ACE inhibition. This protective 
effect on glomerular filtration is presumably due to changes in afferent 
arteriolar tone or glomerular function itself (Packer, Lee, Medina, et al 
1987b). Renal prostaglandins may also increase salt and water excretion by 
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enhancing renal tubular sodium transport (lino, lmai 1978) or by opposing 
the actions of anti-diuretic hormone in the collecting duct (Berl, Raz, Wald, et 
al 1977). Furosemide also stimulates renal synthesis of prostaglandin E2 
either directly or by enhancing production of bradykinin (Katayama, Attallah, 
Stahl, et al 1984; Mackay, Nath, Cumming, et al 1985; Fujimura, Ebihara 
1988). Administration of agents such as indomethacin impair glomerular 
filtration rate and promote sodium retention in patients with heart failure 
(Packer 1988b), supposedly by inhibiting renal cyclo-oxygenase and 
prostaglandin production, an effect that is more pronounced in patients with 
heart failure treated with diuretics and ACE inhibitors. Therefore, increased 
renal prostaglandin production, possibly in synergy with furosemide, could 
be responsible for the effects of captopril on salt and water excretion. 
A decline in filtration fraction is one of the most consistent haemodynamic 
responses to an ACE inhibitor (Cleland, Dargie 1987b). Effective renal 
plasma flow was increased following administration of captopril; GFR and 
hence filtration fraction was reduced. The time course of the effects of 
captopril on plasma concentrations of angiotensin II and on filtration fraction 
were remarkably similar. This suggests either that efferent arteriolar tone, a 
major determinant of filtration fraction, is regulated mainly by the circulating 
renin-angiotensin system or that changes in tissue and circulating renin-
angiotensin systems in response to captopril are closely related. 
Implications for the Optimal Therapeutic Dose of ACE Inhibitors 
The dose of captopril used in our study was chosen to achieve powerful 
supression of angiotensin II concentrations for some hours, but allowing the 
concentrations to recover towards the end of the study period. A larger dose 
of captopril would be unlikely to produce more intense suppression of 
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circulating angiotensin II, although the duration of suppression of 
angiotensin II would have been longer. Although recent studies support the 
use of larger doses of ACE inhibitors in patients with heart failure (Pacher, 
Globits, Bergler-Kiein, et al 1993; Pacher, Stanek, Globits, et al 1996), in 
clinical practice, many patients are maintained on doses of this magnitude. 
These data suggest that intense ACE inhibition either by frequent 
administration or by larger doses of ACE inhibitor may enhance a 
furosemide induced diuresis as well as prevent diuretic induced increases in 
angiotensin II. This may explain preliminary evidence that suggests that 
high-dose ACE inhibition is more effective than low-dose· ACE inhibition in 
heart failure, in terms of symptoms and possibly prognosis (Poleur, Rosseau, 
Oakley, et al 1991; Vagelos, Vee, Boyle, et al 1992; Pacher, Globits, Bergler-
Kiein, et al 1993; Pacher, Stanek, Globits, et al 1996). An enhanced diuresis 
observed with high-dose ACE inhibition, by causing a degree of pre-renal 
uraemia, may also contribute to the greater increase in plasma urea 
observed with long-acting ACE inhibitors (Packer, Lee, Yushak, et .al 1986b). 
Limitations 
Atrial natriuretic peptide (ANP) and bradykinin were not measured. Rouleau, 
Bichet and Kortas (1988) suggested that the relationship between plasma 
concentrations of ANP and atrial pressure are altered by ACE inhibition such 
that for a given pressure a higher plasma concentration of ANP exists. 
However, this resetting of the relationship between ANP and atrial pressure 
appears related to long- rather than short-term ACE inhibitor effects and it is 
not clear that increases in ANP concentrations will enhance a furosemide 
induced diuresis in patients with heart failure (Molina, Fowler, McCrory, et al 
1988). Intense ACE inhibition may potentiate the effects of bradykinin on 
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renal medullary blood flow and thus promote a diuresis. In addition, ACE 
inhibitor therapy has been shown to result in delayed reduction in circulating 
argenine vasopressin concentrations which would favour diuresis and 
natriuresis (Cleland, Dargie, Ball, et al 1985a; Cleland, Gillen, Dargie 1988) 
but we did not measure it in this study. This study is not directly applicable to 
clinical practice as furosemide was given intravenously and captopril was 
used in a dose that would be considered sub-therapeutic by many. 
However, for the purposes of looking at the mechanisms of ACE-inhibitor 
effect, the use of intravenous furosemide to overcome variable oral 
absorption appears preferable. Lower than recommended doses of 
captopril were used so that patients could be studied at times when ACE-
inhibition was no longer effective in suppressing angiotensin II, however it 
should be noted that less than a third of all prescriptions for captopril are for 
12.5mg tid or less. 
Conclusions 
Short-term inhibition of ACE in patients with heart failure has been shown to 
reduce the diuretic efficacy of furosemide. In contrast in patients treated with 
ACE inhibitors chronically, the natriuretic and diuretic responses to 
furosemide are enhanced by intense supression of angiotensin II. The 
precise renal mechanism for this effect remains to be disclosed, but altered 
baroreceptor function with a change in the "set point" for sodium is possible. 
The implications of these findings as to the optimal dosing regime for ACE 
inhibitors should be resolved by ongoing studies. 
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Chapter 5 Investigation of the effects of agents which increase 
cardiac output 
5.1 Introduction 
Increasing cardiac output in patients with heart failure might be expected to 
potentiate a furosemide-induced diuresis, but little is known about the 
precise mechanism, nor which the most appropriate agent would be. 
Sodium nitroprusside increases cardiac output by balanced arterial and 
venous dilatation, associated with a fall in arterial pressure and in peripheral 
vascular resistance (Berkowitz, McKeever, Croke, et al 1977; Franciosa, 
Silverstein 1982a; Young, Leon, Pratt, et al 1988; Ferrari, Ceconi, De Guili, 
et al 1992). Dobutamine has both inotropic and vasodilator effects, usually 
causes arterial pressure to rise and has been shown to improve urine output 
in uncontrolled studies of patients with cardiac failure both alone and with 
concomitant furosemide administration (Berkowitz McKeever, Croke, et al 
1977, Leier, Webel, Bush 1977; Leier, Heban, Huss, et al 1978). It is not 
clear whether any beneficial effect on diuresis is due to an increase in 
cardiac output or blood pressure or due to improved renal perfusion 
pressure. 
The aim of the present study was to determine whether dobutamine or 
sodium nitroprusside augmented the renal effects of furosemide in patients 
with chronic heart failure and, if so, to establish by which mechanism this 
occurs: 
a) Improved systemic and renal perfusion pressure 
b) Increased renal blood flow 
c) Altered delivery of furosemide to the loop of Henle. 
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Patients and methods 
Eight patients aged 51-67 (mean age 62) years with chronic stable heart 
failure requiring diuretics to control symptoms were studied on three 
occasions in single blind fashion. Diuretic requirements ranged from 40mg-
160mg furosemide per day (mean 1 OOrng/day). 
Table 5.1 · Patient characteristics 
Table showing individual patients' age, sex, New York Heart Association classification 
(NYHA), daily diuretic requirements in milligrams (furosemide-F. metolazone-MET), type 
of ACE-inhibitor and daily dosage (captoprii-CAP, enalaprii-ENAL, lisinoprii-LISIN) and 
aetiology of heart failure (ischaemic heart disease-IHD, dilated cardiomyopathy-DCM). 
PATIENT AGE SEX NYHA DIURETIC ACE-I (mg) AETIOLOGY 
1 64 M liB F 80 CAP 75 IHD 
2 67 M liB F 120 CAP 75 IHD 
3 65 M liB F 120 IHD 
4 55 M Ill F 120 ENAL 20 IHD 
5 62 M Ill F 40, MET 2.5 LISIN 10 IHD 
6 63 M Ill F120 ENAL 15 DCM 
7 62 M liB F 80 ENAL 10 IHD 
8 51 M Ill F160 ENAL 20 DCM 
After the run-in period of one hour, sodium nitroprusside, dobutamine or 
matching placebo was infused as set out in the methods section. 
Dobutamine and sodium nitroprusside were infused at low dose for the 
second hour and at high dose for the third hour then discontinued for the 
final hour. Hourly urine and blood samples were collected for electrolytes, 
PAH, urinary cGMP and plasma ANP and active renin. Adrenaline and 
noradrenaline were measured during placebo and nitroprusside infusion 
only. Heart rate and blood pressure were measured at 15 minute intervals 
(figure 5.1 ). 
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Figure 5.1. Study design (Dobutamine, nitroprusside) 
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Results: 
Urine output was not significantly different from placebo after nitroprusside 
although there was a significant rise in urine volume during the hour after 
high dose dobutamine infusion (figure 5.2). 
Electrolyte excretion: There was no change in excretion of any of the 
electrolytes measured after sodium nitroprusside infusion (table 5.2). 
Natriuresis was potentiated by low and high-dose dobutamine infusion 
(p<0.02 and p<0.04 respectively) with a trend still evident an hour after the 
infusion was terminated (p=0.08); Figure 5.3. (Of note, urinary sodium 
excretion fell progressively during the placebo arm of the study examining 
the effect of captopril, suggesting that preservation of a constant natriuresis 
over 4 hours is an improvement). Chloride excretion increased after 
dobutamine, reaching significance only during low dose infusion (13±4 to 
20±4mmol, p<0.02; table 5.2). Phosphate excretion tended to fall during 
dobutamine infusion. There was no change in renal excretion of furosemide 
or urinary cyclic GMP with either intervention (table 5.2). 
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Figure 5.2 Hourly urine output during placebo, 
dobutamine and sodium nitroprusside infusions. 
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Figure 5.3: Hourly sodium excretion during infusion 
of placebo, dobutamine and sodium nitroprusside. 
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Table 5.2 Urine parameters during infusion of placebo, 
dobutamine and SNP 
Changes in urine volume and excretion of sodium (Na), potassium (K), urea, creatinine (Cr), 
chloride (CI), magnesium (Mg), phosphate (Phos), furosemide (F'SEMIDE) and cyclic GMP 
(cGMP). *denotes significance at p<0.05. 
VOLUME 
MLS 
Na 
mmol 
K 
mmol 
Urea 
mmol 
Cr 
mmol 
Cl 
mmol 
Mg 
mmol 
Phos 
mmol 
F'SEMIDE 
mg 
cGMP 
nmol/min 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
0-1 HRS 
229±28 
201±35 
211±40 
18±5 
21±4 
15±4 
6.9±0.8 
7.1±1.3 
5.8±1.1 
21±3 
24±3 
18±2 
0.59±0.06 
0.62±0.09 
0.56±0.06 
17±4 
20±3 
15±4 
PLACEBO 0.41 ±0.05 
DOBUT AMINE 0.40±0.06 
NITRO 0.34±0.06 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
1.17±0.21 
1.18±0.14 
0.88±0.11 
1.99±0.26 
1.51±0.2 
1.66±0.26 
2.98±0.94 
2.64±0.46 
3.36±1.01 
1-2 HRS 
218±28 
211±35 
210±33 
14±4 
20±4* 
13±2 
6.7±0.4 
6.8±1.2 
5.8±1.1 
18±2 
20±3 
16±1 
0.48±0.04 
0.49±0.09 
0.44±0.05 
13±4 
20±4* 
13±3 
2-3 HRS 
228±31 
272±28* 
191±21 
11±3 
19±4* 
14±2 
6.1±0.7 
5.6±1.1 
6.6±1.3 
16±2 
16±2 
15±2 
0.41±0.04 
0.38±0.06 
0.45±0.08 
13±2 
18±4 
12±2 
0.3203±0.02 0.30±0.03 
0.34±0.06 0.27±0.05 
0.32±0.04 0.30±0.05 
0.92±0.12 
1.07±0.12 
0.84±0.08 
1.93±0.15 
2.04±0.51 
2.25±0.32 
2.52±0.68 
2.79±0.70 
2.90±0.87 
1.02±0.08 
0.88±0.1 0 
0.91±0.15 
1.81 ±0.2 
2.86±0.79 
1.92±0.22 
2.67±0.61 
3.27±0.81 
2.23±0.43 
3-4 HRS 
237±32 
271±41 
210±21 
15±3 
20±4 
14±3 
6.3±0.6 
7.4±1.3 
6.8±1.6 
16±1 
20±2 
15±3 
0.43±0.02 
0.48±0.05 
0.44±0.09 
13±2 
19±3 
14±3 
0.30±0.02 
0.32±0.05 
0.30±0.0 
1.12±0.07 
0.93±0.1 
1.12±0.18 
1.86±0.22 
2.74±0.6 
2.40±0.35 
2.21±0.69 
3.11±1.01 
2.71±0.70 
Fractional excretion of all urinary indices were calculated to eliminate the 
effect of inaccuracies of urine measurement. There was no significant 
change in fractional excretion of any of the electrolytes measured during 
nitroprusside infusion but fractional excretion of sodium and chloride 
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increased during low-dose dobutamine infusion (p<0.03) 
Table 5.3 Fractional excretion of electrolytes, furosemide and 
cyclic GMP 
Table of fractional excretion of sodium (Na), potassium (K), urea (U), chloride (CI), 
magnesium (Mg), phosphate (Phos), furosemide (FRUS) and cyclic GMP (cGMP). * p<0.05. 
Na/Cr 
K/Cr 
U/Cr 
CI/Cr 
Mg/Cr 
Phos/Cr 
FRUS/Cr 
cGMP/Cr 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
PLACEBO 
DOBUTAMINE 
NITRO 
0-1 HRS 
32±7 
36±8 
28±7 
12±2 
12±2 
1 0±1 
35±2 
40±2 
34±4 
30±6 
34±6 
28±8 
0.70±0.07 
0.65±0.08 
0.62±0.1 0 
1.9±0.2 
2.1 ±0.3 
1.7±0.7 
3.7±0.4 
2.7±0.4 
3.5±0.9 
5.1±1.8 
4.8±1.2 
6.4±2.0 
1-2 HRS 
31±9 
44±8* 
34±9 
14±1 
15±2 
13±1 
38±2 
43±2 
38±3 
29±8 
42±6* 
32±8 
0.70±0.06 
0.72±0.08 
0.74±0.07 
2.0±0.3 
2.5±0.4 
2.0±0.1 
4.5±0.5 
6.1 ±2.7 
5.8±1.3 
5.2±1.3 
7.5±3.0 
8.1±3.0 
2-3 HRS 
36±8 
51±6 
35±7 
15±1 
15±2 
14±1 
39±2 
44±2 
36±3 
34±7 
46±6 
28±4 
0.75±0.07 
0.72±0.07 
0.69±0.08 
2.7±0.3 
2.6±0.4 
2.0±0.2 
5.1±0.4 
11.2±4.9* 
5.0±1.0 
6.8±1.8 
11.9±4.4 
6.2±1.5 
3-4 HRS 
35±6 
45±9 
37±6 
14±1 
15±2 
15±1 
37±2 
41±2 
37±3 
31±4 
42±7 
36±7 
0.68±0.05 
0.66±0.07 
0.71±0.06 
2.6±0.2 
2.1 ±0.4 
2.7±0.2 
4.9±0.5 
6.5±2.2 
8.4±3.6* 
4.9±1.5 
6.9±2.1 
9.8±3.3 
Plasma electrolyte concentrations were not significantly different after 
placebo, dobutamine and nitroprusside infusions with the exception of 
phosphate, which fell during high-dose dobutamine infusion (Table 5.4). 
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Table 5.4 Plasma electrolyte concentrations 
Changes in plasma concentrations of sodium (Na), potassium (K), urea, creatinine (Cr), 
chloride (CI), magnesium (Mg) and phosphate (Phos) one, two and three hours from the 
start of each study. 
* p<0.05. 
Na PLACEBO 
mmol DOBUT AMINE 
NITROPRUSSIDE 
K PLACEBO 
mmol DO BUT AMINE 
NITROPRUSSIDE 
Urea PLACEBO 
mmol DO BUT AMINE 
NITROPRUSSIDE 
C r PLACEBO 
mmol DOBUT AMINE 
NITROPRUSSIDE 
C I PLACEBO 
mmol DOBUT AMINE 
NITROPRUSSIDE 
Mg PLACEBO 
mmol DOBUT AMINE 
NITROPRUSSIDE 
Phos PLACEBO 
mmol DOBUT AMINE 
NITROPRUSSIDE 
1 HOUR 
137±1 
137±1 
136±2 
4.1 ±0.2 
3.9±0.2 
3.8±0.1 
8.0±0.7 
8.1±0.7 
9.0±1.0 
114±9 
112±1 0 
123±10 
99±1 
100±2 
99±2 
0.82±0.03 
0.79±0.03 
0.81±0.04 
1.06±0.07 
0.92±0.05 
0.96±0.04 
Neuroendocrine effects 
2 HOURS 
136±1 
137±1 
136±2 
4.0±0.1 
3.8±0.1 
3.7±0.1 
7.9±0.7 
8.0±0.7 
8.8±1.0 
112±9 
11 0±1 0 
120±10 
99±1 
101±1 
99±2 
0.81±0.03 
0.79±0.03 
0.79±0.04 
1.07±0.05 
0.90±0.05 
0.98±0.04 
3 HOURS 
137±1 
137±1 
136±2 
3.9±0.1 
3.6±0.1 
3.8±0.1 
7.7±0.7 
7.8±0.7 
8.8±1.1 
109±9 
109±9 
120±10 
100±1 
1 01±1 
98±2 
0.80±0.03 
0.78±0.03 
0.79±0.04 
1.13±0.05 
0.87±0.04* 
1.06±0.03 
After high dose infusion of sodium nitroprusside, ANP concentrations 
decreased (100 to 70 pg/ml; p<0.03, figure 5.4) and noradrenaline and 
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adrenaline concentrations rose (3.8±0.62 and 0.25±0.08 to 6.0±1.3 and 
0.39±0.12, P<0.03 for noradrenaline and adrenaline respectively, figure 5.6). 
Plasma active renin concentrations did not change (figure 5.5, table 5.5). 
Catecholamines were not measured after dobutamine infusion as it was not 
possible to distinguish endogenous secretion from exogenous 
administration. ANP concentrations were significantly higher at baseline 
prior to infusion of dobutamine than prior to placebo but concentrations did 
not differ from placebo after low or high dose dobutamine infusion (table 
5.5). However plasma active renin concentrations increased significantly 
after high dose dobutamine infusion (figure 5.5). 
Table 5.5 Plasma hormone concentrations 
Changes in plasma concentrations of atrial natriuretic peptide (ANP), plasma renin (PARC), 
noradrenaline (N ADREN) and adrenaline (ADREN) at one, two and three hours from the start of the 
studies. * p<0.05. 
1 HR 2 HRS 3HRS 
ANP PLACEBO 1 01±43 117±49 100±31 
pg/ml DOBUTAMINE 143±52 117±42 121±53 
NITROPRUSSIDE 140±75 112±49 70±26* 
PARC PLACEBO 352±144 303±143 285±132 
JJU/ml DOBUTAMINE 245±112 242±108 499±184* 
NITROPRUSSIDE 239±75 228±67 314±105 
N ADREN PLACEBO 4.4±0.93 4.4±0.91 3.8±0.62 
nmol/1 DOBUTAMINE 
NITROPRUSSIDE 5.0±1.2 5.8±1.6 6.0±1.3* 
ADREN PLACEBO 0.27±0.09 0.22±0.07 0.25±0.08 
nmol/1 DOBUTAMINE 
NITROPRUSSIDE 0.25±0.05 0.26±0.06 0.39±0.1 2* 
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Figure 5.4: Changes in plasma concentrations of ANP during infusion 
of placebo, dobutamine and nitroprusside. 
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Figure 5.5 Changes in plasma active renin concentration during 
infusion of placebo, dobutamine and sodium nitroprusside 
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Figure 5.6 Changes in plasma noradrenaline concentrations 
during infusion of placebo and sodium nitroprusside 
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Haemodynamic effects 
Heart rate rose during low-dose (p<0.05) and during high-dose 
dobutamine infusion (p<0.02), figure 5. 7). Heart rate did not change during 
nitroprusside infusion, despite relative hypotension during high dose 
infusion (74±2 to 79±5bpm, p=NS). 
Mean arterial pressure fell during high dose nitroprusside infusion 
(p=0.018) but was unchanged by dobutamine (figure 5.8). 
Renal blood flow increased during low-dose nitroprusside infusion but 
not high-dose, and during high-dose dobutamine infusion but not low dose 
infusion (figure 5.9). 
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Figure 5. 7 Changes in heart rate during infusion of 
placebo, dobutamine and sodium nitroprusside 
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Figure 5.8 Changes in mean arterial pressure during placebo, 
dobutamine and nitroprusside infusion 
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Figure 5.9 Changes in ERPF during infusion of placebo, 
dobutamine and sodium nitroprusside. 
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Creatinine clearance tended to rise after high dose dobutamine infusion 
was terminated although this did not reach statistical significance. 
Table 5.6 Renal haemodynamics 
Changes in glomerular filtration rate (GFR) measured by creatinine clearance (CR. CLEAR), 
changes in effective renal plasma flow (ERPF) measured by hippurate clearance (PAH 
CLEAR). *Denotes p<O.OS 
0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
GFR PLACEBO 92±13 79±10 67±11 70±6 
(CR. CLEAR.) DOBUTAMINE 97±17 76±15 58±9 76±9 
NITRO 80±12 63±7 64±10 62±12 
ERPF PLACEBO 193±18 179±13 212±19 222±20 
(PAH CLEAR.) DOBUTAMINE 185±18 200±20 305±33* 225±25 
NITRO 196±18 257±25* 214±26 208±28 
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5.4 Discussion 
This study set out to explore the relative ability of nitroprusside and 
dobutamine to potentiate a furosemide induced diuresis by improving 
cardiac output. Indices of improved haemodynamics included changes in 
heart rate, arterial pressure and renal plasma flow. Unfortunately it proved 
impossible to measure changes in cardiac output using the Bomed, however 
nitroprusside induced a significant fall in arterial pressure and increase in 
renal plasma flow, compatible with improved cardiac output (Cogan, 
Humphreys, Carlson, et al 1980; Miller, Fennell, Young, et al 1982; 
Franciosa, Silverstein 1982a; Olivari, Levine, Cohn 1986; Young, Leon, 
Pratt, et al 1988). 
Dobutamine improved the furosemide induced natriuresis and diuresis in 
the present study although the diuretic effect only reached statistical 
significance during the hour after high dose dobutamine infusion. Leier, 
Heban, Huss, et al (1978) compared the effects of dopamine and 
dobutamine infused over 24 hours in patients with severe congestive heart 
failure without coronary disease (12 of the 13 patients were assigned to 
NYHA class IV) in whom maintenance oral diuretics were continued. They 
demonstrated diuresis, natriuresis and increased fractional excretion of 
sodium with dobutamine infusion but as these findings were not compared 
with a control infusion, changes from baseline may have been partly due to 
an effect of circadian variation. 
There are several mechanisms by which dobutamine could enhance a 
furosemide-induced diuresis and natriuresis: 
a) enhanced furosemide delivery (Nomura, Yasuda, Minami, et al .. 1981) in 
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patients with heart failure and in normal subjects (Fujimura, Ebihara 1988), 
where natriuresis and renal furosemide excretion were correlated. The 
natriuresis associated with dobutamine infusion was not accompanied by 
increases in renal furosemide excretion. To compensate for the potential 
inaccuracies of urine collections, fractional excretion of furosemide wqs 
examined. As this increased during high-dose dobutamine infusion, it is 
possible that the natriuresis was mediated by increased delivery of 
furosemide to its site of action in the proximal tubule, associated with the 
improvement in ERPF. However fractional excretion of furosemide also 
increased in the hour following high-dose nitroprusside infusion, which was 
not associated with natriuresis. 
b) An alternative explanation for the diuresis and natriuresis could be that of 
an enhanced effect on tubular responsiveness to furosemide, however there 
was no data to support this from the present study. 
c) By increasing ERPF. The increase in renal plasma flow with dobutamine 
coincided with natriuresis in the present study although Leier, Heban, Huss, 
et al (1978) showed that diuresis and natriuresis occurred without changes 
in renal blood flow during sustained infusion of dobutamine at similar doses. 
By contrast, ERPF was enhanced during low-dose nitroprusside infusion 
without concomitant potentiation of diuresis or natriuresis. It is possible that 
the kidney is more sensitive to changes in arterial pressure than changes in 
ERPF. 
d) By an effect on blood pressure. There was no significant increase in 
arterial pressure during dobutamine infusion but most patients were not able 
to tolerate the maximum dose of dobutamine (1 O~glkg/min) for the third hour. 
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Leier, Webel and Bush (1977) did not induce a significant rise in blood 
pressure at dobutamine doses of less than 1 OJ.Ig/kg/min. This relative 
dobutamine intolerance may have been due to underlying ischaemic heart 
disease in some of the patients although Leier's patients, none of whom had 
ischaemic heart disease, developed significant ventricular extrasystoles with 
dobutamine at doses of 1 OJ.Ig/kg/min. Nitroprusside infusion caused 
hypotension in all patients and failed to improve the furosemide induced 
diuresis or natriuresis. Thus it seems that while a fall in blood pressure is 
detrimental to the renal effects of nitroprusside, the beneficial renal actions 
of dobutamine are not dependent on a rise in arterial pressure. 
e) Via a local renal sympathetic effect. Adrenoceptor agonists such as 
dobutamine affect the renal tubule via activation of receptors influencing 
cAMP production. a1-adrenoceptor agonists mimic the effect of renal nerve 
stimulation, resulting in vasoconstriction and increased renal vascular 
resistance. They have been implicated in the decrease in renal blood flow 
and alteration in intrarenal perfusion found in cardiac failure (Schrier, De 
Wardener 1971 ). Catecholamines release renin from juxtaglomerular cells 
through activation of intrarenal ()-receptors, mediated by a rise in cAMP, 
calcium flux or renal prostaglandins. Thus sympathetic stimulation should 
tend to decrease salt and water excretion. However selective a2-
adrenoceptor stimulation causes diuresis in vivo, probably due to 
modulation of the action of vasopressin on the collecting tubule (Garg 1992). 
A direct renal sympathetic effect is thus unlikely to be responsible for the 
natriuretic and diuretic effects observed with dobutamine infusion, although 
this mechanism cannot be entirely ruled out. 
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f) By enhancing creatinine clearance. Creatinine clearance did not change 
during either infusion, despite the rise in ERPF, suggesting a degree of 
glomerulo-tubular imbalance. Garg (1992) proposed that the failure of 
adrenergic drugs to increase renal papillary flow (as opposed to renal 
plasma flow) was responsible for the lack of change in GFR. Creatinine 
clearance is not the most accurate method of measuring glomerular filtration 
rate in patients with impaired cardiac function (Motwani, Fenwick, Struthers 
1992c), tending to overestimate GFR. As patients acted as their own 
controls and changes in clearance were assessed rather than absolute 
values, it is unlikely that changes in GFR were responsible for the enhanced 
diuresis and natriuresis caused by dobutamine infusion. 
g) Increased cardiac output. The renal haemodynamic changes support an 
improvement in cardiac output with low dose nitroprusside infusion and 
high-dose dobutamine infusion. In studies comparing similar groups of 
patients during nitroprusside infusion, these changes have been 
accompanied by increased total cation excretion, natriuresis or diuresis, in 
different studies (Cogan, Humphreys, Carlson, et al 1980; Miller, Fennell, 
Young, et al 1982; Young, Leon, Pratt, et al 1988). They differ from the 
present study in that the effect of nitroprusside alone was assessed, not how 
nitroprusside modified the diuretic or natriuretic effects of furosemide. 
Patients were also generally in a lower functional class with decompensated 
heart failure. The powerful diuretic actions of furosemide may have masked 
smaller changes in salt excretion in the present study. 
h) A rise in cGMP. There was no change in urinary cGMP excretion or 
fractional excretion during nitroprusside infusion or dobutamine infusion 
although nitroprusside is itself a producer of cyclic GMP in the papillary 
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collecting tubule. Chiu, Vemulapalli and Sybertz (1991) compared the 
vascular and renal excretory effects of atrial natriuretic peptide, sodium 
nitroprusside and bromium labelled cGMP infused into spontaneously 
hypertensive rats and showed that the natriuretic effects of ANP could not be 
reproduced by infusion of exogenous cGMP or by generation of cGMP from 
soluble guanylate cyclase (the mechanism of action of sodium 
nitroprusside). These findings are in agreement with the present study, but 
do not explain by what mechanism diuresis and natriuresis occurred with 
nitroprusside in other trials. 
The relatively modest diuretic effect of dobutamine demonstrated in the 
present study may have been due to relative salt depletion, but the 3 day 
period with controlled sodium intake of 1 OOmmol/day should have been 
sufficient to correct more gross salt depletion. There is some evidence from 
animal studies that the action of many if not all drugs may be modulated by 
interstitial osmolality in the renal medulla, which itself depends on the state 
of hydration of the subject at the time (Garg 1992). The average ANP 
concentrations for the present group were well above normal, suggesting 
raised atrial pressure, not hypovolaemia (Lewis, Makhoul, Dakak, et al 
1992). It is possible that the patients with decompensated heart failure who 
benefited the most from dobutamine infusion in the acute studies reported 
(Leier, Webel, Bush 1977; Leier, Heban, Huss, et al 1978; Applefeld, 
Newman, Sutton, et al 1987) had a greater improvement in haemodynamic 
variables and thus a greater diuresis and natriuresis than those in the 
present study who had compensated, moderate heart failure. In addition, in 
most of the studies describing diuresis with dobutamine infusion, furosemide 
was not administered concurrently. 
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Although ANP concentrations fell during dobutamine infusion in the present 
study, baseline concentrations were significantly different from placebo. 
Concentrations during infusion did not differ significantly from placebo at the 
same time·point. Stangl, Baumann, Gerzer, et al (1991) described a fall in 
ANP and cGMP during dobutamine infusion at comparable dosage, with 
prompt return to baseline concentrations when the infusion was terminated. 
The reasons for the discrepancy are unclear. 
Limitations of the study 
The study population was small. Clinically significant changes in blood 
pressure were apparent during nitroprusside infusion and thus it was 
assumed that clinically significant changes in water or electrolyte excretion 
too would be evident if present. Small changes could have been 
overlooked because of the small sample size but would have been of less 
clinical relevance. 
The study was single·blind, introducing observer error in the measurement 
of urine volume, although heart rate and blood pressure were measured by 
an automated device. In addition error may have been introduced into urine 
volume measurements by incomplete bladder emptying in some of our 
patients as urinary catheters were not used to collect samples. However all 
assays were performed blind, by independent departments. Between· 
patient variability was wide which may have been accentuated by the 
inclusion criteria, with heart failure due to ischaemic heart disease, 
previously corrected valvular heart disease and dilated cardiomyopathy all 
included. It is possible that the aetiology of heart failure influences the 
response to diuretics in some cases however patients were their own 
controls. 
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Patients may not have adhered strictly to the prescribed diet as 24 hour 
urinary collections were not analysed for electrolyte excretion in all patients, 
however the effect of marked variation in sodium intake on diuresis and 
natriuresis (chapter 3) was modest. 
As the measure of changes in cardiac output or stroke volume used in the 
present study proved unreliable, it was not possible to determine whether 
changes in these variables had actually taken place with acute 
interventions. However there was a clear change in ERPF. While several 
studies have documented the haemodynamic response to dobutamine and 
nitroprusside infusions in patients with decompensated heart failure (Cogan, 
Humphreys, Carlson, et al 1980; Bendersky, Chatterjee, Parmley, et al 1981; 
Young, Leon, Pratt, et al 1988) there is a lack of data on the hae~odynamic 
response to dobutamine and nitroprusside in well-diuresed stable patients. 
Conclusion: Both dobutamine and sodium nitroprusside have been 
reported to produce diuresis and natriuresis in with patients with heart 
failure. The renal effects of intravenous dobutamine and nitroprusside 
combined with furosemide, as they would usually be administered in clinical 
practice, were far less impressive in the present study. Dobutamine 
furosemide induced natriuresis at high dose, but had only a modest effect on 
diuresis, while sodium nitroprusside tended to impair both diuresis and 
natriuresis. These results could not be accounted for by changes in renal 
plasma flow, which was augmented by both agents. Nitroprusside infusion 
was distinguished from dobutamine infusion by the dramatic fall in blood 
pressure seen during high dose nitroprusside infusion. While dobutamine 
had no effect on blood pressure, preservation of blood pressure seems to 
have been important in augmenting the diuretic and natriuretic effects of 
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furosemide and possibly exerts a permissive effect on the enhancement of 
sodium excretion by increasing ERPF. Enhanced renal excretion of 
furosemide may have been partly responsible for the natriuresis and 
diuresis, as fractional excretion of furosemide increased. In compensated 
heart failure treated with diuretics, both dobutamine and nitroprusside were 
poorly tolerated, even at modest doses. 
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Chapter 6 The effect of digoxin on a furosemide induced 
diuresis 
6. 1 Introduction 
Digoxin is a cardiac glycoside, one of a family of substances synthesized by 
plants and animals. The therapeutic benefits of extracts from digitalis 
purpurea (the foxglove) were described by William Withering (1785), but the 
extracts had been used in topical preparations as far back as 1250 (Greeff, 
Schadewaldt 1981 a; Skou 1986). Similar products include the 
bufadienolides from the bulb of the sea squill (used to induce diuresis in 
Roman times: Greeff, Wirth 1981 b; Movitt 1949) and the skin of toads (used 
by the Chinese and Japanese for the treatment of dropsy: Fieser, Fieser 
1959), and ouabain from the bark and roots of the Ouabaio tree and the 
seeds of Strophanthus gratus. Despite this, the role of digoxin in heart 
failure and the mechanism by which it produces its effect remain 
controversial. Withering alluded to several mechanisms by which the 
beneficial effects of digitalis glycosides might be mediated, including a 
reduction in heart rate, a "strengthening" of the pulse and a diuresis. The 
opening paper in the first edition of the British Heart Journal (Gavey, 
Parkinson 1939) was on the subject of the benefit of using digoxin on 
patients with heart failure in sinus rhythm. The authors reported a marked 
diuresis in response to digoxin in many patients. Although ouabain 
extracted from plants has been used extensively as a research tool and 
binding sites or receptors had been discovered in nearly all cells in higher 
animals, it is only recently that it has been identified as the endogenous 
cardiac glycoside in animals (Hamlyn, Blaustein, Bova, et al 1991 ). Ouabain 
is an adrenal cortical hormone (Hamlyn, Blaustein, Bova, et al 1991; 
Ludens, Clark, Robinson, et al 1992) but the identity of the cells in the 
adrenal cortex that synthesize and store it remain unknown. Ouabain, unlike 
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digoxin, is highly soluble in aqueous media and thus poorly absorbed from 
the gastro-intestinal tract (Greeff, Wirth 1991 b). A high salt diet causes 
plasma ouabain levels to rise (Manunta, Rogowski, Hamilton, et al 1992a) 
and concentrations are elevated in. patients with congestive heart failure 
(Gottlieb, Rogowski, Weinberg, et al 1992b). 
The molecular basis for the actions of cardiac glycosides is their selective 
and potent inhibition of the Na+ pump (Schatzmann 1953). The Na-K-
ATPase is associated with the Na + pump and is specifically inhibited by the 
cardiotonic steroids (Skou 1986). This enzyme, found on all eukaryotic cells, 
represents the major pathway for sodium-potassium exchange across the 
cell membrane. It is found on the basolateral aspect of renal tubular 
epithelial cells and may promote the renal tubular reabsorption of sodium. 
Low concentrations of ouabain interact with and inhibit the Na+ pump, 
causing intracellular concentrations of sodium to rise and potasium to fall. 
This results in a change in the resting membrane potential, which can 
influence calcium permeability in smooth muscle (Nelson, Standen, 
Brayden, et al 1988; Nelson, Patlak, Worley, et al 1990; Brayden, Nelson 
1992). In addition the impairment of sodium transport can affect 
neurotransmitter release and re-uptake as many are co-transported with 
sodium (Johnson, Carty, Scarpa 1985; Kanner, Shuldiner 1987). Cytosolic 
calcium ions are major intracelular second messengers and regulate a 
variety of enzyme systems, membrane excitability, contraction, secretion, 
mitochondrial metabolism and cell division. Control of intracellular calcium 
is via the ATP-driven calcium pump and the Na+-Ca2+-exchanger. Most of 
the calcium is buffered by cytoplasmic proteins or sequestered in the 
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sarcoplasmic reticulum. The Na+-ca2+ exchanger plays a dominant role in 
extrusion of calcium from the cell when calcium concentrations are high. 
When the Na+ pump is slightly inhibited, a small rise in resting cytoplasmic 
calcium concentration results in a vast increase in the cytosolic to 
endoplasmic reticulum calcium ratio and in the case of cardiac muscle, 
enhanced contraction. 
In vascular smooth muscle, ouabain modulates vascular contractility, 
probably also by increasing the stores of calcium in the sarcoplasmic 
reticulum (Blaustein 1993). Increased dietary salt intake causes plasma 
ouabain levels to rise (Manunta, Rogowski, Hamilton, et al 1992b) and 
chronic ouabain infusion in normal rats causes chronic hypertension 
(Doursout, Chelly, Liang, et al 1992; Manunta, Rogowski, Hamilton, et al 
1992a; Yuan, Manunta, Chen, et al 1992). These findings have lent support 
to the theory of pressure natriuresis in patients with low-renin-hypertension. 
The primary problem is felt to be the inability of the kidney to excrete a salt 
load at a normal blood pressure. This leads to volume expansion and 
promotion of ouabain secretion. This results in a rise in blood pressure and 
pressure-natriuresis (Blaustein, Hamlyn 1991; Guyton 1991 ). However Luft, 
Aronoff, Fineberg, et al (1989) failed to demonstrate a natriuretic effect of 
digoxin in 14 normal volunteers during conditions of salt loading. 
Interestingly, elevated concentrations of ouabain in patients with heart 
failure correlate not with plasma volume but inversely with cardiac index 
(Gottlieb, Rogowski, Weinberg, et al 1992b). Perhaps ouabain helps 
support the blood pressure at the expense of plasma volume in heart failure. 
Uncontrolled studies by Starr & Luchi (1969); Dall (1970) and Hull & 
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Mackintosh (1977) suggested that digoxin could be safely withdrawn from 
many patients with stable heart failure in sinus rhythm. This lead to concern 
about the efficacy of digoxin (Gavey & Parkinson 1979), however several 
subsequent controlled trials (Lee, Johnson, Bingham, et al 1982; Guyatt, 
Sullivan, Fallen, et al 1988; The Captoprii-Digoxin Multicentre Research 
Group 1988; DiBianco, Shabetai, Kostuk, et al 1989) have shown that 
digoxin improves symptoms and exercise tolerance in patients with heart 
failure in sinus rhythm. Packer, Gheorghiade, Young, et al (1993) showed 
that withdrawal of digoxin from patients with chronic heart failure treated with 
ACE inhibitors resulted in worsening heart failure and in decreased exercise 
tolerance. The present study sought to determine in a controlled fashion 
whether digoxin potentiated the renal effects of fur semide in 8 patients 
receiving what is currently optimal therapy for the treatment of heart failure. 
6. 2 Patients and methods 
8 patients with chronic stable heart failure requiring maintenance diuretics to 
control symptoms of heart failure were studied on two occasions in random, 
single blind fashion. All patients were in sinus rhythm and no patients were 
taking digoxin. Seven patients were taking ACE inhibitors. 
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Table 6.1 Patient characteristics 
Individual patient characteristics: age, sex, New York Heart Association classification NYHA), 
usual diuretic requirements (furosemide-F. metolazone-MET, bumetanide-BUMET), ACE-
inhibitor (captoprii-CAP, enalaprii-ENAL, lisinoprii-LISIN, all expressed as daily dose) and 
aetiology of heart failure (ischaemic heart dise.ase-IHD, dilated cardiomyopathy-DCM). 
PATIENT AGE SEX NYHA DIURETIC ACE-I AETIOLOGY 
(mg) 
64 M liB F 80 CAP 75 IHD 
2 67 M liB F120 CAP 75 IHD 
3 65 M liB F120 IHD 
4 55 M Ill F 120 ENAL 20 IHD 
5 62 M Ill F 40, MET 2.5 LISIN 10 IHD 
6 63 M Ill F 120 ENAL 15 DCM 
7 62 M liB F 80 ENAL 10 IHD 
8 69 M Ill BUMET 4 ENAL 10 IHD 
After the run-in period of one hour, digoxin 500JJg or matching placebo 
(saline) was infused. Digoxin was infused as a single bolus over 30 minutes 
at the start of the 2nd hour, as set out in chapter 2, because of its. long half-
life. Hourly urine and blood samples were collected for electrolytes, urinary 
cGMP, PAH and plasma ANP, plasma renin, adrenaline and noradrenaline. 
Heart rate and blood pressure were measured at 15 minute intervals. 
6. 3 Results 
Urine volume did not change although sodium and chloride excretion were 
greater during the 3 hours following digoxin administration (p<0.03). 
Excretion of potassium, urea, magnesium, phosphate, creatinine, 
furosemide and cyclic GMP did not change. 
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Table 6.2 Urine volume and excretion of electrolytes, 
furosemide and cGMP 
Changes in urine volume, excretion of electrolytes (sodium-Na, potassium-K, urea, creatinine-Cr. 
magnesium-Mg. chloride-CI and phosphate-Ph), cGMP and furosemide (F'MIDE). 
0-1 hrs 1-2 hrs 2-3 hrs 3-4 hrs 
U VOL PLACEBO 229±28 216±29 240±28 247±27 
mfs DIGOXIN 227±32 227±28 247±26 258±31 
Na PLACEBO 19±5 14±4 15±3 17±3 
mmol DIGOXIN 19±4 18±3" 19±2" 20±2" 
K PLACEBO 6.7±0.9 6.2±0.6 6.1±0.7 6.1±0.7 
mmol DIGOXIN 5.7±0.9 6.2±0.8 6.5±0.9 6.4±0.6 
Urea PLACEBO 20±3 16±2 16±2 16±1 
mmol DIGOXIN 17±1 16±2 14±2 16±1 
Cr PLACEBO 0.56±0.07 0.43±0.05 0.40±0.04 0.42±0.02 
mmol DIGOXIN 0.43±0.03 0.41±0.04 0.41±0.04 0.43±0.02 
Mg PLACEBO 0.39±0.05 0.31±0.03 0.31±0.04 0.29±0.02 
mmol DIGOXIN 0.36±0.05 0.34±0.05 0.33±0.04 0.30±0.03 
Cl PLACEBO 17±3 13±4 14±2 14±2 
mmol DIGOXIN 20±4 18±4" 19±3" 18±2" 
Phos PLACEBO 1.1 0±0.23 0.91 ±0.12 1.06±0.07 1.13±0.07 
mmol DIGOXIN 0.84±0.11 0.92±0.10 1.00±0.13 1.15±0.1 
c GMP PLACEBO 2.86±0.82 2.14±0.62 2.63±0.60 2.1 0±0. 71 
(nmol) DIGOXIN 2.71±0.54 2.36±0.38 2.16±0.46 2.54±0.61 
F'MIDE PLACEBO 1 0.3±1.6 1 0.2±1.6 10.5±1.8 1 0.6±1.8 
(mg) DIGOXIN 1 0.6±1.5 11.0±1.6 9.6±1.5 10.1±1.6 
Fractional excretion of chloride was higher during the 3 hours after 
digoxin compared with placebo (p<0.05) while fractional excretion of sodium 
showed a trend to increase which did not reach statistical significance. 
Fractional excretion of potassium, urea, magnesium, phosphate, cyclic GMP 
and furosemide did not change (Table 6.3, Figure 6.1 and 6.2). 
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Table 6.3 Fractional excretion of electrolytes, furosemide and 
cGMP 
Changes in excretion of electrolytes (sodium-Na, potassium-K, urea, chloride-CI, magnesium-Mg and 
phosphate-Phos), furosemide (F'MIDE) and cGMP /creatinine (Cr). *denotes significance at p<0.05. 
0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
Na/Cr PLACEBO 36±7 35±8 41±8 41±7 
mM/mM DIGOXIN 43±6 45±5 48±5 48±6 
K/Cr PLACEBO 12.4±1.5 14.7±1.2 15.5±1.2 14.5±1.2 
mM/mM DIGOXIN 13.1±1.6 14.9±1.4 15.8±1.3 15.0±1.4 
U/Cr PLACEBO 35±2 38±2 40±2 38±2 
mM/mM DIGOXIN 40±1 40±2 40±1 38±2 
CI/Cr PLACEBO 33±6 31±7 37±6 35±4 
mM/mM DIGOXIN 45±7 44±6 47±6* 44±6* 
Mg/Cr PLACEBO 0.71±0.07 0.74±0.06 0.79±0.06 0.71 ±0.04 
mM/mM DIGOXIN 0.83±0.07 0.81±0.07 0.78±0.05 0.69±0.05 
Phos/Cr PLACEBO 1.86±0.26 2.13±0.21 2.78±0.21 2.77±0.18 
mM/mM DIGOXIN 2.0±0.24 2.27±0.19 2.45±0.20 2.65±0.18 
F'MIDE/Cr PLACEBO 4.2±0.6 4.8±0.5 5.2±0.4 5.6±0.9 
pg/mM DIGOXIN 4.9±0.5 5.3±0.6 6.0±0.9 5.9±0.8 
cGMP/Cr PLACEBO 5.2±1.5 5.1±1.3 6.9±1.8 4.8±1.5 
ng/mM DIGOXIN 6.5±1.4 5.8±0.8 5.2±1.0 6.0±1.6 
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Figure 6.1 Changes in hourly sodium excretion after 
placebo and digoxin 
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Figure 6.2 Changes in fractional excretion of sodium 
after placebo and digoxin. Changes were not significant(NS) 
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Although fractional excretion rose after digoxin, baseline levels were higher 
than placebo and the change from baseline was not significantly different 
after the 2 interventions. · 
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Plasma electrolyte concentrations did not differ significantly. 
Table 6.4 Plasma electrolyte concentrations 
Changes in plasma concentrations of sodium-Na, potassium-K, urea, creatinine-Great, chloride-CI, 
magnesium-Mg and phosphate-Phos one, two and three hours from the start of the study. 
1 HOUR 2 HOURS 3 HOURS 
Na PLACEBO 139±1 138±1 139±1 
mmol/1 DIGOXIN 138±1 138±1 138±1 
K PLACEBO 4.1±0.2 4.1±0.1 4.1 ±0.1 
mmol/1 DIGOXIN 3.8±0.1 4.0±0.1 3.8±0.1 
Urea PLACEBO 8.2±0.6 8.1±0.6 7.9±0.6 
mmol/1 DIGOXIN 7.9±0.5 7.7±0.5 7.5±0.5 
Creat PLACEBO 113±9 112±9 11 0±9 
t.~m/1 DIGOXIN 109±10 105±10 106±9 
Cl PLACEBO 1 00±1 100±1 100±1 
mmol/1 DIGOXIN 1 01±1 100±1 99±1 
Mg PLACEBO 0.84±0.04 0.83±0.03 0.83±0.03 
mmol/1 DIGOXIN 0.80±0.03 0.80±0.04 0.77±0.04 
Phos PLACEBO 1.02±0.08 1.05±0.06 1.1 0±0.06 
mmol/1 DIGOXIN 0.92±0.04 0.97±0.04 1.01±0.03 
Plasma hormone concentrations 
Plasma concentrations of ANP, catecholamines and plasma renin did not 
change after digoxin infusion with respect to placebo (table 6.5). 
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Table 6.5 Plasma hormone concentrations 
Changes in plasma concentrations of ANP, plasma renin, noradrenaline (N ADREN) and adrenaline 
(A OREN). 
1 HR 2 HAS 3 HAS 
ANP PLACEBO 105±44 107±48 106±33 
(pg/ml) DIGOXIN 100±48 111 ±38 98±38 
Plasma renin PLACEBO 240±107 174±69 173±65 
(JJU/ml) DIGOXIN 225±100 153±64 143±58 
N ADREN PLACEBO 4.7±0.9 4.5±0.9 4.0±0.6 
(nmol/1) DIGOXIN 5.1±1.1 4.3±0.7 3.9±0.7 
A OREN PLACEBO 0.30±0.09 0.23±0.07 0.25±0.08 
(nmol/1) DIGOXIN 0.32±0.09 0.25±0.05 0.26±0.06 
Haemodynamic variables 
Heart rate decreased during the 3 hours after digoxin compared with 
placebo but arterial pressure was unchanged. ERPF increased during the 3 
hours after digoxin compared to placebo. Creatinine clearance did not 
change (table 6.6, figure 6.3). 
182 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Table 6.6 Haemodynamic variables 
Changes in systolic blood pressure (SSP), diastolic blood pressure (DBP), mean arterial pressure 
(MAP), heart rate (HR), GFR and ERPF after digoxin and placebo . 
.. denotes rx at least 0.05. 
0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
SBP PLACEBO 111 ±5 113±3 112±5 111±4 
mmHg DIGOXIN 112±4 115±5 115±4 118±5 
DBP PLACEBO 73±3 74±3 74±2 74±2 
mmHg DIGOXIN 73±3 77±3 74±3 75±3 
MAP PLACEBO 86±3 88±2 88±3 87±3 
mmHg DIGOXIN 87±3 90±3 89±3 89±4 
HR PLACEBO 73±4 71±4 70±4 71±3 
bpm DIGOXIN 74±4 72±4* 67±3* 69±4* 
GFR PLACEBO 86±12 69±8 65±10 66±6 
ml/min DIGOXIN 71±8 70±8 68±7 73±6 
ERPF PLACEBO 198±19 175±12 212±19 224±21 
ml/min DIGOXIN 209±22 242±28* 265±21* 273±32* 
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Figure 6.3 Changes in ERPF after placebo and digoxin 
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6. 4 Discussion 
Bolus administration of digoxin enhanced the natriuresis but not the diuresis 
induced by furosemide in patients with moderately severe heart failure in 
sinus rhythm. 
Previous authors have described an increase in urine volume in patients 
with heart failure after oral administration of digoxin or the need for 
increased diuretic therapy when digoxin has been withdrawn, both in 
patients in atrial fibrillation and in sinus rhythm (Withering 1785; Gavey & 
Parkinson 1939; Farber, Alexander, Pellegrino, et al 1961; Hull & 
Mackintosh 1977) although other authors have shown no significant diuretic 
effect in the setting of sinus rhythm (Starr & Luchi 1969). Packer, 
Gheorghiade, Young, et al (1993) showed that 20% of patients with left 
ventricular systolic dysfunction and an ejection fraction of less than 35% 
deteriorated when digoxin was withdrawn. The patient population (placebo 
N=93, digoxin N=85) were all in sinus rhythm and were stable on digoxin, 
diuretics and ACE inhibitors. All had the dose of digoxin adjusted to achieve 
plasma concentrations of 0. 9-2ng/ml, resulting in a mean digoxin dose of 
0.38mg, slightly higher than the dose of digoxin used in other studies. 11 
patients in the placebo group required an increase in their diuretic dose 
compared with 4 in the digoxin group over a 12 week follow-up period. 
Lloyd, Sandberg and Edwards (1992) demonstrated that ouabain, a 
naturally ocurring cardiac glycoside, has diuretic and natriuretic actions in a 
dog model of heart failure. 
The use of powerful diuretics which produce an intense anti-diuresis, may 
have obscured the modest diuretic properties of digoxin when given in the 
post-diuretic phase. Rader, Smith, Berger, et al (1966) found no further 
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diuresis when digoxin was added to full diuretic therapy. Another possibility 
is that the diuretic properties of repeated oral doses of digoxin may be 
greater than that of a single intravenous bolus. 
There are several mechanisms by which digoxin could produce a 
natriuresis. 
Local renal effects: Inhibition of renal Na+-K+-ATPase produces a 
diuresis and natriuresis in experimental models of heart failure by inhibiting 
fluid reabsorption in the proximal tubule (Hyman, Jaques, Hyman 1956) 
although Luft, Aronoff, Fineberg, et al (1989) failed to demonstrate 
natriuresis when infusing digoxin in normal volunteers. Ouabain is 
synthesised in the human body, is elevated in heart failure and 
hypertension, and has been proposed as an endogenous natriuretic factor 
(Bova, Blaustein, Ludens, et al 1991; Harris, Clark, Fisher, et al 1991; 
Mathews, Ducharme, Hamlyn, et al 1991; Blaustein 1993). 
Cardiotonic effects: Digoxin exerts cardiac effects within 15 minutes of 
injection (Powell, Horowitz, Hasin, et al 1990). The effects of digoxin on 
cardiac output were not measured in the present study but heart rate fell 
within the first hour, and ERPF rose, possibly reflecting a cardiotonic effect 
on myocardial cells and a rise in cardiac output (Mason, Braunwald 1964; 
Heistad & Abboud 1980; Eisner & Smith 1992). 
Vasoconstrictor effects and pressure natriuresis: Blaustein and 
Hamlyn (1991) suggest that ouabain is responsible, at least in part, for the 
hypertension in low-renin hypertension. They proposes that the primary 
problem of inability to excrete a sodium load results in ouabain secretion 
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and hypertension. The rise in blood pressure allows normal plasma volume 
to be maintained by causing pressure natriuresis. Ouabain concentrations 
are also elevated in heart failure and may be important in maintaining blood 
pressure. No change in blood pressure was detectable after digoxin 
infusion in the present study, but changes in systemic pressure might have 
been observed had a more prolonged infusion been administered. Despite 
the rise in ERPF in the present study, urinary creatinine excretion did not 
increase. SNP increases renal blood flow but fails to cause a diuresis. 
However digoxin does not reduce renal perfusion pressure or GFR and this 
may enhance diuresis. 
Neuro-endocrine effects: Cardiopulmonary reflexes are impaired in 
heart failure (Eckberg, Drabinski, Braunwald 1971; Goldstein, Beiser, 
Stampfer, et al 1975; Bristow, Ginsburg, Minobe, et al 1982; Brodde 1991; 
1991 ), with reduced sensitivity of atrial stretch receptors, leading to 
impairment of inhibitory influences on renin release, sympathetic activity and 
anti-diuretic hormone secretion (Francis 1985a). Other studies have 
indicated that acute administration of digoxin inhibits renin secretion either 
directly or mediated through changes in cardiac output or antagonism of 
sympathetic activity (Ribner, Plucinski, Hsieh, et al 1985; Covit, Schaer 
1983). Similarly, digitalis glycosides exert direct sympatho-inhibitory effects 
in heart failure (Ribner, Plucinski, Hsieh, et al 1985; Alicandri, Fariello, Bani, 
et al 1987; Ferguson, Berg, Sanders, et al 1989; Gheorghiade, Hall, Lakier, 
et al 1989) possibly by restoring cardiac and aortic baroreceptor sensitivity 
and thus reducing the outflow of sympathetic impulses from the central 
nervous system and minimising their sodium retaining effects. Digoxin also 
suppreses renin release by virtue of its inhibitory action on the renal tubular 
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Na+-K+-ATPase (Churchill 1979; Covit, Schaer, Sealey, et al 1983; Ribner, 
Plucinski, Hsieh, et al 1985). 
Yamamoto, Shouji, Kimura, et al (1988) reported that high dose ouabain 
increases circulating ANP which could in theory result in enhanced salt and 
water excretion. Although plasma concentrations of renin and 
noradrenaline fell after digoxin administration, similar falls, presumably the 
result of prolonged supine rest, were observed after placebo. ANP did not 
fall in either group. The failure of ANP to increase in-vivo may reflect a fall in 
atrial pressure balancing any stimulus to increased secretion. 
Furosemide delivery: Digoxin could theoretically enhance delivery of 
furosemide to the renal tubules but this mechanism for natriuresis is unlikely 
to have been responsible in the present study as an increase in urinary 
furosemide excretion was not observed. 
limitations of the study 
As with the previous studies, the major limitation was the size of the study 
sample. Reliable monitoring of changes in cardiac output or ejection fraction 
were not available, thus it was only possible to speculate on the 
haemodynamic response to digoxin infusion in the patients. Most invasive 
studies describing positive haemodynamic effects of digoxin infusion have 
been performed on patients with decompensated heart failure and the 
literature suggests that stable, well diuresed patients may not demonstrate 
improvement in stroke volume or ejection fraction with intravenous digoxin 
administration (Ribner, Plucinski, Hsieh, et al 1985; Gheorghiade, Hall, 
Lakier, et al 1989). The dose of digoxin infused may not have been 
adequate as other authors have used bolus doses of 1 mg (Ribner, Plucinski, 
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Hsieh, et al 1985; Gheorghiade, Hall, Lakier, et al 1989) and 1-1.5 mg 
(Farber, Alexander, Pellegrino, et al 1961 ). Measurement of creatinine 
clearance as an index of GFR would have tended to overestimate GFR but 
changes in GFR were being assessed rather than absolute values so this 
was unlikely to have introduced significant error. 
Conclusion 
Digoxin modestly enhanced furosemide induced natriuresis but not diuresis. 
The present study suggests that the likely cause of the increase in sodium 
output was either from a direct effect on renal Na-K-ATPase or through an 
improvement in haemodynamics. This natriuretic effect may contribute to the 
beneficial effects of digoxin in heart failure. 
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Chapter 7 The effect of infusion of ANP on the renal response to 
furosemide 
7. 1 Introduction 
ANP is one of a group of naturally occurring peptides with powerful diuretic, 
natriuretic and haemodynamic properties in animals, normal volunteers and 
hypertensive patients. Since the description by De Bold, Borenstein, 
Veress, et al (1981) of the diuretic and natriuretic properties of extracts of 
atrial tissue injected into rats and the subsequent identification and 
synthesis of ANP, a considerable volume of literature exists on the action of 
ANP in health and disease. ANP is a cardiac hormone that in health is 
secreted primarily by atrial myocytes in response to atrial stretch. Secretion 
may result in a fall in arterial pressure (De Bold, Borenstein, Veress, et al 
1981; Maack, Marion, Camargo, et al 1984), augmentation of salt and water 
excretion (Camargo, Kleinert, Atlas, et al 1984; Maack, Marion, Camargo, et 
al 1984), facilitation of transudation of plasma water to the interstitium (Cody, 
Atlas, Laragh, et al 1986a) and inhibitory effects on the release or actions of 
a variety of hormones, including aldosterone, plasma renin, A-11, (Goetz 
1988; Donckier, De Coste, Vanoverschelde, et al 1991) and AVP (Maack, 
Marion, Camargo, et al 1984; Sampson 1985; Cody, Atlas, Laragh, et al 
1986a). The overall effects of ANP result in both acute and chronic 
reduction in systemic blood pressure and intravascular volume. The 
beneficial renal actions are mediated by cG MP, the second messenger for 
ANP {Appel, Dunn 1987; Brenner, Ballerman, Gunning, et al 1990; Wilkins,· 
Settle, Needleman 1990). 
Plasma concentrations of ANP are elevated in a number of pathological 
conditions characterised by volume overload or increased right atrial wall 
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tension such as renal failure, malignant hypertension and heart failure 
(Tikkanen, Fyhrquist, Metsarinne, et al 1985; Raine, Erne, Burgisser, et al 
1986; Takemura, Fujiwara, Mukoyama, et al 1991 ). Not only do patients with 
heart failure demonstrate inappropriate salt and water retention in the face of 
significantly elevated plasma concentrations of ANP, but they also 
demonstrate a blunted renal response to infusion of ANP (Moe, Canepa-
Anson, Armstrong 1992; Cody, Atlas, Laragh, et al 1986a). However 
beneficial changes in pulmonary wedge pressure, left atrial pressure and 
systemic vascular resistance still occur (Cody, Atlas, Laragh, et al 1986a). 
In animal models of heart failure, sympathetic inhibition, either by sectioning 
the vagus nerve or by administration of a central a-adrenergic antagonist 
such as clonidine is able to restore renal responsiveness to ANP (Feng, 
Hedner, Hedner, et al 1990). Recent work suggests that the responsiveness 
to ANP can likewise be partially restored in patients and in animal models of 
heart failure when plasma concentrations of ANP are increased by inhibition 
of neutral endopeptidase, the enzyme responsible for degradation of ANP 
(Cavero, Margulies, Winaver, et al 1990; Trippodo, Gabel, Harvey, et al 
1991; Good, Peters, Wilkins, et al 1995; MOnzel, Kurz, Holtz, et al 1992). 
The interaction of ANP and furosemide is less well understood. 8 patients 
with stable heart failure on chronic diuretic therapy were studied to 
determine whether ANP had any influence on the natriuresis and diuresis 
induced by furosemide. 
7. 2 Patients and methods 
Eight patients with chronic heart failure aged 63~69 years (mean 66 years) 
were studied on two occasions, not less than 48 hours apart, having 
adhered to a fixed salt intake for 3 days prior to each study, as set out in 
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Chapter 2. A constant, steady diuresis was maintained by hourly 
administration of furosemide and replacement of urinary and insensible 
losses with oral water. Mean daily furosemide dose was 90mg and 
intravenous dose for the 4 hour period of study was 12-20mg, mean 17mg. 
During the 2nd hour of study, ANP (0.01J1g/kg/min) or normal saline was 
infused. During the 3rd hour, the dose of ANP was increased in incremental 
fashion at 5 minute intervals from 0.05J1g/kg/min to 0.1Jlg/kg/min to 
0. 15J1glkg/min and maintained at this rate for the duration of the 3rd hour. 
The 1st and 4th hour periods acted as internal control periods. Urine was 
collected at the end of each hour and retained for estimation of cGMP, 
furosemide, electrolytes and PAH. Plasma samples were taken at the end of 
the 1 sti 2nd and 3rd hours for estimation of electrolytes, ANP, 
catecholamines and plasma renin in addition to PAH. Blood pressure and 
heart rate were measured at 15 minute intervals. At the end of the study, 
patients were examined and discharged. 
Table 7.1 Patient characteristics 
Table showing individual patients' age, sex, New York Heart Association classification 
(NYHA), daily diuretic requirements in milligrammes (furosemide-F. bumetanide-BUMET), 
type of ACE-inhibitor and daily dosage (captoprii-CAP, enalaprii-ENAL) and aetiology of 
heart failure (ischaemic heart disease-IHD). 
PATIENT AGE SEX NYHA DIURETIC ACE-I (mg) AETIOLOGY 
1 63 M 118 F40 CAP 37.5 IHD 
2 68 M 118 F 40 CAP 12.5 IHD 
3 63 M 118 F 80 CAP 37.5 IHD 
4 68 M 118 F 120 CAP 75 IHD 
5 66 M Ill F40 IHD 
6 74 F Ill F40 ENAL5 IHD 
7 69 M Ill 8UMET 4 ENAL10 IHD 
8 65 M Ill F 120 IHD 
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7.3 Results 
All results are expressed as the mean and one standard error of the mean. 
Urine volume showed a trend towards increasing during high dose infusion 
(not significant) and electrolyte excretion did not change significantly. cG MP 
rose after low and high dose ANP infusion with effects persisting 1 hour after 
discontinuation. Furosemide excretion did not change (table 7.2, figure 7.1 ). 
Table 7.2 Hourly changes in urine volume and excretion of 
electrolytes, furosemide and cGMP 
Changes in hourly urine volume (U.Vol), sodium (Na), potassium (K), urea, creatinine (Great), chloride 
(CI), magnesium (Mg), phosphate (Phos), cGMP and furosemide (F'MIDE). "denotes significance at p< 
at least 0.05. 
U.Vol 
mls 
Na 
mM 
K 
mM 
Urea 
mM 
Creat 
mM 
Cl 
mM 
Mg 
mM 
Phos 
mM 
cGMP 
nmol/min 
F'MIDE 
mg/hr 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
Placebo 
ANP 
0-1 hrs 
231±26 
238±37 
20.5±3.6 
18.1 ±3 
5.5±1.0 
5.0±0.7 
20.7±3.0 
18.1 ±3.6 
0.51 ±0.08 
0.44±0.05 
20.0±3.5 
17.8±4.1 
0.40±0.06 
0.36±0.08 
1.07±0.23 
0.88±0.15 
2.0±0.4 
1.9±0.4 
2075±276 
1609±223 
193 
1-2 hrs 
204±17 
241±30 
14.2±1.7 
14.0±2 
4.5±0.8 
4.7±0.8 
15.8±2.2 
16.6±2.9 
0.37±0.05 
0.36±0.06 
12.9±1.9 
13.8±3.0 
0.29±0.05 
0.32±0.07 
0.78±0.1 0 
0.90±0.11 
1.5±0.2 
2.3±0.5" 
1554±159 
1692±230 
2-3 hrs 
234±16 
288±47 
17.4±2.1 
17.7±2 
5.3±0.9 
4.9±0.7 
17.5±1.8 
17.7±2.1 
0.41±0.04 
0.40±0.05 
16.3±1.4 
15.4±2.5 
0.33±0.04 
0.34±0.04 
0.95±0.08 
0.99±0.09 
2.0±0.5 
5.4±0.9" 
1792±277 
1772±378 
3-4 hrs 
238±17 
252±36 
15.1 ±1.3 
18.1±2 
4.5±0.9 
4.4±0.8 
14.7±1.9 
16.6±2.3 
0.34±0.05 
0.39±0.05 
14.0±1.4 
15.4±2.7 
0.27±0.04 
0.35±0.06 
0.93±0.09 
1.08±0.11 
1.3±0.3 
4.1 ±0.4" 
1914±277 
1934±252 
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Figure 7. 1 Changes in hourly cGMP excretion after 
placebo and ANP infusion 
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TIME FROM START 
Fractional excretion of sodium increased during high dose infusion. 
Fractional excretion of cG MP increased during low and high-dose ANP 
infusion and for the hour afterwards. Fractional excretion of urea and 
furosemide did not change (Table 7.3). 
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Table 7.3 
cGMP 
Fractional excretion of electrolytes, furosemide and 
Changes in hourly excretion of sodium (Na}, potassium (K}, urea (U}, chloride (CI}, magnesium (Mg}, 
phosphate (Phos}, furosemide (F'MIDE) and cGMP/creatinine (Cr). 
*denotes p< at least 0.05. 
NaiCr PLACEBO 
mM/mM ANP 
K I C r PLACEBO 
mM/mM ANP 
U I C r PLACEBO 
mM/mM ANP 
CIICr PLACEBO 
mM/mM ANP 
MgiCr PLACEBO 
mM/mM ANP 
PhosiCr PLACEBO 
mM/mM ANP 
F' Ml DEICr PLACEBO 
pg/mM ANP 
c G M PIC r PLACEBO 
ng/mM ANP 
0-1 HRS 
46±7 
42±7 
11.1±1.6 
11.5±1.4 
42±3 
45±2 
46±9 
41±8 
0.87±0.14 
0.90±0.16 
2.08±0.24 
2.15±0.20 
22±5 
18±5 
4.3±1.1 
4.6±1.0 
195 
1-2 HRS 
44±8 
44±9 
11.9±1.2 
12.3±0.9 
43±1 
45±1 
39±7 
40±7 
0.81±0.1 0 
0.62±0.12 
2.20±0.22 
3.07±0.60 
24±5 
27±8 
4.5±0.9 
7 .7±1.9* 
2-3 HRS 
47±9 
51±14* 
12.5±1.45 
11.8±1.0 
43±1 
44±1 
44±7 
48±13 
0.84±0.08 
0.91±0.11 
2.38±0.13 
2.69±0.25 
19±2 
23±8 
4.8±1.1 
14.2±1.7* 
3-4 HRS 
50±8 
48±8 
12.4±1.6 
11.1±1.1 
43±1 
43±1 
45±5 
41±8 
0.82±0.08 
0.92±0.09 
2.88±0.24 
3.03±0.29 
27±5 
27±7 
4.4±1.4 
12.2±2.1 * 
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Plasma electrolyte concentrations did not change (table 7.4) 
Table 7.4 Plasma electrolyte concentrations 
Changes in plasma concentrations of sodium (Na), potassium (K), urea, creatinine (Great), chloride (CI), 
magnesium (Mg) and phosphate (Phos). 
Na 
mmol/1 
K 
mmol/1 
Urea 
mmol/1 
Creat 
J]mol/1 
Cl 
mmol/1 
Mg 
mmol/1 
Phos 
mmol/1 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
1 HOUR 
140±1 
138±1 
3.9±0.2 
3.6±0.2 
7.2±0.5 
8.2±1.4 
93±3 
101±8 
103±2 
104±1 
0.82±0.04 
0.86±0.02 
0.87±0. 1 
0.83±0.06 
196 
2 HOURS 
140±1 
138±1 
3.9±0.2 
3.5±0.2 
7.0±0.6 
8.4±1.4 
92±3 
98±8 
103±2 
104±1 
0.83±0.03 
0.84±0.02 
0.89±0.08 
0.89±0.05 
3 HOURS 
140±1 
139±1 
4.0±0.2 
3.6±0.2 
6.9±0.6 
8.2±1.4 
91±3 
99±7 
1 03±1 
105±1 
0.82±0.03 
0.81 ±0.01 
0.94±0.07 
0.93±0.04 
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Plasma hormone concentrations 
ANP levels increased from 70±22 to 157±35pg/ml, p<0.02 (mean±one 
standard error) after low dose infusion and from 91±29 to 225±31 pg/ml, 
p<0.02, (figure 7.2) after high dose infusion (normal range <50pg/ml). 
Plasma renin rose from 84±27 to 150±61J1U/ml, p<0.05 after high dose ANP 
infusion compared with placebo (figure 7.3). 
Plasma catecholamine concentrations did not change (table 7.5). 
Table 7.5 Hormonal data during infusion of placebo and ANP 
Changes in plasma concentrations of atrial natriuretic peptide (ANP), plasma renin (PARC), 
noradrenaline (NA) and adrenaline (ADREN). *denotes significance at p< at least 0.05. 
ANP 
pg/ml 
PARC 
JJU/ml 
NA 
nmol/1 
ADREN 
nmol/1 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
PLACEBO 
ANP 
1 HOUR 
63±18 
56±12 
119±44 
107±40 
4.3±0.8 
4.6±0.8 
0.2±0.07 
0.3±0.08 
197 
2 HOURS 3 HOURS 
70±22 
157±35* 
86±25 
99±36 
3.9±0.7 
3.7±0.7 
0.2±0.06 
0.3±0.09 
91±29 
225±31* 
84±27 
150±61* 
4.1±0.6 
5.3±1.3 
0.3±0.07 
0.3±0.1 
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Figure 7.2 Changes in plasma concentrations of ANP 
during infusion of placebo and ANP 
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Haemodynamic variables 
Heart rate was unchanged despite a fall in systolic blood pressure, 
diastolic pressure and mean arterial pressure during high dose infusion after 
placebo and ANP respectively. The hypotensive effect persisted for a further 
hour after the infusion was terminated (table 7.6, figure 7.4). 
ERPF increased (225±35 to 254±31, p=0.036) during low dose ANP 
infusion but not during high dose (figure 7.5). 
Creatinine clearance did not change significantly after ANP infusion 
(table 7.6). 
Table 7.6 Haemodynamic variables during infusion of 
placebo and ANP 
The table shows hourly changes in heart rate (HR), systolic and diastolic blood pressure (SBP, DBP), 
ERPF and creatinine clearance (GREAT C) ... denotes significance at p< at least 0.05 
0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
HR PLACEBO 69±4 70±5 69±5 69±5 
ANP 68±4 68±4 69±3 70±4 
SBP PLACEBO 118±8 122±8 121±8 123±9 
(MM HG) ANP 116±8 116±8 108±8* 1 04±7* 
DBP PLACEBO 74±3 76±4 76±3 79±4 
(MM HG) ANP 75±2 77±4 69±4* 66±3* 
ERPF PLACEBO 239±31 225±35 234±27 244±28 
(MLS/MIN) ANP 233±35 254±31* 226±25 259±32 
CREAT C PLACEBO 89±12 67±9 76±8 63±8 
(MLS/MIN) ANP 71±5 63±8 64±6 66±8 
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Figure 7.4 
blood pressure 
Changes in systolic and diastolic 
during infusion of placebo and ANP 
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Figure 7.5 Changes in ERPF during infusion of placebo 
and ANP 
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7. 4 Discussion 
Exogenous ANP administration did not augment the diuretic response to 
furosemide. This finding was not unexpected as the response to 
endogenous or exogenous ANP administration is blunted in heart failure 
(Cody, Atlas, Laragh, et al 1986a; Molina, Fowler, McCrory, et al 1988). 
ANP infusion does however usually result in a fall in elevated systemic 
vascular resistance, pulmonary capillary wedge pressure and right atrial 
pressure (Cody, Atlas, Laragh, et al 1986a). Changes in cardiac output and 
stroke volume are more variable (Molina, Fowler, McCrory, et al 1988). A fall 
in blood pressure and in cardiac output has been demonstrated in animal 
models (Bie, Wang, Leadley, et al 1988; Ota, Kimura, Masura, et al 1992) 
during ANP infusion and could partly explain the failure of ANP infusion to 
augment a furosemide induced diuresis in the present study. A more 
probable explanation for the fall in blood pressure produced by the infusion 
of ANP is that of alteration of vascular resistance, redistribution of the 
intravascular volume to the extravascular space and decreased venous 
return or venous pooling, resulting in a fall in cardiac output (Cody, Atlas, 
Laragh, et al 1986a, Pegram, Trippodo, Natsume, et al 1986). 
Cody, Atlas, Laragh, et al (1986a) has shown that ANP infusion in normal 
subjects results in suppression of the renin-angiotensin system and 
antagonism of the sympathetic nervous system. Molina, Fowler, McCrory, et 
al (1988) has reported suppression of aldosterone and noradrenaline in 
patients with heart failure after ANP infusion while Moe, Canepa-Anson and 
Armstrong (1992) showed no change in plasma renin activity or 
noradrenaline concentrations but a fall in aldosterone. Suppression of 
plasma renin activity was not seen in studies by Cody, Atlas, Laragh, et al 
(1986a); Riegger, Kromer and Kochsiek (1986a) and Saito, Ogihara, 
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Nakamaru, et al (1987). Aldosterone and A-ll were not measured in the 
present study but plasma renin rose significantly after ANP infusion 
compared to placebo, without changes occurring in adrenaline or 
noradrenaline concentrations. There is in-vitro evidence for direct inhibition 
of renin release by ANP (Hiruma, lkemoto, Yamamoto 1986) although the 
findings of Volpe, Odell, Kleinert, et al (1984 & 1985) and Sosa, Volpe, 
Marion, et al (1985) suggested that the effects of ANP on renin release are 
secondary to renal haemodynamic changes. It is also possible that the 
inhibitory effect of ANP on renin release is overridden by renal sympathetic 
nerve stimulation. There was improvement in ERPF during low dose ANP 
infusion in the present study, but this was not sustained during the high dose 
infusion, possibly due to the associated hypotension, although creatinine 
clearance did not fall. It is likely that the fall in blood pressure caused active 
renin concentrations to rise. In addition, most of these patients were taking 
long-acting ACE inhibitors which could interfere with basal renin production, 
although this does not explain the differences in plasma renin noted after 
ANP compared with placebo, as patients were their own controls. 
ANP infusion did not affect the furosemide induced diuresis or natriuresis, 
despite a significant fall in arterial pressure during high dose ANP infusion 
which persisted for 1 hour after the infusion was stopped. ANP clearance is 
prolonged in older patients and those with heart failure (Ruskoaho 1992) 
and similar prolonged hypotension with ANP has been described in heart 
failure, without compensatory tachycardia (Molina, Fowler, McCrory, et al 
1988). Feng, Hedner, Hedner, et al (1990) showed that ANP-induced 
diuresis can be restored in a rat model of heart failure by simultaneous 
infusion of clonidine, despite further lowering of arterial pressure, suggesting 
that presynaptic noradrenaline release plays a part in the blunted response. 
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There was no significant change in excretion of any of the urinary 
electrolytes measured. Recent work has shown that urinary excretion of 
sodium and chloride in response to BNP infusion was higher in heart failure 
patients than in control subjects, unlike the renal effects of ANP (Yoshimura, 
Yasue, Morita, et al 1991 ). This could be one of the mechanisms for 
improved diuresis and natriuresis observed with neutral endopeptidase (EC 
24.11) inhibitors, which cause elevation of brain natriuretic peptide in 
addition to ANP (Vogt-Schaden, Gagelmann, Hock, et al 1989; Bourne, 
Kenny 1990; Vanneste, Pauwels, Lambotte, et al 1990; Lang, Motwani, 
Coutie, et al1991). 
ERPF increased only during low dose infusion of ANP, perhaps because 
blood pressure was maintained at low dose, but fell during high dose. 
Eiskjaer, Bagger, Danielsen, et al (1991) found a correlation between 
relative increase in natriuresis and renal plasma flow after ANP infusion in 
patients with heart failure, while Molina, Fowler, McCrory, et al (1988) 
demonstrated an insignificant rise in ERPF with higher doses of ANP but 
furosemide was not administered concurrently. Molina, Fowler, McCrory, et 
al (1988) also showed that ANP infusion increased GFR, although Awazu, 
lmada, Kon, et al (1989) found no significant change in GFR after anti-ANP 
antibody administration in rats with acute myocardial infarction, despite 
demonstrating anti-natriuresis. GFR failed to rise after administration of a 
neutral endopeptidase inhibitor in dogs with heart failure (Cavero, 
Margulies, Winaver, et al 1990). In Molina's study patients, striking 
beneficial haemodynamic responses were recorded, which may not have 
been the case in the well diuresed, stable patients in the present study. 
Urinary cGMP increased significantly during ANP infusion in the present 
) 
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study but neither diuresis nor natriuresis were potentiated. Moe, Canepa-
Anson and Armstrong (1992), looking at the cGMP response to ANP in 
patients with heart failure and controls, found that plasma and urinary cG MP 
excretion was higher at baseline in heart failure compared with the normal 
controls; however after ANP infusion, proportional increases in plasma 
cGMP and cGMP excretion were less in patients than in controls. Thus the 
renal cGMP response was attenuated. This may have reflected the blunted 
augmentation of plasma cGMP by ANP infusion due to ANP receptor down-
regulation or dissociation or a more generalised problem with attenuated 
cGMP generation. Molina, Fowler, McCrory, et al (1988) demonstrated 
doubling of urinary cGMP excretion after ANP infusion in their patients with 
severe congestive heart failure and an associated blunted diuretic response. 
Urinary excretion of cGMP did not to correlate with the degree of diuresis or 
natriuresis induced by candoxatrilat (a neutral endopeptidase inhibitor) in 
patients with heart failure (Good, Peters, Wilkins, et al 1995). 
There are many possible causes for the reduced renal response to 
exogenous ANP in heart failure patients. 
Arterial perfusion pressure: Firth, Raine and Ledingham (1988) 
demonstrated in isolated perfused rat kidneys that the response to infused 
ANP varies in response to changes in arterial perfusion pressure, with no 
natriuretic effect at lower perfusion pressures. This mechanism may also 
apply in heart failure, if the predominant nephron site of action of ANP is the 
collecting tubule. Decreased renal perfusion results in decreased delivery of 
sodium to the collecting tubule and thus little opportunity for ANP to 
influence sodium reabsorption at this site (Seitter, Brenner 1989) however 
furosemide should have corrected this. 
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Limitations of the study 
The limitations noted in the previous chapters are applicable in the present 
study as the design, execution and analysis of the studies was similar. 
Conclusion 
ANP infusion did not augment the renal response to furosemide in patients 
with heart failure. The significant hypotensive effect of high dose ANP 
infusion was probably partly responsible, although competition from 
activation of the sympathetic nervous system, arginine vasopressin and the 
renin-angiotensin system may also have played a part. 
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Antagonism by noradrenaline: McMurray, Seidelin, Brown, et al (1989) 
showed that low dose noradrenaline was antinatriuretic in normal volunteers 
without inducing either changes in GFR or systemic blood pressure; the 
natriuretic effects of ANP were also antagonised by noradrenaline. Feng, 
Hedner, Hedner, et al (1990) showed that a 2-adrenergic agonism with 
clonidine reversed the blunted renal response to ANP infusion in a rat 
model of heart failure. Although an additional rise in noradrenaline levels 
was not demonstrated during ANP infusion in the present study, basal 
concentrations were elevated and could theoretically have impaired the 
natriuretic effects of ANP. 
Neurohumoral activation by furosemide: Most neurohumoral systems 
which operate to retain salt and water in heart failure are further stimulated 
by furosemide, including the sympathetic nervous system, the RAAS (Anand, 
Kalra, Harris, et al 1991; Cleland, Gillen, Dargie 1988) and AVP (Yamane 
1968). Further neurohumoral activation could prevent any augmentation of 
the renal effects of furosemide by ANP. 
ANP receptor: The attenuated response to ANP may include attenuation 
of the activity of guanylate cyclase by other peptides, abnormalities in 
guanylate cyclase activation after binding of ANP or may be secondary to 
ANP receptor abnormalities (Molina, Fowler, McCrory, et al 1988). Antibody 
studies suggest that ANP is still active in heart failure as when circulating 
ANP is blocked by antibody administration, clinical deterioration occurs, in 
animal models (Awazu, lmada, Kon, et al 1989; Shepperson, Barclay, 
Bennett, et al 1991 ). 
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Chapter 8 The effect of infusion of tyramine and phentolamine 
on a furosemide induced diuresis 
8.1 Introduction 
Patients with heart failure have evidence of a and (3-adrenergic activation 
with down-regulation of cardiac (3-adrenoceptors and reduced sensitivity to 
endogenous or exogenously administered catecholamines (Chidsey, 
Braunwald 1966; Levine, Francis, Goldsmith 1982; Bristow, Ginsburg, 
Minobe et al 1982; Harden 1983; Bristow, Ginsburg, Umans, et al 1986; 
Brodde, Schuler, Kretsch, et al 1986; Bristow, Port, Hershberger, et al 1989). 
In addition, elevated concentrations of plasma catecholamines correlate 
inversely with prognosis in heart failure (Cohn, Levine, Olivari, et al 1984; 
Rector, Olivari, Levine, et al 1987). Excessive adrenergic drive leads to 
renal artery constriction with resultant sodium and water retention in animal 
models (Dell, Sciacca, Lieberman, et al 1973; Katz, Shear 1975), and 
infusion of phenylephrine or noradrenaline in normal subjects decreases 
sodium excretion (Lang, Rahman, Balfour, et al 1993a; Lang, Rahman, 
Balfour, et al 1993b). Conversely, administration of (3-adrenergic 
antagonists to patients with moderate to severe heart failure often causes 
fluid retention or exacerbation of symptoms (lkram, Fitzpatrick 1981; Binkley, 
Lewe, Lima, et al 1986; Shanes 1987) and ganglion blockade with 
guanethidine results in fluid retention in patients with heart failure (Gaffney, 
Braunwald 1962; Gill, Mason, Bartter, et al 1965). a- blockade with 
prazosin and doxazosin causes fluid retention (Bayliss, Noreel, Canepa-
Anson, et al 1985; Riegger, Haeske, Kraus, et al 1987b). Lang, Rahman, 
Balfour, et al (1993a) have shown that infusions of noradrenaline cause 
antinatriuresis in normal volunteers but paradoxically, direct stimulation of 
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j31, 132 and a 1-adrenergic receptors by dobutamine, a synthetic adrenergic 
agonist, may increase sodium excretion (Leier, Webel, Bush 1977; Leier, 
Heban, Huss, et al 1978) and indirect stimulation with tyramine, which 
mediates its sympathomimetic effects by displacement of nonvesicular 
noradrenaline from noradrenergic neurons, (Goodman, Gilman 1980) has 
also been associated with diuresis in normal volunteers (Lang, Rahman, 
Balfour, et al 1993b). 
This study compares the effects of indirect sympathetic stimulation with 
tyramine with antagonism with phentolamine on diuresis. 
8. 2 Patients and methods 
8 patients with chronic heart failure aged 63-69 years (mean 65 years) on 
chronic diuretic therapy for control of symptoms of heart failure were studied 
on 3 occasions, in random single blind fashion with tyramine, phentolamine 
and placebo. The usual dietary restrictions and study protocol were 
adhered to as set out in the methods section. Phentolamine and tyramine 
were infused at low dose during the second hour (1tJg/kg/min) with 
incremental increases to the maximum dose during the third hour 
(1 OtJg/kg/min). Hourly urine samples were saved for cGMP, PAH, 
electrolytes and furosemide. Urinary and insensible losses were replaced 
hourly with water. Plasma samples were drawn at the end of the 1st, 2nd 
and 3rd hours for analysis of catecholamines, renin, ANP, PAH and 
electrolytes. Heart rate and blood pressure were recorded at 15 minute 
intervals using an automated device (Dynamap Criticon). 
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Table 8.1 Individual patient characteristics 
Individual patients' age, sex, New York Heart Association classification (NYHA), daily diuretic 
requirements (furosemide-F. metolazone-MET), dose of ACE-inhibitor per day (captoprii-CAP, enalapril-
ENAL, lisinoprii-LISIN), aetiology of heart failure (ischaemic heart disease-IHD) and whether patients 
were taking digoxin. 
PATIENT AGE SEX NYHA DIURETIC ACE-I AETIOLOGY . DIGOXIN 
(MG) (MG/D) 
1 63 M liB F 40 CAP 37.5 IHD 
2 68 M liB F 40 CAP 12.5 IHD 
3 63 M liB F 80 CAP 37.5 IHD 
4 68 M liB F 120 CAP 75 IHD YES 
5 66 M Ill F 40 IHD 
6 74 F Ill F 40 ENAL 5 IHD YES 
7 62 M Ill F 40, MET 2.5 LISIN 10 IHD 
8 65 M liB F 120 IHD 
8.3 Results 
Results are expressed as the mean and one standard error of the mean. 
Diuresis and natriuresis were not significantly increased by either 
phentolamine or tyramine. 
Chloride excretion was preserved by low but not high dose phentolamine 
while it tended to fall during placebo and tyramine infusions (p<0.05, table 
8.2). 
There was no significant change in excretion of urea, creatinine, 
magnesium, potassium, phosphate, furosemide or cyclic GMP with either 
intervention (table 8.2). 
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Table 8.2 Changes in urine volume and excretion of 
electrolytes, cGMP and furosemide 
Changes in hourly urine volume and excretion of sodium (Na), potassium (K), urea, creatinine 
(Great), magnesium (Mg), phosphate (Phos), chloride (CI), furosemide (F'MIDE) and cyclic 
GMP during infusion of placebo, tyramine and phentolamine (PHENTOL). Results are 
expressed as mean and one standard error of the mean. * p<0.05. 
VOLUME 
Mlslhr 
Na 
mmol 
K 
mmol 
Urea 
mmol 
Creat 
mmol 
Mg 
mmol 
Phos 
mmol 
Cl 
mmol 
F'MIDE 
mg/ml 
cGMP 
ng/min 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
PLACEBO 
TYRAMINE 
PHENTOL 
0-1 hrs 
225±23 
265±33 
242±35 
20±4 
20±3 
18±3 
5.5±1.0 
5.8±0.8 
4.3±0.7 
21±3 
20±2 
18±2 
0.49±0.09 
0.45±0.04 
0.37±0.04 
0.41±0.06 
0.42±0.08 
0.36±0.07 
1.16±0.20 
0.88±0.09 
0.89±0.19 
21±3 
22±3 
19±3 
1.9±0.3 
1.4±0.2 
1.6±0.3 
2.0±0.4 
2.0±0.3 
1.7±0.4 
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1-2 hrs 
189±21 
215±20 
253±34 
13±2 
15±3 
17±3 
4.7±0.8 
5.0±0.8 
4.7±0.6 
16±2 
16±2 
18±2 
0.37±0.05 
0.35±0.05 
0.38±0.04 
0.29±0.05 
0.31 ±0.06 
0.35±0.05 
0.82±0.09 
0.74±0.08 
0.94±0.19 
13±2 
16±3 
18±3* 
1.5±0.2 
1.9±0.4 
1.8±0.2 
1.5±0.2 
1.5±0.2 
2.0±0.5 
2-3 hrs 
218±21 
234±29 
240±47 
15±2 
15±3 
18±4 
5.1±0.9 
5.0±0.8 
4.6±0.5 
17±2 
15±2 
17±1 
0.38±0.04 
0.34±0.05 
0.39±0.05 
0.31±0.04 
0.30±0.05 
0.33±0.04 
0.95±0.07 
0.79±0.06 
0.91±0.09 
15±2 
15±3 
17±4 
1.6±0.3 
1.9±0.4 
1.5±0.3 
1.8±0.4 
1.7±0.5 
1.5±0.4 
3-4 hrs 
228±18 
245±33 
222±35 
14±1 
17±3 
16±3 
4.6±0.9 
5.0±0.9 
4.8±1.1 
15±2 
16±2 
16±3 
0.34±0.05 
0.39±0.06 
0.41±0.07 
0.28±0.04 
0.33±0.05 
0.31±0.04 
0.96±0.1 0 
0.95±0.11 
0.87±0.16 
14±1 
16±3 
15±2 
1.7±0.2 
2.3±0.6 
1.8±0.2 
1.5±0.3 
1.8±0.3 
1.4±0.5 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Fractional excretion of furosemide increased during low and high dose 
tyramine infusion (p<0.03 and p<0.2 respectively) but fractional excretion of 
electrolytes and cyclic GMP did not differ significantly from placebo. 
Table 8.3 Fractional excretion of electrolytes, cyclic GMP and 
furosemide with respect to creatinine 
Sodium (Na), potassium (K), urea (U), magnesium (Mg), phosphate (Ph), chloride (CI), furosemide (Frus) 
and cyclic GMP excretion divided by creatinine (Cr) excretion during infusion of placebo, tyramine and 
phentolamine (PHENTOL). *denotes significance at p<0.05. 
NaiCr PLACEBO 
mmollmmol TYRAMINE 
PHENTOL 
K I C r PLACEBO 
mmollmmol TYRAMINE 
PHENTOL 
U I C r PLACEBO 
mmol/mmol TYRAMINE 
PHENTOL 
MgiCr PLACEBO 
mmol/mmol TYRAMINE 
PHENTOL 
PhiCr PLACEBO 
mmol/mmol TYRAMINE 
PHENTOL 
CIICr PLACEBO 
mmol/mmol TYRAMINE 
PHENTOL 
F rusl C r PLACEBO 
J.Jmol/mmol TYRAMINE 
PHENTOL 
cGMP ICr PLACEBO 
pmol/mmol TYRAMINE 
PHENTOL 
0-1 HRS 
48±7 
47±6 
55±12 
11.6±1.8 
13.5±1.9 
11.9±1.6 
45±4 
47±6 
50±5 
0.93±0. 15 
1 .0±0.21 
1 .05±0.21 
2.48±0.27 
2.1 2±0.37 
2.70±0.63 
50±10 
51±8 
59±12 
4.5±0.7 
4.1 ±0.9 
4.2±0.6 
5±1 
5±1 
6±2 
1-2 HRS 
41±8 
44±7 
49±10 
1 2.7±1 .6 
1 4.9±1 .8 
1 2.7±1 .3 
45±3 
47±4 
49±4 
0.81±0.10 
0.91±0.1 3 
0.93±0. 1 1 
2.45±0.32 
2.35±0.36 
2.61±0.54 
38±7 
45±7 
50±8 
4.2±0.3 
6.5±2.5* 
4.8±0.6 
5±1 
6±2 
6±1 
2-3 HRS 
44±9 
46±8 
49±12 
1 3.5±1.8 
1 4.9±2. 1 
12.2±1.2 
45±2 
45±3 
45±3 
0.85±0.08 
0.89±0.1 0 
0.89±0.1 2 
2.65±0.3 1 
2.58±0.35 
2.61 ±0.43 
43±8 
48±8 
46±1 1 
4.4±0.5 
6.0±1 .9* 
4.0±0.9 
5±1 
6±2 
4±1 
3-4HRS 
48±8 
48±7 
44±9 
13.4±1.8 
1 3.8±2.0 
11.7±1.4 
45±3 
43±4 
41±3 
0.85±0.08 
0.87±0. 10 
0.81±0.09 
3.09±0.38 
2.66±0.40 
2.24±0.32 
45±5 
47±7 
40±8 
5.5±0.9 
6.0±1 .7 
4.5±0.8 
5±2 
6±2 
4±1 
No significant differences were noted in serum sodium, potassium, urea, 
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creatinine, magnesium, phosphate or chloride concentrations with either 
intervention compared with placebo. 
Table 8.4 Plasma electrolyte concentrations 
Changes in plasma electrolyte concentrations during infusions of tyramine, phentolamine and placebo 
at one, two and three hours from the start of the study. 
1 HOUR 2 HOURS 3 HOURS 
Na PLACEBO 1 40±1 1 39±1 140±1 
mmol TYRAMINE 1 40±1 1 39±1 1 39±1 
PHENTOLAMINE 139±1 1 39±1 1 39±1 
K PLACEBO 3.9±0.2 3.8±0.2 3.9±0.2 
mmol TYRAMINE 3.7±0.2 3.6±0.2 3.5±0.2 
PHENTOLAMINE 3.5±0. 1 3.5±0.2 3.4±0. 1 
Urea PLACEBO 7.5±0.5 7.2±0.6 7.1 ±0.6 
mmol TYRAMINE 8.0±0.9 7.7±0.9 7.4±0.9 
PHENTOLAMINE 8.4±1 .5 7.9±1 .4 7.9±1.4 
C rea t PLACEBO 92±4 90±4 89±4 
mmol TYRAMINE 96±6 93±6 93±5 
PHENTOLAMINE 91±8 88±7 86±7 
Mg PLACEBO 0.79±0.02 0.81 ±0.03 0.79±0.03 
mmol TYRAMINE 0.79±0.03 0.78±0.03 0.78±0.04 
PHENTOLAMINE 0.81 ±0.02 0.80±0.03 0.78±0.02 
Phos PLACEBO 0.91±0.1 0.94±0.09 0.97±0.07 
mmol TYRAMINE 0.86±0.07 0.90±0.06 0.96±0.05 
PHENTOLAMINE 0.84±0.07 0.89±0.05 0.90±0.05 
CJ PLACEBO 1 04±2 1 04±2 1 04±2 
mmol TYRAMINE 101 ±2 1 02±1 1 02±1 
PHENTOLAMINE 1 02±1 1 03±1 1 03±1 
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Plasma hormone concentrations: Table 8.5, Figure 8.1. 
None of the plasma hormones measured were altered significantly by 
tyramine infusion but phentolamine infusion was associated with a rise in 
active renin concentration, a fall in ANP and a rise in noradrenaline and 
adrenaline concentrations. 
Table 8.5 Plasma hormone concentrations 
Changes in plasma concentrations of atrial natriuretic peptide (ANP), plasma active renin (PARC), 
noradrenaline (N ADREN) and adrenaline (ADREN) at one, two and three hours form the start of the 
study with tyramine or placebo. *p<0.05 
1 HOUR 2 HOURS 3 HOURS 
ANP PLACEBO 56±15 73±23 97±32 
pg/ml TYRAMINE 77±32 63±19 69±27 
PHENTOLAMINE 65±24 65±18 63±20* 
PARC PLACEBO 108±40 79±23 77±25 
pU/ml TYRAMINE 72±17 63±18 55±15 
PHENTOLAMINE 103±49 131±72 194±103* 
N ADREN PLACEBO 4.1 ±0.8 3.8±0. 7 4.1 ±0.6 
nmol/1 TYRAMINE 3.8±0.6 4.0±0.6 4.4±0.7 
PHENTOLAMINE 4.1 ±0.7 5.3±0.6* 1 1 .5±1 .8* 
A OREN PLACEBO 0.23±0.06 0.22±0.06 0.25±0.08 
nmol/1 TYRAMINE 0.24±0.06 0.26±0.07 0.25±0.08 
PHENTOLAMINE 0.27±0.08 0.30±0.07 0.34±0. 1 1 
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Figure 8.1 Changes in plasma concentrations of ANP, 
PARC and noradrenaline during infusion of phentolamine 
and placebo. 
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Haemodynamic variables 
Blood pressure fell during high dose phentolamine infusion with effects 
persisting an hour afterwards (Figure 8.2). Mean arterial pressure rose 
during high dose tyramine infusion (Figure 8.3). 
ERPF increased significantly during phentolamine infusion (218.9±101.3 to 
272.7 ±131.2, and 222.9±80.6 to 272.0±122.1 for low and high dose 
respectively, p=.0357 for both doses). ERPF tended to fall during tyramine 
infusion although this did not reach statistical significance (table 8.6, figure 
8.4). 
Creatinine clearance did not change significantly with tyramine or 
phentolamine infusion (table 8.6). 
Table 8.6 Renal haemodynamics 
Changes in hourly glomerular filtration rate (GFR) and effective renal plasma flow 
(ERPF)during infusion of placebo, tyramine and phentolamine (PHENTOL). * p<O.OS 
0-1 HRS 1-2 HRS 2-3 HRS 3-4 HRS 
GFR PLACEBO 87±13 67±9 71±8 63±8 
MLS/MIN TYRAMINE 78±5 63±7 61±8 69±10 
PHENTOL 69±9 74±9 78±11 77±10 
ERPF PLACEBO 227±33 219±36 223±29 228±30 
MLS/MIN TYRAMINE 214±36 214±31 191±29 234±37 
PHENTOL 212±35 273±46* 272±43* 224±32 
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Figure 8.2 Changes in mean arterial pressure during infusion of 
placebo, phentolamine and tyramine 
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Figure 8.3 Changes in heart rate during placebo, phentolamine 
and tyramine infusions 
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Figure 8.4 Changes in effective renal plasma flow during 
infusion of placebo, phentolamine and tyramine. 
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8. 4 Discussion 
Indirect sympathetic nervous system stimulation with tyramine did not alter 
diuresis or natriuresis in response to furosemide in this study. There was 
also no significant difference between the effect of stimulation with tyramine 
and a-adrenergic blockade with phentolamine on diuresis. 
The interventions differed in effect as follows: phentolamine caused a 
marked and sustained fall in arterial pressure, while tyramine caused a 
modest increment in mean arterial pressure during high dose infusion. 
Tyramine had no effect on circulating renin activity, ANP or catecholamine 
concentrations while phentolamine caused significant suppression of ANP 
during high dose infusion with elevation of and renin and plasma 
catecholamine concentrations. Tyramine did not improve, or even tended to 
impair ERPF, while phentolamine augmented ERPF both at high and low 
dose. Neither intervention had any effect on renal cyclic GMP or furosemide 
excretion. 
These results demonstrate that a fall in arterial pressure may override any 
diuretic or natriuretic forces resulting from an improvement in ERPF, yet an 
increase in arterial pressure without associated beneficial renal 
haemodynamic effects likewise fails to enhance diuresis or natriuresis. 
Phentolamine failed to enhance a furosemide induced diuresis or natriuresis 
despite improving renal plasma flow significantly but blood pressure was 
depressed during high dose infusion with compensatory tachycardia and a 
rise in catecholamines. Garg (1992) has suggested that enhancement of 
natriuresis and diuresis depends not only on total renal plasma flow, which 
is increased by a number of drugs which do not improve natriuresis or 
diuresis, but also on enhancement of renal papillary flow. 
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Although phentolamine inhibited the renal adrenergic sodium-retaining 
effects directly, the associated hypotension activated the renin-angiotensin 
system. The net effect on natriuresis was neutral. 
Tyramine had modest effects on blood pressure and no effect on heart rate 
in the present study. Tyramine infusion titrated to achieve a rise in blood 
pressure of approximately 25mmHg in 9 patients with coronary disease 
failed to produce a significant fall in heart rate, in keeping with the present 
study (Forman, Robertson, Goldberg, et al 1984). Circulating noradrenaline 
levels did not change significantly during tyramine infusion, although there 
was an upward trend. This may have been due to receptor downregulation 
or inadequate dosing. Tyramine infusion at slightly higher dose than that 
used in the present study (15tJglkg/min) in 6 normal volunteers resulted in a 
rise in plasma noradrenaline concentration (0.8 to 1.4ng/ml) and a 
significant fall in plasma renin activity (Lang, Rahman, Balfour, et al 1993b). 
Lang, Rahman, Balfour et al also proposed that circulating noradrenaline 
(infused) and neuronally released noradrenaline (from tyramine 
administration) may have opposite effects on renal sodium handling in man. 
The lack of suppression of plasma renin activity by tyramine infusion in the 
present study may reflect the smaller rise in arterial pressure which was 
achieved or blunting of baroreflex suppression of renin release. It has been 
shown that a-adrenoceptor-mediated renal vasoconstriction predominates 
over ~-adrenoceptor-mediated vasodilatation (Drew, Whiting 1979). Renin 
release from juxta glomerular cells is controlled by ~-adrenoceptors (Katz, 
Lindheimer 1977; Osborn, DiBona, Thames 1981 ). Selective a2-adrenergic 
agonists have been shown to cause diuresis in vivo in part due to inhibition 
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of vasopressin release, and via a2-adrenergic-mediated decreases in renin 
release (Keeton, Campbell 1980; Gellai 1990). Renal nerve stimulation 
results in augmentation of renin release (Osborn, Holdaas, Tharnes, et al 
1983). The mechanism of tyramine-induced renin suppression is thought to 
be secondary to increased solute delivery to the macula densa as well as 
via the baroreceptor mechanism in response to increased blood pressure 
(Lang, Rahman, Balfour, et al 1993b). Ferrari, Ceconi, De-Guili, et al (1991) 
demonstrated that sympathectomised SHR and WKY rats had less 
pronounced pressor and tachycardic responses to tyramine than control 
rats. Patients with heart failure have decreased baroreceptor function 
(Eckberg, Drabinski, Braunwald 1971; Goldstein, Beiser, Stampfer, et al 
1975; Manthey, Dietz, Opherk, et al 1992) and decreased receptor 
responsiveness to exogenous and endogenous catecholamines (Bristow, 
Ginsburg, Minobe, et al 1982; Bogaert, Fraeyman 1991 ). Exaggerated 
sympathetic activity may represent a pathogenetic factor contributing to 
baroreceptor reflex impairment in these patients. Manthey, Dietz, Opherk, et 
al (1992) provide evidence that arterial baroreceptor unloading with 
hydralazine may induce a dissociation between reflex responses of the 
sympathetic nervous system and vasopressin release in patients with severe 
heart failure. Reflex release of vasopressin in response to a significant fall in 
blood pressure was not impaired, yet sympathetic stimulation in response to 
the fall in arterial pressure was impaired. Vasopressin was not measured in 
the present study. 
A study by Yusuf, Garg, Held, et al (1992) shows that tyramine blocks 
sodium channels by suppressing maximal sodium channel conductance in 
frog ventricular myocytes and it is open to speculation that similar effects in 
the kidney might act to impair natriuresis. 
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Limitations of the study 
Adequate sympathetic stimulation may not have been achieved by tyramine 
infusion at the dose used as plasma catecholamine concentrations did not 
rise and the rise in blood pressure was relatively small. One patient with 
milder heart failure had a more marked hypertensive response to tyramine 
which was dose related. Thus it was suspected that patients with more 
severe failure exhibit a blunted hypertensive response to tyramine, as was 
the case with dopamine and dobutamine infusions. All the limitations 
relating to the study design documented in the previous chapters apply to 
this chapter as well but have not been repeated. 
Conclusion 
In patients with heart failure, neither sympathetic inhibition (phentolamine) 
nor indirect stimulation with tyramine had any clinically significant effect on 
the diuresis and natriuresis induced by furosemide. 
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Chapter 9 The effect of dopamine and dobutamine on a 
furosemide induced diuresis 
9.1 Introduction 
In animal models, increased renal sympathetic activity stimulates renin 
release, constricts the glomerular arterioles, alters the pattern of intrarenal 
blood flow and enhances proximal tubular sodium reabsorption. All these 
effects apparently act in concert to inhibit natriuresis (Zambraski, DiBona, 
Kaloyanides 1976; Bunag, Page, McCubbin 1967). Sympathetic 
denervation of the kidney (Gill1979; Gottschalk 1979; Bello-Reuss 1980) or 
sympathetic inhibition with guanethidine and phenoxybenzamine reverses 
these changes in animal models (Zambraski,DiBona, Kaloyanides 1976; 
DiBona 1978). In contrast, inhibition of sympathetic nerve efferent activity 
with guanethidine results in sodium retention in patients with heart failure 
(Gill, Mason, Bartter 1965), as does a-adrenergic blockade (Riegger, 
Haeske, Kraus, et al 1987b). ~-adrenergic blockade, although advocated by 
some for the management of heart failure, are known to exacerbate the 
condition in some patients (lkram, Fitzpatrick 1981; Binkley, Lewe, Lima, et 
al 1986; Shanes 1987; Waagstein, Caidahl, Wallentin, et al 1989; Lang R 
1990; Packer 1992). This may be attended by salt and water retention. Thus 
pharmacological interruption of sympathetic efferent pathways in human 
heart failure in contrast to animal models, generally results in sodium 
retention. This may be due to a reduction in blood pressure rather than 
effects of interfering with the local sympathetic nervous system, nonetheless 
it puts the importance of renal mechanisms into clinical perspective. 
Dobutamine, an agent which stimulates ~1, ~2 and a1 adrenergic receptors 
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increases urine and sodium output in patients with heart failure (Leier, 
Webel, Bush 1977; Leier, Heban, Huss 1978; Applefeld, Newman, Sutton, et 
al 1987). No specific renal vasodilatation is believed to occur with 
dobutamine, suggesting that the diuresis and natriuresis is due to an 
increase in cardiac output, blood pressure and thus renal blood flow. 
Dopamine, the precursor of noradrenaline, activates a- and (3-adrenergic 
receptors and binds to dopamine-1 and -2 receptors. The inotropic effects of 
dopamine in heart failure are mediated mainly by (31-adrenoceptor 
activation, probably indirectly through dopamine-induced release of 
endogenous noradrenaline (Brown, Lorenz, Erdmann 1985; Brodde 1991). 
The observed clinical effects of dopamine infusion in patients with heart 
failure depend on which receptor is activated predominantly. At very low 
doses (0.5-2.Jlg/kg/min) the dopamine receptors alone are activated, 
resulting in renal vasodilatation, decreased peripheral vascular resistance, 
a fall in blood pressure, increased renal blood flow and natriuresis. At doses 
from 2J1g/kg/min some increases in myocardial contractility may be evident 
with improved left ventricular function. At larger doses (2-5JJg/kg/min), 
cardiac (31-adrenoceptors are stimulated, with positive inotropic and 
chronotropic effects being manifested with preservation of decreased 
peripheral vascular resistance, however at doses of 1 OJJg/kg/min, peripheral 
vasoconstriction and increased systemic vascular resistance results. 
Dopamine and dobutamine are widely used in the management of 
decompensated, severe left ventricular failure. There are several anecdotal 
reports and uncontrolled studies in patients with heart failure showing 
beneficial diuresis and natriuresis during dopamine (Goldberg, McDonald, 
Zimmerman 1963; McDonald, Goldberg, McNay, et al 1964; Beregovich, 
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Bianchi, Rubler, et al 1974) and dobutamine infusion (Leier 1978, Applefeld 
1987) although the precise mechanism for these renal effects is not known. 
Infusion of dobutamine caused greater increments in blood pressure and 
cardiac index (Leier, Heban, Huss 1978) than with similar doses of 
dopamine with an associated fall in peripheral vascular resistance. This 
suggests that the mechanism for natriuresis and diuresis with dobutamine is 
improved renal perfusion pressure. Whether there is an additional effect of 
specific dopamine receptor stimulation on a furosemide induced diuresis in 
patients with heart failure is not known. Dopamine receptor stimulation may 
specifically induce a natriuresis, especially when used in low doses. To 
differentiate this effect from that of increasing cardiac output alone, the renal 
effects of equivalent doses of dopamine and dobutamine were compared. 
9. 2 Patients and methods 
8 patients with chronic stable heart failure requiring diuretics to control 
symptoms were studied on three occasions in single blind fashion as set out 
in Chapter 2. After the run-in period of one hour, dobutamine, dopamine or 
matching placebo infusions were commenced at 1j.Jg/kg/min, for one hour. 
During the next (3rd) hour, the dose was increased incrementally to a 
maximum of 1 Oj.Jg/kg/min and maintained at this dose for the remainder of 
the hour for both agents. The infusions were discontinued for the final hour. 
Infusion rate was reduced if heart rate increased to over 11 Obpm, if frequent 
ventricular premature beats appeared or if symptoms such as chest pain or 
breathlessness occurred. Mean maximum infusion rate was 5J1glkg/min and 
6j.Jg/kg/min for dopamine and dobutamine respectively. 
Hourly urine and blood samples were collected for electrolytes, . urinary 
cGMP, urinary frusemide, urinary and plasma PAH and plasma ANP and 
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active renin. Heart rate and blood pressure were measured at 15 minute 
intervals. 
Table 9.1 Patient characteristics 
Individual patient characteristics: age, sex, New York Heart Association classification (NYHA), 
maintenance diuretic requirements in milligrammes per day (furosemide-F. metolazone-MET), type and 
dose of ACE-inhibitor in milligrammes per day (captoprii-CAP, enalaprii-ENAL, lisinoprii-LISIN) and 
aetiology of heart failure (ischaemic heart disease-IHD, dilated cardiomyopathy-DCM). 
PATIENT AGE SEX NYHA DIURETIC ACE-I (mg) AETIOLOGY 
1 67 M liB F 120 CAP 75 IHD 
2 65 M liB F 120 IHD 
3 55 M Ill F 120 ENAL 20 IHD 
4 62 M Ill F 40, MET 2.5 LISIN 10 IHD 
5 63 M Ill F 120 ENAL 15 DCM 
6 62 M liB F 80 ENAL 10 IHD 
7 77 M Ill F 40 CAP 37.5 IHD 
8 54 M liB F 40 ENAL 10 IHD 
9.3 Results 
Urine volume tended to rise with respect to placebo during high dose 
dopamine and dobutamine infusion, although this did not reach significance. 
There was a significant fall in urine volume during the hour after dopamine 
infusion. (Table 9.1 ). 
Electrolyte excretion. There was no significant change in sodium or 
chloride excretion after dobutamine, although sodium excretion and chloride 
excretion increased after dopamine infusion compared to placebo at high 
dose (p=0.036 and p=0.05 respectively, figure 9.1 and 9.2). The difference 
in sodium and chloride excretion between dopamine and dobutamine was 
however not significant. Slight but statistically significant increases in 
potassium excretion were seen during high dose infusion of both dopamine 
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and dobutamine. 
Furosemide excretion did not alter during dopamine or dobutamine 
infusion although fractional excretion of furosemide increased in the hour 
following high-dose dopamine infusion. 
cGMP excretion was not altered by dobutamine infusion but both 
excretion and fractional excretion of cyclic GMP fell during high-dose 
dopamine infusion. 
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Table 9.2 Urine indices 
Hourly changes in urine volume (millilitres) and excretion of sodium, potassium, urea, creatinine, 
chloride, magnesium, phosphate (millimols), furosemide (milligrammes per hour) and cyclic GMP 
(nanograms per minute) ... denotes significance at p<0.05. 
URINE 
(MLS) 
SODIUM 
mmol 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
POTASSIUM PLACEBO 
mmol DOPAMINE 
UREA 
mmol 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
CREATININE PLACEBO 
mmol DOPAMINE 
CHLORIDE 
mmol 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
MAGNESIUM PLACEBO 
mmol DOPAMINE 
DOBUTAMINE 
PHOSPHATE PLACEBO 
mmol DOPAMINE 
DOBUTAMINE 
FUROSEMIDE PLACEBO 
(mg/hr) DOPAMINE 
CGMP 
(ng/min) 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
0-1 HRS 
228±29 
247±40 
225±34 
21±5 
24±4 
21±4 
6±0.7 
6±1 
6±1.3 
21±9 
23±3 
22±3 
0.62±0.08 
0.63±0.07 
0.58±0.09 
19±4 
24±5 
20±4 
0.39±0.06 
0.41 ±0.07 
0.37±0.06 
1.3±0.2 
1.4±0.21 
1.3±0.09 
8.3±1.3 
7.3±1.1 
7.5±1.5 
3.1 ±0.9 
3.8±0.7 
3.3±0.5 
1-2 HRS 
231±26 
232±31 
234±32 
17±4 
21±3 
22±4 
6±0.7 
6±1 
6±1.1 
17±2 
18±3 
21±4 
0.47±0.04 
0.46±0.05 
0.53±0.1 
16±4 
21±3 
21±4 
0.31±0.02 
0.28±0.06 
0.37±0.07 
1.0±0.07 
1.0±0.08 
1.2±0.09 
9.0±1.4 
6.4±0.7 
8.7±1.7 
2.7±0.6 
2.8±0.7 
2.9±0.6 
2-3 HRS 
232±30 
328±47 
275±32 
15±2 
31±6* 
20±4 
5±0.9 
7±1* 
6± 1 .1 * 
15±2 
20±7* 
17±2 
0.39±0.04 
0.51±0.04 
0.42±0.06 
15±5 
29±5* 
18±4 
0.28±0.04 
0.34±0.05 
0.28±0.04 
1.0±0.09 
1.3±0.16 
0.9±0.05 
7.8±1.2 
6.3±0.4 
9.3±2.2 
3.1 ±0.6 
2.9±0.7* 
3.2±0.8 
3-4 HRS 
251±26 
221±23* 
277±36 
17±3 
20±3 
22±4 
6±0.8 
6±1 
6±1.3 
16±2 
15±3 
20±2 
0.44±0.05 
0.39±0.07 
0.49±0.07 
15±2 
17±3 
20±3 
0.29±0.03 
0.20±0.04 
0.32±0.05 
1.1±0.07 
0.9±0.09 
1.0±0.08 
7.7±1.1 
8.4±1.0* 
9.3±1.7 
2.8±0.7 
2.0±0.5 
3.0±0.9 
Hourly excretion of sodium and chloride rose significantly after dopamine 
infusion compared to placebo (p=0.036 and p<0.05; figure 9.1 and 9.2). 
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Figure 9.1 Changes in hourly sodium excretion during 
infusion of placebo and dopamine 
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Figure 9.2 Changes in hourly chloride excretion during 
infusion of placebo and dopamine 
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Fractional excretion of sodium and chloride increased during high dose 
dopamine infusion compared with placebo while cGMP fell. The trend to 
increase with high dose dobutamine did not reach statistical significance. 
Fractional excretion of furosemide increased in the hour following high dose 
dopamine infusion compared with placebo. 
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Table 9.3 
cyclic GMP 
Fractional excretion of electrolytes, furosemide and 
Excretion of sodium (Na), potassium (K), urea, chloride (CI), magnesium (Mg), phosphate (Phos), 
furosemide (FRUS) and cyclic GMP (cGMP)/creatinine (Cr). w denotes significance at P<0.05. 
Na/Cr 
mM/mM 
K/Cr 
mM/mM 
U/Cr 
mM/mM 
CI/Cr 
mM/mM 
Mg/Cr 
mM/mM 
Phos/Cr 
mM/mM 
FRUS/Cr 
JJg/mM 
cGMP/Cr 
ng/mM 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
0-1 HRS 
34±7 
37±5 
39±8 
1 1 ±2 
10±2 
1 1 ±2 
33±2 
36±2 
39±2 
31±6 
37±6 
34±6 
0.64±0.08 
0.65±0.07 
0.65±0.08 
2.06±0. 17 
2.29±0.21 
2.35±0.24 
2.89±0.48 
2.78±0.47 
2.93±0.63 
4.92±1 .54 
6.84±1 .74 
5.97±1 .02 
1-2 HRS 
37±8 
48±7 
46±7 
13±2 
12±2 
13±2 
37±2 
39±2 
41±2 
34±7 
48±8 
41±6 
0.68±0.05 
0.63±0. 1 1 
0.71±0.08 
2.24±0. 19 
2.34±0.21 
2.62±0.37 
3.86±0.44 
3.43±0.62 
5.72±2.76 
5.74±1 .25 
6.89±1 .74 
7.46±2.94 
2-3 HRS 
37±8 
58±7* 
49±7 
14±2 
14±2 
13±2 
38±2 
39±2 
42±2 
39±6 
54±6* 
42±6 
0.72±0.06 
0.66±0.09 
0.68±0.07 
2.67±0.28 
2.56±0.21 
2.52±0.44 
4.08±0.46 
4.1 2±0.64 
9.2±4.94 
8.26±1 .80 
5.71±1.20* 
8.43±2.09 
3-4 HRS 
42±6 
56±10 
48±8 
13±2 
15±2 
13±2 
38±2 
39±2 
41±2 
36±4 
48±8 
43±6 
0.67±0.05 
0.60±0. 10 
0.67±0.06 
2.70±0.33 
2.82±0.56 
2.38±0.36 
4.03±0.51 
6.21±1.7* 
6.01±2.26 
7.37±2.44 
8.38±3.73 
6.33±1.54 
Plasma electrolytes: Plasma concentrations of sodium, potassium, urea, 
creatinine and magnesium did not differ significantly between interventions. 
Plasma chloride concentrations fell during high dose dopamine infusion with 
respect to placebo and plasma phosphate concentrations were significantly 
lower during low and high dose dobutamine infusion and during high dose 
·dopamine infusion. 
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Table 9.4 P~asma electrolyte concentrations 
Changes in plasma sodium {Na), potassium {K), urea, creatinine {Great), chloride {CI), magnesium {Mg) 
and phosphate {Phos) at one, two and three hours from the start of each study. *indicates significance 
at p<0.05. 
Na 
mmol/1 
K 
mmol/1 
Urea 
mmol/1 
Creat 
pmol/1 
Cl 
mmol/1 
Mg 
mmol/1 
Phos 
mmol/1 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
1 HOUR 
138±1 
138±1 
137±1 
4.0±0.2 
4.0±0.1 
3.9±0.2 
8.0±0.7 
8.0±0.6 
8.1±0.7 
114±8 
11 0±1 0 
112±10 
99±1 
100±1 
100±2 
0.79±0.03 
0.78±0.04 
0.79±0.03 
1.02±0.08 
0.96±0.04 
0.92±0.05 
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2 HOURS 
137±1 
138±1 
137±1 
3.9±0.1 
3.9±0.2 
3.8±0.1 
7.9±0.7 
7.9±0.6 
8.0±0.7 
113±8 
108±10 
11 0±1 0 
1 01±1 
1 00±1 
101 ±1 
0.80±0.03 
0.76±0.04 
0.79±0.03 
1.03±0.07 
0.97±0.04 
0.90±0.05 
3 HOURS 
137±1 
137±1 
137±1 
3.8±0.1 
3.7±0.1 
3.6±0.1 
7.7±0.7 
7.8±0.6 
7.8±0.7 
110±9 
111 ±9 
109±9 
1 01±1 
98±1* 
101 ±1 
0.79±0.03 
0.76±0.04 
0.78±0.03 
1.07±0.06 
0.97±0.04 
0.87±0.04 
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Plasma hormone concentrations: There was no change in ANP or 
active renin concentrations during high or low dose dopamine infusion but 
there was a significant rise in plasma renin after high dose dobutamine 
infusion (figure 9.3, table 9.5). 
Table 9.5 Plasma hormone concentrations 
Plasma concentrations of active renin (PARC) measured in micro-units per millilitre and atrial natriuretic 
peptide (ANP) measured in picograms per millilitre at one, two and three hours from the start of the 
studies. *denotes significance at p<0.05. 
1 HOUR 2 HOURS 3 HOURS 
ANP PLACEBO 96±43 103±47 91±30 
pg/ml DOPAMINE 104±45 92±34 70±19 
DOBUTAMINE 109±46 92±38 77±34 
PARC PLACEBO 235±108 172±70 167±66 
pU/ml DOPAMINE 181±81 146±61 133±49 
DOBUTAMINE 128±38 140±54 306±142* 
Adverse responses 
Dopamine infusion was poorly tolerated at doses above 4Jlg/kg/min with 
only one patient able to remain on the maximum infusion rate of 1 OJ1glkg/min 
for the entire third hour. Two patients developed angina and five developed 
significant ventricular arrhythmia. Dobutamine was also poorly tolerated at 
doses greater than 6J1g/kg/min with similar adverse effects including 
paradoxical hypotension in one patient and profound bradycardia in two. 
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Figure 9.3 Changes in plasma renin during infusion of 
placebo and dobutamine 
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Haemodynamics: 
Creatinine clearance did not change significantly after dopamine or 
dobutamine (table 9.7). 
Effective renal plasma flow increased during low and high dose 
dopamine infusion while the differences with dobutamine were only 
significant during high dose infusion (figure 9.4). 
Heart rate did not change significantly during dopamine infusion but 
increased significantly during high dose dobutamine infusion (figure 9.5). 
Systolic blood pressure rose significantly during high dose dobutamine 
infusion (table 9.6). 
Table 9.6 Haemodynamic variables 
Hourly changes in creatinine clearance (CR. CLEAR), ERPF, systolic, diastolic and mean 
blood pressure (BP) and heart rate. *denotes significance at p<0.05. 
CR. CLEAR 
(MLS/MIN) 
ERPF 
(MLS/MIN) 
SYSTOLIC 
BP 
(mmHg) 
DIASTOLIC 
BP 
(mmHg) 
MEAN 
BP 
(mmHg) 
HEART 
RATE 
(bpm) 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
PLACEBO 
DOPAMINE 
DOBUTAMINE 
0-1 HRS 
98±17 
99±16 
91±15 
174±14 
179±13 
171±14 
115±7 
115±6 
116±5 
74±3 
73±3 
77±3 
88±4 
88±4 
92±4 
75±3 
74±3 
77±3 
235 
1-2 HRS 
75±8 
71±9 
85±18 
171±11 
220±17* 
189±18 
118±6 
112±5 
119±5 
77±3 
73±3 
77±3 
91±4 
86±4 
93±3 
73±2 
72±2 
79±3 
2-3 HRS 
61±8 
78±7 
67±11 
192±14 
297±27* 
288±31* 
113±5 
119±6 
123±6* 
76±3 
73±2 
75±4 
89±3 
89±3 
92±4 
73±2 
77±3 
90±5* 
3-4 HRS 
69±12 
62±15 
80±14 
207±16 
209±29 
208±20 
115±7 
113±6 
118±6 
74±2 
73±3 
77±4 
89±4 
87±4 
92±4 
70±2 
76±3 
78±3 
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Figure 9.4 Changes in ERPF during placebo, dopamine 
and dobutamine infusion 
Dopamine increased ERPF at low and high dose while the differences 
were only significant during high dose dobutamine infusion 
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Figure 9.5 Changes in hourly heart rate during placebo 
and dobutamine infusion 
High dose dobutamine infusion resulted in a significant increase in heart rate 
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Figure 9.6 Changes in hourly systolic blood pressure 
during placebo and dobutamine infusion 
High dose dobutamine infusion lead to a significant increase in systolic blood pressure 
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9. 4 Discussion 
Dobutamine is used extensively for inotropic support in patients with 
decompensated heart failure with or without acute myocardial ischaemia 
and intermittent dobutamine infusions have been used on an outpatient 
basis for control of symptoms in patients with severe heart failure (Applefeld, 
Newman, Sutton, et at 1987). While side effects such as tachycardia, 
ventricular extrasystoles and angina have been reported with its use, 
dobutamine is usually well tolerated at doses of 1 0-20pg/kg/min. The 
frequency of adverse effects experienced in the present study at relatively 
low infusion rates was thus unexpected. 
Patients with and without ischaemic heart disease have been shown to 
develop idiosyncratic hypotension with or without bradycardia during 
dobutamine infusion (Marcovitz, Bach, Mathias, et al 1993). The exact 
mechanism is debated. Peripheral vasodilatation, a fall in pulmonary 
capillary wedge pressure and ventricular mechanoreceptor stimulation 
leading to reflex bradycardia and vasodilatation are possible mechanisms. 
Heart failure patients may be particularly sensitive to these effects due to the 
abnormal baroreceptor sensitivity which is found in chronic heart failure 
(Eckberg, Drabinsky, Braunwald 1971; Mancia 1990). 
A high proportion of the study patients developed tachyarrhythmias during 
relatively low dose dobutamine infusion. These results suggest that an 
arrhythmic mechanism may have played a part in the increased incidence of 
sudden death noted in the treatment arm of the study of chronic dobutamine 
therapy by Dies (1988). 
Leier, Heban, Huss, et al (1978) reported similar undesirable effects with 
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infusions of dopamine as low as 4pg/kg/min in their patients with severe 
non-ischaemic congestive failure but their patients were able to tolerate 
dobutamine infused at 8pg/kg/min for 24 hours. Beregovich, Bianchi, 
Rubler, et al (197 4) described an increase in urine flow and renal sodium 
excretion in patients with heart failure but only at dopamine doses of greater 
than 5pglkg/min, concentrations which from the present study are not safely 
achieved or are poorly tolerated. 
Dopamine augmented the furosemide induced diuresis in the final hour of 
the present study compared with placebo, however dobutamine did not. 
Dobutamine had no significant effect on natriuresis compared with placebo 
but dopamine caused a 30% increase in sodium and chloride excretion 
during high dose infusion. This contrasted with the 4.8 fold increase in 
sodium excretion after dopamine infusion described by Rosenblum, Tai and 
Lawson (1972) in patients not receiving concomitant diuretics and the 2.8 
fold increase in urine flow and 4.6 fold increase in urinary sodium excretion 
with dopamine infusion relative to dobutamine infusion in a study of patients 
after open-heart surgery (Hilberman, Maseda, Spencer, et al 1984). A more 
recent study of low-dose dopamine infusion in elderly patients with 
congestive heart failure showed no diuretic or natriuretic effect (Robinson, 
Gariballa, Fancourt, et al 1994) and Graves, Cioffi, Vaughan, et al (1993) 
found inconsistent natriuretic effects in hyperdynamic thermally injured 
patients. 
There are several mechanisms by which dopamine could cause a diuresis 
and natriuresis: 
a) Stimulation of renal dopamine receptors. Selective renal 
vasodilatation by dopamine was suggested by the increase in ERPF 
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during low dose dopamine but not dobutamine infusion. However 
renal vascular resistance and filtration fractions were no different from 
those seen with dobutamine. Hilberman, Maseda, Spencer, et al 
(1980a) suggested that the most likely mechanism for the diuresis 
and natriuresis produced by dopamine was a direct action on renal 
tubular solute transport, although they did not rule out an effect on 
intrarenal redistribution of blood flow. The data from the present study 
do not support this mechanism for enhanced natriuresis as it was only 
seen during infusion of higher doses and the effects were no different 
from those observed during dobutamine infusion. 
b) Improved renal perfusion pressure. ERPF increased with low 
dose and high dose dopamine infusion, supporting an effect of 
dopamine-1 receptor stimulation in the kidney at both doses, but 
natriuresis was enhanced only at high dose infusion, thus other 
factors such as arterial pressure appear to have a permissive role. 
ERPF also increased during high dose dobutamine infusion. 
c) Increased tubular delivery of furosemide. Although no change in 
urinary furosemide excretion was apparent, fractional excretion of 
furosemide rose in the final hour after dopamine infusion. This was a 
period when diuresis fell, making increased tubular delivery of 
furosemide an unlikely mechanism. There may also have been an 
alteration in intrarenal haemodynamics or a direct effect on the renal 
tubule. 
d) A fall in filtration fraction. Ramdohr, SchOren, Biamino, et al (1973) 
showed that dopamine infusions result in a fall in filtration fraction and 
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a rise in ERPF which is more marked in patients with heart failure than 
in normal subjects. Filtration fraction was not calculated in the 
present study as creatinine clearance was used to estimate GFR 
rather than a more accurate method such as inulin clearance. 
e) Improvement in GFR. Creatinine clearance did not change 
significantly although there was a trend during high dose dopamine 
infusion. Beregovich, Bianchi, Rubler, et al (1974) noted a dose-
related increase in creatinine clearance, urine flow and sodium 
excretion with dopamine administration in patients with congestive 
cardiac failure. However McDonald, Craig and Watson (1989) 
demonstrated a four-fold increase in sodium excretion during 
dopamine infusion in patients with congestive heart failure without 
evidence of significant increases in glomerular filtration rate or ERPF. 
Thus changes in G FA were probably not responsible for the observed 
natriuresis with dopamine infusion although the mechanism may 
have played a part in other patient groups. 
f) Neuroendocrine modulation. A fall in plasma renin activity has 
been demonstrated in patients with heart failure during low dose 
dopamine infusion, although the opposite is usually seen in normal 
subjects. Concentrations fell during both placebo and dopamine 
infusions in the present study, without any statistical difference 
between the two. Plasma renin was elevated during high dose 
dobutamine infusion however these opposite effects had little impact 
on diuresis or natriuresis, hence this is unlikely to be an important 
mechanism. Aldosterone secretion is inhibited by dopamine 
(McKenna 1979) and the oral dopamine analogue, ibopamine, 
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reduced aldosterone levels in an uncontrolled study of heart failure 
patients (Nakano, Morimoto, Kakuta, et al 1986). Concentrations were 
not measured in the present study and some patients were taking 
ACE-inhibitors which could have influenced results, although these 
were stopped 18 hours before each study. In patients with congestive 
heart failure, ibopamine lowers noradrenaline levels (Nakano, 
Morimoto, Kakuta, et al 1986; Van Veldhuisen, Girbes, Crijns, et al 
1989) but catecholamines were not measured in the present study. 
ANP concentrations were unaffected by either agent. Urinary cyclic 
GMP actually fell during dopamine-enhanced natriuresis. ANP 
concentrations may fall during dopamine infusion in congestive heart 
failure (Fontana 1991) but this probably depends on whether 
significant changes in right atrial pressure occur during infusion. 
g) Pressure natriuresis. Blood pressure increased only with 
dobutamine infusion in the present study and changes were modest, 
probably because the mean maximum dose of dopamine tolerated for 
the third hour was only 5J1glkg/min, which has little effect on 
peripheral vascular resistance or blood pressure. While maintaining a-
minimum arterial pressure clearly has a vital permissive role the 
diuretic and natriuretic actions of other agents, raising pressure alone 
does not appear to have a natriuretic action in patients with heart 
failure. 
h) Decreased proximal tubular reabsorption of sodium leads to 
increased distal (and thus the macula densa) delivery of sodium and 
thus natriuresis, which is probably the mechanism for the diuresis 
caused by saline infusion (Martinez-Maldonado, Tsaparas, Eknoyan, 
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et al 1972) as well as that induced by prostaglandin infusion (Vander 
1968; Daugherty, Belleau, Martino, et al 1968; Martinez-Maldonado, 
Tsaparas, Eknoyan, et al 1972). It is possible that this was the 
mechanism for the observed natriuresis in the present study. 
Limitations of the study 
(The limitations applying to all the studies have not been repeated). In 
Chapter 5, dobutamine infusion potentiated diuresis and natriuresis 
compared to sodium nitroprusside. In the present chapter, changes in 
diuresis and natriuresis with dobutamine were not significant but were 
directionally similar. The reason for the discrepancy between this study and 
the previous one is not clear, but probably relates to the small sample size 
and the modest changes in urine volume and natriuresis effected by the 
infusions. The role of chronic dopamine or dobutamine infusion was not 
addressed but recent clinical trials of inotropic agents in heart failure 
patients have demonstrated increased mortality in the treatment arm (Dies 
1988; The Xamoterol in Severe Heart Failure Study Group 1990; Uretsky, 
Jessup, Konstam, et al 1990; Packer, Carver, Rodeheffer, et al 1991 ). The 
small sample size did not allow any assessment of the effect of other 
maintenance therapy such as digoxin or calcium antagonists although 
cardioactive drugs were omitted on study days to reduce possible errors. 
Conclusion 
Dopamine infusion at doses of 4-5pg/kg/min has a modest additive 
natriuretic and diuretic effect when administered with furosemide. The trend 
with dobutamine infusion failed to reach significance compared with placebo 
although differences between dobutamine and dopamine were not 
significant (with the exception of ERPF during low dose infusion). Significant 
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natriuretic actions similar to those seen with dopamine were recorded with 
dobutamine infusion in Chapter 5. This raises the question of whether any 
true difference exists between the effects of the two agents on diuresis and 
natriuresis or whether differences were due to the small sample size. The 
mechanism for the natriuresis probably relates to the beneficial adrenergic 
systemic and renal haemodynamic effects of dopamine and dobutamine 
increasing solute delivery to Henle's Loop where furosemide can act. 
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Chapter 10 Final discussion 
Diuretic agents remain one of the mainstays of therapy for symptoms of heart 
failure and no-one would contest that they are lifesaving in acute heart 
failure. There is little direct evidence to support a beneficial effect of 
diuretics on mortality in patients with chronic heart failure, probably because 
it would be unethical to perform such a. trial (Taylor 1993). The 
neurohormonal activation induced by diuretic administration may be harmful 
in the long-term (Gavras, Kremer, Brown, et al 1975; Packer 1992). 
Blunting of the renal effects of furosemide is an important and costly clinical 
problem in heart failure. Treatment with combinations of loop diuretics and 
thiazide diuretics may restore diuresis but at the expense of further activation 
of the renin-angiotensin system and development of hyponatraemia. The 
diuretic sparing effects of infusion of dopamine and dobutamine are largely 
anecdotal and these agents are not practical for routine outpatient treatment 
(Unverferth, Blanford, Kates, et al 1980; Unverferth, Magorien, Altschuld, et 
al 1983; Robinson, Gariballa, Fancourt, et al 1994). A better understanding 
of the renal mechanisms in heart failure is of academic importance, while 
restoration of diuretic efficacy without further activation of the renin-
angiotensin system remains a clinical challenge. 
At the time of starting the project there was a lack of studies in this area. For 
this reason, a large number of small studies were performed so that future 
investigators would have some insights from which to work. The 
mechanisms of diuretic resistance were addressed, correlating changes in a 
furosemide induced diuresis and natriuresis with changes in urinary 
furosemide excretion, cyclic GMP excretion, neuroendocrine activation, 
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changes in arterial pressure and changes in renal haemodynamics. The 
decision to perform several studies with small numbers of patients rather 
than fewer studies with larger numbers was based on a need to explore 
potential therapeutic stategies without devoting the entire thesis to one or 
two negative studies, a situation which could easily have arisen had only the 
phentolamine and ANP studies been performed. The conflicting reports 
from animal, normal volunteer and heart failure studies in the literature show 
that it is impossible to predict which agents would be beneficial. 
The studies presented do not have great statistical power, but the trends 
indicated in the digoxin and captopril studies can be confirmed in larger 
studies. Both diuresis and natriuresis were measured. In health, free water 
clearance occurs when plasma osmolality is low, and sodium excretion in 
excess of water excretion in the setting of high plasma osmolality and 
normal plasma volume. In heart failure, plasma volume is expanded and 
although there is total body sodium excess, plasma sodium is normal or 
reduced. Administration of furosemide prevents reabsorption of sodium, 
which enhances water clearance. Because of the technical difficulty in 
obtaining precise hourly urine volumes without indwelling urinary catheters, 
changes in urine volume were somewhat imprecise, while changes in 
sodium could be corrected for urine volume by expressing them as a ratio of 
creatinine excretion and as such were a more sensitive measure of changes 
in salt and water excretion. It is likely that diuresis and natriuresis occurred 
simultaneously. 
Several of the agents investigated, drugs used in the treatment of acute 
decompensated heart failure, had little or no effect on the diuresis and 
natriuresis induced by furosemide in well controlled patients. One of the 
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reasons may be precisely because of the patient group chosen: stable 
patients with compensated heart failure. The omission of patients' morning 
diuretic dose on study days allowed a small positive fluid balance to develop 
during the course of the day. It should thus have been possible to increase 
a very modest diuresis with low-dose intravenous furosemide by the addition 
of other pharmacological agents. Although these negative results may be a 
reflection of the small sample size and lack of statistical power to detect 
changes, they do challenge the assumption of the benefit of such agents in 
chronic stable heart failure. 
Captopril, digoxin and dobutamine appeared to improve natriuresis but not 
diuresis. These results were not unexpected, as all these agents have been 
used to treat heart failure, and have been shown to be natriuretic in some 
clinical settings. However no unifying hypothesis could be invoked for the 
mechanism. If the captopril study was excluded, the pressure hypothesis 
could be invoked, as in all the other studies a fall in blood pressure was 
associated with failure of the agent to enhance diuresis and natriuresis. 
ACE inhibition with captopril potentiated natriuresis despite causing a fall in 
GFR and arterial pressure; this finding was in disagreement with the results 
of other investigators who maintain that a fall in blood pressure and G FR 
negates the enhancement of natriuresis by captopril (Motwani, Fenwick, 
Morton, et al 1992b). Although not measured in this study, increased 
concentrations of vasodilator prostaglandins induced by chronic therapy 
with captopril could have protected renal function despite the fall in 
perfusion pressure and GFR. Bradykinin is inactivated by two kininases, one 
being identical to angiotensin converting enzyme, thus it accumulates during 
ACE inhibitor treatment. Bradykinin has vasodilator properties in part due to 
247 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
an increased conversion of arachidonic acid to prostaglandins. 
Prostaglandins have an important role in renal autoregulation and may be 
important modulators of the renal response to furosemide during chronic 
ACE inhibition. While it would have been interesting to study the effect of 
supression of prostaglandin synthesis by a non streroidal anti-inflammatory 
agent such as indomethacin, such a study was deemed unethical. Renal 
vasodilator prostaglandins may alter intrarenal haemodynamics and prevent 
the fall in blood pressure and glomerular filtration rate from causing a fall in 
renal plasma flow and diversion of blood to the medullary nephrons. Non 
steroidal anti-inflammatory drugs abolish the diuresis and natriuresis caused 
by captopril administration, at least in normal volunteers, although studies 
investigating the effects of chronic use are not available. 
ACE inhibition may also influence vascular remodelling and alter 
baroreceptor function, maintaining renal perfusion pressure. Reduction in 
renal angiotensin II concentrations may thus cause enhanced sodium 
excretion because the kidney is in some way protected from the fall in blood 
pressure and glomerular filtration rate by chronic but not acute ACE inhibitor 
treatment 
Potentiation of the natriuretic effect of furosemide by digoxin has not, to our 
knowledge been reported before, although several authors have reported 
natriuretic effects of cardiac glycosides on their own (Hyman, Jaques, 
Hyman 1956; Gavey, Parkinson 1939; Hull, Mackintosh 1977; Lloyd, 
Sandberg, Edwards 1992). The most probable cause for this was inhibition 
of the renal tubular Na+-K+-ATPase and improvement in renal perfusion. 
Although it was not possible to document any significant change in cardiac 
output or arterial pressure after intravenous digoxin, ERPF increased. 
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Although plasma renin concentrations did not change after digoxin infusion 
in the present study, digoxin does inhibit renin release from the kidney 
(Montanaro, Antonello, Baggio, et al 1980; Covit, Schaer, Sealey, et al 
1983). It is possible that chronic administration of digoxin may confer 
additional renal benefits as a result of neuroendocrine modulation, 
particulary of the renin-angiotensin system and baroreceptor function. 
The role of pressure-natriuresis in heart failure was assessed using 
infusions of dopamine, tyramine and dobutamine to elevate systemic 
pressure. Tyramine raised systolic blood pressure but had no significant 
effect on natriuresis and dobutamine raised blood pressure marginally, but 
improved natriuresis no more than dopamine, which failed to augment blood 
pressure. The failure of tyramine to enhance natriuresis may have been 
because renal sympathetic stimulation caused enhanced sodium retention 
and masked the effects of increased renal perfusion pressure (Lang, 
Rahman, Balfour, et al 1993a; Lang, Rahman, Balfour, et al 1993b). These 
results do not exclude a beneficial diuretic effect of raising blood pressure in 
heart failure. 
In experimental models of heart failure, renal sympathectomy restores 
diuresis but in the setting of this study, the systemic effects of phentolamine 
caused a fall in perfusion pressure, stimulated the RAAS, diminished 
creatinine clearance and reduced solute delivery to the Loop of Henle in 
addition to blocking the renal a-adrenergic outflow._ These sodium retaining 
effects outweighed any natriuretic effects. 
In the present study, dopamine and dobutamine had little impact on a 
furosemide induced diuresis in stable compensated heart failure. In 
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addition, they were poorly tolerated at doses usually safely prescribed for 
decompensated heart failure. Ventricular bigeminy was the limiting factor in 
several patients with infusions of both agents, while sudden hypotension 
occurred in two patients during dobutamine infusion. Dopamine infusion 
caused chest pain when the dose was increased above 5J,Jglkg/min in 3 
patients who had underlying ischaemic heart disease. Although these 
studies did not address the usefulness of dopamine infusions in acute heart 
failure, a recent study in the elderly did not show consistent benefit 
(Robinson, Gariballa, Fancourt, et al 1994). The high incidence of 
arrhythmias seen in our patients may also provide a mechanism for the 
adverse effect these agents have been shown to have on survival in patients 
with heart failure when administered on a chronic basis. The natriuretic 
properties of dobutamine dift'ered little from those of dopamine in the 
present study and were seen at doses of 5-1 OJ,Jg/kg/minute but not at 
concentrations likely to stimulate the dopamine receptors specifically. These 
findings were more consistent with the concept of pressure natriuresis, 
raised ERPF and possible additional dopamine effect. 
Afterload reducing agents such as sodium nitroprusside and phentolamine 
which improve cardiac output in situations of acute pulmonary congestion 
and cardiac decompensation cause significant hypotension when infused 
into stable, well diuresed patients, without any detectable diuretic-sparing 
effect despite an improvement in renal plasma flow. This once again 
highlights the importance of renal perfusion pressure in modulating diuresis 
and natriuresis. 
The general lack of change in renal furosemide excretion in our studies 
suggests that increased delivery of furosemide to the loop of Henle is not the 
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mechanism for the improved natriuresis observed with digoxin, dopamine, 
dobutamine and captopril administration. We were not able to support 
Nomura's findings of a relationship between urinary furosemide levels and 
sodium excretion after different treatment modalities in our patient 
population. 
Renal cyclic GMP excretion did not change significantly during enhanced 
natriuresis with digoxin and captopril and. was thus probably not involved in 
the enhanced natriuretic response. Conversely, the pronounced rise in 
cyclic GMP excretion seen during ANP infusion was not accompanied by 
enhanced diuresis or natriuresis. The relatively low dose of ANP infused did 
not augment natriuresis or diuresis with furosemide. Although it is possible 
that larger doses of ANP might have augmented natriuresis, just as the 
blunted effects in heart failure can be partially overcome, it is more likely that 
hypotension would again have offset any natriuretic effects. The rise in 
concentrations of plasma active renin measured during high dose ANP 
infusion may be explained by the fall in blood pressure as the effect of ANP 
otherwise is to leave plasma renin activity unaffected or to suppress it. 
Attempts to modify the diuretic response to furosemide in patients with heart 
failure by suppression of antinatriuretic systems tend to be confounded by 
activation of additional sodium conserving neuroendocrine systems, thus 
isolation and inhibition of a single system does not reverse the inappropriate 
sodium and water retention found in heart failure. Natriuresis was enhanced 
by agents with diverse effects on neuroendocrine activation but preservation 
of adequate renal perfusion appeared to be essential for the response. 
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Strategies for the future 
The role of arginine vasopressin in diuretic resistance was not investigated. 
Elevated plasma concentrations of arginine vasopressin are associated with 
vasoconstriction and antidiuresis in heart failure but as yet, no suitable 
receptor antagonist is available for clinical studies (Laszlo, Laszlo, De Wied 
1991 ). Such antagonists may have an adjunctive role in the treatment of 
heart failure in the future. 
Neutral endopeptidase (NEP) is a protease which inactivates a number of 
peptides including ANP. Inhibitors of NEP cause concentrations of ANP to 
rise and the diuretic and natriuretic response is greater in relation to the 
plasma concentration of ANP than is found with infusion of ANP in patients 
with heart failure. The combination of an ACE inhibitor and a neutral 
endopeptidase inhibitor may be beneficial. This could result in supression 
of the renin-angiotensin system, the sympathetic nervous system and 
argenine vasopressin as well as protection of GFR and ERPF and 
appropriate natriuretic and diuretic properties. Whether these actions will all 
be preserved when the agents are combined remains to be seen, but a 
recent study in a rat model of heart failure proved disappointing (Helin 
1993). 
The assumption is made that the statistically significant and insignificant 
results were genuine. This may not have been the case as the sample size 
was small and the power to detect differences may not have been adequate 
in all studies for all measurements. However the mean differences were 
generally small where no significant changes were found which suggests 
that the lack of differences were genuine. 
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The patients studied had adequately treated, compensated, stable heart 
failure, unlike patients being admitted for relief of acute left ventricular 
failure. The effect of a fall in blood pressure and thus renal perfusion 
pressure offset any gains from neuroendocrine manipulation. There is no 
evidence that salt restriction is any less harmful than increasing the diuretic 
dosage in stable, compensated patients. 
Table 10.1 Haemodynamic effects with all interventions 
The table shows increases(>>), decreases(<<) or lack of change (NC) of blood pressure 
(BP), heart rate (HR), effective renal plasma flow (ERPF), glomerular filtration rate (GFR) and 
urinary sodium excretion (UNa) for each intervention. 
INTERVENTION BP HR ERPF GFR UNa 
SALT RESTRICTION. « NC « NC « 
CAPTOPRIL « NC » « » 
DOBUTAMINE » » » NC » 
SNP « NC » NC NC 
DIGOXIN NC « » NC » 
ANP « NC » NC NC 
TYRAMINE » NC NC NC NC 
PHENTOLAMINE « » » NC NC 
DOPAMINE NC NC » NC » 
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Table 10.2 Endocrine effects with all interventions 
The table shows increases (>>), decreases (<<) or lack of change (NC) of plasma 
concentrations of atrial natriuretic peptide (ANP), plasma active renin (plasma renin), 
noradrenaline (NADREN), of urinary cyclic GMP (cGMP) and of urinary sodium excretion (UNa) 
during the interventions. 
INTERVENTION ANP renin NADREN cGMP UNa 
SALT RESTRICTION « » » « 
CAPTOPRIL » NC » 
DOBUTAMINE NC » NC » 
SNP « NC » NC NC 
DIGOXIN NC NC NC NC » 
ANP » » NC » NC 
TYRAMINE NC « NC NC NC 
PHENTOLAMINE » » » NC NC 
DOPAMINE NC NC NC » 
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Abbreviations used in the text 
ACE 
ADREN 
A-1 
A-ll 
ANP 
AVP 
BP 
cGMP 
Cl 
Cr, Great 
ERPF 
GFR 
HR 
K 
Mg 
Na 
NADREN 
Na-K-ATPase 
PARC 
Phos 
RAAS 
SNP 
TBI 
u 
Angiotensin converting enzyme 
Adrenaline 
Angiotensin- I 
Angiotensin II 
Atrial natriuretic peptide 
Arginine vasopressin 
Blood pressure 
Guanosine 3',5'-cyclic monophosphate 
Chloride 
Creatinine 
Effective renal plasma flow 
Glomerular filtration rate 
Heart rate 
Potassium 
Magnesium 
Sodium 
Noradrenaline 
Sodium, potassium adenosine triphosphatase 
Plasma active renin concentration 
Phosphate 
Renin-angiotensin-aldosterone system 
Sodium nitroprusside 
Thoracic bioimpedance 
Urea 
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